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ABSTRACT
FACTORS AFFECTING CYP2C9-MEDIATED METABOLISM
James Matthew Hutzler
Cytochrome P450 enzymes can exhibit non-Michaelis-Menten, or atypical kinetics. In
particular, dapsone activates CYP2C9-mediated flurbiprofen 4’-hydroxylation. However,
the mechanism of activation of CYP2C9 is poorly understood. The activation of
flurbiprofen, naproxen, and piroxicam metabolism by dapsone was investigated, fitting
kinetic data to a two-site effector model, indicating that the CYP2C9 active site may have
multiple binding regions. In addition the structural requirements for activation of
CYP2C9 were explored using structural analogs of dapsone, with results suggesting that
a sulfone group between two benzene rings is necessary for activation. CYP2C9
*2(R144C) and *3(I359L) allelic variants and the F114L mutant enzymes have also been
used to see if these amino acid changes alter dapsone activation of CYP2C9. In this
study, flurbiprofen 4’-hydroxylation was activated ~5-fold in the F114L mutant, but only
~2-fold for wild-type enzyme in the presence of dapsone. Also, piroxicam 5’hydroxylation was not activated by dapsone in the F114L mutant, which had higher
piroxicam hydroxylase activity than CYP2C9 wild-type, suggesting a role for F114 in
activation. In addition, substrate metabolism was studied in CYP2C9/19 chimeric and
CYP2C19 mutant enzymes. Results suggest that amino acids 228-292 are important for
catalysis of flurbiprofen, naproxen, and piroxicam. In addition, the CYP2C19 KSN
mutant has the greatest activity towards flurbiprofen 4’-hydroxylation, indicating that
changes at residues 241, 286, and 289 confer activity to CYP2C19. It has also been
discovered that hydroxy-dapsone, the major phase I metabolite of dapsone activates
flurbiprofen metabolism, although through a different mechanism. Spectral binding
studies confirm kinetic data, indicating that dapsone directly affects the binding of
flurbiprofen, whereas hydroxy-dapsone does not. Additional studies with ibuprofen
indicates that dapsone alters the binding orientation of this substrate, as the ratio of 3-OH
to 2-OH ibuprofen changes in the presence of dapsone. Lastly a urine and plasma assay
for detection of flurbiprofen and 4’-hydroxy flurbiprofen was developed for use in
analysis of samples in a clinical study investigating activation of metabolism in vivo. It
was found that dapsone activates flurbiprofen 4’-hydroxylation in vivo about 10%, much
less than that observed in vitro.
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CHAPTER 1

Literature Review

1

1.1. Introduction to Atypical Kinetics
It is well established that the cytochrome P450 monooxygenase family of
enzymes are the most important enzymes involved in the biotransformation of both
xenobiotic and endobiotic hydrophobic compounds [1;2]. The cytochrome P450
enzymes most often play a protective role against foreign chemicals, although they are
also implicated in the bioactivation of certain procarcinogens [e.g. benzo[a]pyrene], and
in many metabolism-based drug-drug interactions in patients taking concomitant
medications. Consequently, it is the goal of drug metabolism and toxicology labs to not
only determine CYP450 isoform contribution for the metabolism of a given compound,
but also to understand the various factors that affect the activity and behavior of these
isoforms. Classically, the metabolism of a particular compound is described kinetically
using the Michaelis-Menten equation, which yields estimates of maximal reaction
velocity (Vmax) and substrate affinity (Km). However, it is becoming increasingly evident
that the kinetic profile of the metabolism of some drugs may be better described by a
non-Michaelis-Menten, or atypical kinetic model, complicating interpretation of data.
Examples of these atypical kinetic profiles have become more numerous over the past
several years and are proposed to fall into five categories: activation, autoactivation,
substrate inhibition, partial inhibition, and biphasic metabolism [3]. Activation is evident
when P450 enzyme activity for a substrate is increased in the presence of another
substrate, due to structural or electronic changes of the enzyme, and is often referred to as
heterotropic positive cooperativity (activator is different than the substrate).
Autoactivation (homotropic positive cooperativity) occurs when a compound activates its
own metabolism, as has been observed with such compounds as carbamazepine [3]and
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progesterone [4], resulting in a sigmoidal kinetic profile. Kinetic parameters from
sigmoidal data are often estimated using the Hill equation, with the Hill coefficient
describing the degree of sigmoidicity (n>1). Substrate inhibition occurs when the
reaction velocity of product formation decreases once a particular substrate concentration
is surpassed, resulting in a convex reaction profile, while partial inhibition is when
incomplete inhibition is observed even in the presence of saturating concentrations of
inhibitor. The final atypical kinetic phenomenon reported is a biphasic saturation profile,
indicative of an enzyme with both a low affinity and a high affinity binding component.
This is similar to a dual-enzyme model, but interpreted as a single enzyme with multiple
binding regions [3].
Previously, atypical kinetic profiles were most likely overlooked, citing assay or
experimental variability, or not observed, perhaps due to lack of sensitive analytical
techniques or the paucity of data points collected, particularly at the low end of the
substrate concentration range. However, with today’s improved analytical technology,
scientists in drug metabolism are capable of designing more complete kinetic studies to
fully characterize the biotransformation of the compounds of interest, and thus are
becoming more cognizant of these atypical kinetic events. This is reflected by the
increase in atypical kinetic profiles reported in the literature over the past few years.

1.2. Activation (Heterotropic Positive Cooperativity)
Activation of drug metabolism was first observed many years ago in microsomes
from rat tissue, as 7,8-benzoflavone (α-naphthoflavone) was shown to activate the
hydroxylation of benzo[a]pyrene in control and phenobarbital treated rats [5]. Several
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other studies undertaken shortly thereafter concurred with these findings [6-8], but the
particular isoforms involved in this metabolism and activation had not been isolated or
identified. Later studies established that purified CYP3A enzymes are directly activated
by 7,8-benzoflavone [4;9]. Schwab and colleagues concluded that both progesterone 6βhydroxylation and 17β-estradiol 2-hydroxylation are activated by 7,8-benzoflavone in
man and rabbit, based on the observation that the Km of these reactions decreased and
Vmax increased in the presence of 7,8-benzoflavone. Similarly, Shou and co-workers
demonstrated that 7,8-benzoflavone activates phenanthrene metabolism by increasing the
Vmax, although the Km was unaffected. Also discovered was that 7,8-benzoflavone is a
substrate for CYP3A4, as phenanthrene was found to decrease the Vmax of 7,8benzoflavone metabolism, without affecting the Km. This particular finding generated
ideas as to the mechanism of activation (discussed later).
Because of the numerous studies showing 7,8-benzoflavone activation of
CYP3A4 (Table 1.1), it has been labeled as the classic CYP3A4 activator. However,
several groups have observed that compounds other than 7,8-benzoflavone may activate
CYP3A4 activity. Maenpaa et al. [10] have shown that testosterone stimulates the
formation of 4-hydroxymidazolam from midazolam in liver microsomes and expressed
CYP3A4, while Ludwig et al. [11] observed that meloxicam metabolism is activated by
quinidine in a dose-dependent manner. Interestingly, quinidine also activates the
metabolism of diclofenac to its 5-hydroxy derivative and warfarin to its 4’- and 10hydroxy metabolite in human liver microsomes, recombinant CYP3A4, and in human
hepatocyte suspensions, indicating that this interaction occurs in intact cells, and is likely
not an in vitro artifact [12;13]. These observations are not altogether surprising,
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considering the number of substrates with varying sizes and molecular weights that
CYP3A4 accommodates. In fact, Wang et al. [14] suggest that these types of interactions
with CYP3A4 are substrate dependent, implying that perhaps the interactions driving
these atypical kinetic observations depend at least partially upon a compound’s physical
and chemical properties. One particularly interesting observation from Wang and
colleagues was that 50-100 µM testosterone inhibited midazolam 1’-hydroxylation, but
stimulated the formation of the 4-hydroxylated product, suggesting an alteration of
regiospecificity, perhaps due to the presence of testosterone in the active site. In
addition, testosterone did not interact at all with nifedipine metabolism, but partially
inhibited terfenadine t-butyl-hydroxylation [14].
Just as compounds other than 7,8-benzoflavone can activate CYP3A4, the activity
of other isoforms may be stimulated by the presence of certain compounds. For example,
Korzekwa et al. [3]have shown that dapsone activates CYP2C9-mediated metabolism of
both flurbiprofen and naproxen, albeit to differing degrees, further supporting the
contention that these interactions may be substrate dependent. Furthermore, Korzekwa et
al. demonstrated that dapsone is also metabolized by CYP2C9, analogous to 7,8benzoflavone metabolism by CYP3A4 [3]. Thus, there appears to be some possible
mechanistic similarities for activation between these isoforms. Table 1.1 shows some of
the important examples of activation that have been observed in various expression
systems.
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1.3. Autoactivation (Homotropic Positive Cooperativity)
With regards to autoactivation, according to a review by Ekins et al. [15], the
most frequently reported CYP3A4 substrates that display autoactivation kinetics include
aflatoxin B1, amitriptyline, and progesterone, though some other compounds displaying
autoactivation kinetics have been reported (Table 1.2). In addition to CYP3A4, it has
been demonstrated that E. coli expressed and RECO expressed CYP1A2 show
autoactivation kinetics for ethoxyresorufin O-deethylation [15]. However,
ethoxyresorufin O-deethylation in human liver microsomes and insect expressed sources
of CYP1A2 showed classical Michaelis-Menten kinetics, suggesting that atypical kinetic
profiles may not only be substrate dependent, but also enzyme source dependent. One
other CYP450 that displays autoactivation kinetics is CYP2B6, as Ekins et al. [16]
observed that CYP2B6-mediated testosterone 16β-hydroxylation metabolism data are
best fit to the Hill equation (n=1.3). More recent evidence suggests that phase II enzymes
can display autoactivation kinetics as well. In a study by Fisher et al. [17], kinetic
profiles of estradiol-3-glucuronide and acetaminophen-O-glucuronide were best fit to the
Hill equation, as Eadie-Hofstee plots of the data were indicative of autoactivation. This
observation is the first report involving autoactivation of glucuronosyltransferases in
microsomal incubations, although bilirubin conjugation by UGT1A1 in hepatocytes has
been shown to display autoactivation kinetics as well [18]. These data suggests that
atypical kinetics may not be limited to phase I metabolic reactions.
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1.4. Substrate Inhibition
Substrate inhibition is another atypical kinetic phenomenon that has been
observed in in vitro studies. Although the mechanism of substrate inhibition has yet to be
fully determined, it has been described by a two-site model in which one binding site is
productive, while the other site is inhibitory and operable at high substrate
concentrations, resulting in decreased velocity with increasing concentrations [19]. One
early study showed that tenoxicam 5’-hydroxylation by the CYP2C family strongly
inhibits its own metabolism at concentrations higher than 100-150 µM [20].
Interestingly, our lab has demonstrated that piroxicam 5’-hydroxylation also
demonstrates substrate inhibition in both human liver microsomes and purified
baculovirus expressed CYP2C9, although not in expressed CYP2C9 microsomes (T.S.
Tracy et al.-submitted for publication). Yet another CYP2C9 substrate displaying
substrate inhibition kinetics is the new COX-2 selective NSAID celecoxib [21].
Furthermore, Spracklin et al. [22] have observed that halothane metabolism by CYP2E1
to trifluoroacetic acid and bromide displays substrate inhibition, one of the few examples
of atypical kinetics with CYP2E1. With regard to CYP3A4, Schrag and Wienkers [23]
observed that triazolam 1’-hydroxylation displayed substrate inhibition kinetics at higher
concentrations, confirmed by an Eadie-Hofstee plot, which showed a hook in the upper
quadrant, indicative of substrate inhibition. Most recently, Lin et al. [24] have observed
substrate inhibition kinetics for several compounds that are routinely used as probes for
particular CYP450 isoforms. For example, CYP1A2-catalyzed ethoxyresorufin
metabolism to resorufin, CYP2D6-catalyzed dextromethorphan metabolism to
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dextrorphan, as well as testosterone and progesterone metabolism by CYP3A4 all
displayed substrate inhibition kinetics [24]. The data for ethoxyresorufin is particularly
interesting, considering the work done by Ekins and coworkers [15] suggesting
autoactivation of ethoxyresorufin metabolism, not substrate inhibition. At this time, the
incongruency of these findings is not readily explained, though as stated earlier, enzyme
source and inter-lab variability may be factors. Several examples of substrate inhibition
are shown in Table 1.3.

1.5. Partial Inhibition
Partial inhibition occurs when a compound acting as either a substrate or inhibitor
for a particular CYP450 isoform incompletely inhibits another substrate’s metabolism,
even under saturating concentrations of the inhibitor. It has been suggested that both
substrate and inhibitor may have access to the reactive oxygen within the active site,
forming a substrate-inhibitor-enzyme complex that is still productive [19]. It is no
surprise then, that partial inhibition is often observed with CYP3A4, since this enzyme
has been shown to accommodate multiple substrates simultaneously. While studying the
simultaneous metabolism of testosterone and erythromycin by CYP3A4, Wang et al. [25]
observed that the inhibition mechanism for this interaction was not purely competitive.
At a fixed concentration of 60 µM testosterone, the rate of 6β-hydroxylation was greatly
reduced by high concentrations of erythromycin, suggesting competitive inhibition
between substrates. However, at higher fixed amounts of testosterone (250 and 500 µM),
only partial inhibition of 6β-hydroxylation was observed [25]. This suggested that both
compounds were being simultaneously metabolized, and may have distinct binding
regions within the active site. Wang and co-workers have also observed partial inhibition

8

by midazolam and terfenadine of CYP3A4-mediated testosterone metabolism [14]. In a
similar study, Korzekwa et al. [3] discovered that phenanthrene displayed partial
inhibition of 7,8-benzoflavone metabolism, while not affecting its Km, suggesting that
7,8-benzoflavone was not displaced from the active site. To date, few other identified
examples exist for partial inhibition, although it is likely that this phenomenon has been
observed for other CYP isoforms, and not labeled as such, or perhaps saturating inhibitor
concentrations were not reached.

1.6. Biphasic Kinetics
A biphasic kinetic profile is characterized by an initial Michaelis-Menten-like
increase in velocity with increasing substrate concentration. However, the profile does
not become asymptotic, with the reaction profile eventually becoming linear with
increasing substrate concentration. This results in the inability to predict an apparent
Vmax and thus, Km. Some examples include naproxen demethylation by CYP2C9, in
which saturation is unobtainable up to 1800 µM, and CYP3A4-mediated naphthalene
metabolism to 1-naphthol [3]. More recent evidence for biphasic kinetics includes 7ethoxycoumarin O-deethylation and aminopyrine N-demethylation in recombinant yeast
microsomes expressing rat CYP1A1 and yeast NADPH-P450 reductase [26]. This is the
first report showing atypical kinetics of P4501A1-mediated 7-ethoxycoumarin
metabolism, an often used probe for CYP1A1 activity. In addition, Oda et al. [27]
discovered that levo-α-acetylmethadol (LAAM) demethylation, as well as nor-LAAM
demethylation to dinor-LAAM exhibits biphasic Eadie-Hofstee plots in cDNA expressed
CYP3A4 enzyme. Most recently, it was discovered that the rates of 4-nitrophenol and
formaldehyde production from the O-demethylation of 1-methoxy-4-nitrobenzene by
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CYP1A2 isolated from rabbit liver produced biphasic plots [28]. As suggested by the
above studies, examples of biphasic kinetics are becoming more prevalent, with several
CYP isoforms apparently exhibiting this type of behavior (Table 1.4).

1.7. Mechanistic Models of Atypical Kinetics
Since the first observation of 7,8-benzoflavone activating the metabolism of
benzo[a]pyrene, much effort has been put forth to understand the mechanism of this and
other atypical kinetic events. Shou et al. [9] first suggested that both substrate and
activator may be simultaneously present in the active site, both having access to the
reactive oxygen. This conclusion was based on kinetic evidence that 7,8-benzoflavone
increased the Vmax of phenanthrene metabolism without changing the Km. Conversely,
phenanthrene decreased the Vmax of 7,8-benzoflavone metabolism without increasing the
Km, suggesting that neither compound displaces the other from the active site, resulting in
near-simultaneous metabolism. This study provided the first indirect evidence that more
than one molecule could be present in, and influence the active site. In related and
perhaps the most comprehensive initial work examining atypical kinetics, Korzekwa et
al. [3] provide further evidence for the theory of multiple binding regions within the
active site. This group suggested that a two-site binding model may be used to describe
all atypical kinetic observations, including those observed in isoforms other than
CYP3A4. Korzekwa and coworkers also demonstrated several of the theoretical
saturation profiles for an enzyme showing sigmoidal, biphasic, and substrate inhibition
kinetics, comparing the Km and Vmax parameters of the two proposed binding sites. One
of the most interesting observations from this study was that of the biphasic metabolism
of naproxen by CYP2C9, as well as naphthalene by CYP3A4. The authors suggest that
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this profile may also be explained by a two site binding model, one site having a low
affinity (Km), low capacity (Vmax), the other with high affinity and high capacity. This
type of profile is similar to that of a two-enzyme model, except that the data is derived
from a single purified or expressed enzyme.
Site-directed mutagenesis studies by Harlow and Halpert [29] have added
compelling structural evidence supporting the multi-site hypothesis. Their group
constructed a L211F/D214E double mutant of CYP3A4, which was designed to mimic
the action of effector (7,8-benzoflavone) by reducing the size of the active site with the
bulkier phenylalanine and glutamate residues. Results showed that the double mutant
exhibited an increased rate of testosterone and progesterone 6β-hydroxylation and a
lower level of activation by 7,8-benzoflavone, suggesting that the active site was the most
likely location of activator (effector) binding. In addition, studies have shown that
residues 301, 304, 305, and 309, predicted to be within substrate recognition site 4 of
CYP3A4, are also involved in steroid and effector binding [30;31]. Other studies
supporting the multi-site hypothesis include those of Ngui et al. [12] and Schrag and
Wienkers [23]. Briefly, Ngui and coworkers observed that quinidine stimulated
diclofenac metabolism, while maintaining normal access to the ferriheme-oxygen
complex, while Schrag and Wienkers observed an alteration of the metabolite ratio (4hydroxy triazolam/1’-hydroxy triazolam) for triazolam due to the presence of
testosterone, referred to as differential kinetics (when an effector activates the
metabolism of a given substrate at one position but inhibits metabolism at a different
position). In addition, Hosea et al. [32] provide evidence for multiple binding sites for
CYP3A4 through spectral binding studies with a number of CYP3A4 substrates and a
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series of peptide ligands, while Szklarz and Halpert [33] have generated a threedimensional homology model of CYP3A4, which shows the ability to dock multiple
substrates, or substrate and effector within the active site simultaneously.
In agreement with Korzekwa et al., Lin et al. [24] suggest that substrate inhibition
may be explained by a two-site binding model, in which the two sites may either be
neighboring or distant from each other within the active site. They hypothesize that in
the case of substrate inhibition, one site is favorable for oxidation, while the other site is
nonproductive, which differs from the theory that both sites may have access to the
reactive oxygen. This is further explained by suggesting that when a substrate binds to
the inhibitory site (at high concentrations), the complex (SES) is less capable of forming
product than the ES complex. A scheme representing the possible enzyme-substrateeffector interactions and product formation has been presented in a recent paper by Shou
et al. [19]. Nonetheless, whether one or the other or both sites are productive will likely
depend on the physical and chemical properties of the compounds in question.
Though most studies show evidence for a multi-site binding model, other
possibilities such as the presence of an allosteric site have not been completely disproven.
Ueng et al. [34] suggested an allosteric model for CYP3A4, although the proximity of the
allosteric site relative to the active site is not defined. Another study hypothesized that as
many as three conformers of CYP3A4 exist, based on kinetic studies of carbon monoxide
binding, depending on the substrate bound to CYP3A4 [35]. This group later suggested
that activation of benzo[a]pyrene (BaP) metabolism by 7,8-benzoflavone resulted from
an allosteric mechanism in which the presence of 7,8-benzoflavone converts an
unproductive enzyme conformation to a productive one, resulting in increased levels of
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BaP metabolite [36]. One of the most intriguing explanations for the cause of atypical
kinetics is one in which the multiple binding-site model and a conformationally based
model are combined, as suggested by Atkins et al. [37]. The author’s reasoning is that
multiple conformations alone can not account for sigmoidal velocity versus substrate
concentration curves, while the multiple binding-site theory does not fully explain the
lack of reciprocal effects of certain drug interactions. Therefore, a scheme is proposed by
which two enzyme conformers are in equilibrium, and each conformer can bind two
substrates at a single active site. Another possibility suggested by Ekins et al. [15] is the
contribution of water molecules in the active site and hydrogen bonding. They theorized
that the displacement of water molecules by a second substrate or effector may cause
fluctuations in the conformation of the enzyme, perhaps leading to changes in active site
characteristics and enhanced catalytic activity.
The interaction between CYP450 and cytochrome b5 and oxidoreductase may
also be involved in the production of atypical kinetic profiles. It is possible that effector
binding increases or enhances the interaction of CYP450 with either or both cytochrome
b5 and oxidoreductase. However, Ngui et al. [12] were able to exclude the role of
cytochrome b5 in the stimulation of diclofenac metabolism by quinidine, as the effect of
quinidine was maximal in the absence of cytochrome b5. In addition, Ngui and
coworkers observed no change in cytochrome c reduction by oxidoreductase in the
presence of quinidine. Similarly, our lab has observed that flurbiprofen 4’-hydroxylation
is activated by dapsone, despite the absence of cytochrome b5 (T.S.T. and J.M.H.,
unpublished observations). However, in a study using rat liver microsomes by Lee et al.
[38], it is suggested that the mechanism of cytochrome P450 activation involves electron
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transfer steps, likely from cytochrome b5. This was based on the observation that the
formation of NAPQI from acetaminophen was not stimulated by 5 mM caffeine or 50
µM 7,8-benzoflavone in liver microsomes when supported with cumene hydroperoxide
via the peroxide shunt, while approximately 3-fold activation was observed for both
caffeine and 7,8-benzoflavone in NADPH-supported incubations [38]. In addition, Lee
and coworkers observed that an inhibitory cytochrome b5 antibody significantly
diminished the activation of NAPQI formation by caffeine, but not 7,8-benzoflavone,
suggesting different mechanisms of activation by these compounds. Interestingly,
Yamazaki et al. [39] observed that apo-b5 (without heme), was as effective as holo-b5
(with heme) in stimulating testosterone 6β-hydroxylation and nifedipine oxidation in a
system containing NADPH-P450 reductase, suggesting that b5 may activate CYP3A4 by
inducing a conformational change in the enzyme, and not by increasing electron flow.
However, it has recently been suggested that apo-b5 may be converted to holo-b5 by a
heme transfer reaction from the CYP3A4 preparation, which may explain stimulation of
CYP3A4 activity [40].
While much evidence exists for the preceding mechanisms of atypical kinetics, no
one theory has been proven conclusively. It is possible that one or a combination of the
above- mentioned mechanisms, or some as yet undetermined mechanism(s) is/are likely
operable and contributing to the atypical kinetic profiles of many drugs.
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1.8. Kinetic Modeling of Atypical Kinetics
Along with observing atypical kinetic profiles comes the task of determining how
to properly model the data, so as to generate accurate kinetic parameter estimates. As
mentioned previously, atypical kinetic profiles have in the past likely been overlooked or
ignored. However, it is now apparent that ignoring or truncating nonhyperbolic data can
lead to erroneous kinetic parameter estimates, as standard Michaelis-Menten hyperbolic
curves are forced through the data, rather than the use of a more appropriate kinetic
model. For example, it has been suggested that substantial underestimation of Vmax may
occur when substrate inhibition is observed if the high concentration data points are
ignored [41]. This is validated by Lin and co-workers, who observed that the estimated
Vmax values for several reactions showing substrate inhibition were 0.91- to 1.8-fold
lower when fitted to the Michaelis-Menten equation, rather than a more appropriate
substrate inhibition equation [24]. Likewise, Houston and Kenworthy [41] suggest that
for a sigmoidal kinetic profile, either underestimation or overestimation of intrinsic
clearance (Clint) may occur if a hyperbolic curve is forced through the data, with the Km
(S50) term most likely affected. Therefore, it is imperative that the proper kinetic model
be used to estimate kinetic parameters from the data, although there may be several
solutions that satisfactorily model the same set of data [42]. With respect to the equations
used for modeling atypical kinetic data, most have been derived to describe the presence
of multiple binding sites within the active site. A comprehensive discussion of the
modeling of atypical kinetic data and the equations typically used can be found in several
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articles [3;41;43;44], with each showing enzyme-substrate-effector kinetic schemes from
which these equations are generated.

1.9. Artifactual Sources of Atypical Kinetics
Though the presence of atypical kinetics appears to be real, it is important to
perform experiments in a fashion so as to eliminate any artifactual causes of atypical
kinetic profiles. Several examples of artifactual sources of sigmoidicity and substrate
inhibition have been mentioned by Houston and Kenworthy [41]. Examples cited include
significant substrate depletion, nonspecific binding of substrate to the incubation matrix,
cellular active transporter systems, lack of analytical sensitivity, and low substrate
solubility. Significant substrate depletion results in deviations from initial rate
conditions, and leads to erroneous estimation of kinetic parameters, even in the absence
of atypical kinetics. As a result, it is important to monitor substrate consumption, and
even effector consumption, if the effector happens to be metabolized as well.
Nonspecific binding to microsomal proteins has been shown to be another potential
problem in in vitro studies [45;46]. One such example is the observation that addition of
750 µg/ml inactive control microsomes produced a 1.8-fold increase in the apparent S50
for amitriptyline metabolism, although no effect on the Vmax or Hill coefficient was
observed [46]. As a result, it may be beneficial to run the experiment at the lowest
possible protein concentration to help avoid any artifactual results. With respect to low
analytical sensitivity and solubility issues, these cause a lack of confidence in
quantitation or “effective” substrate concentration at the low, and high end of the
concentration range, respectively. In addition, Houston and Kenworthy suggest attaining
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a minimum of ten data points before concluding the presence of atypical kinetic profiles.
Meanwhile, Shou et al. [43] suggest attaining upwards of 20-30 data points, especially
around the inflection points to better define the fitted curve.
Other considerations when conducting these types of studies may be salt and
organic solvent concentrations in the incubation. Schrag and Wienkers [47] have
observed that pyrene metabolism by CYP3A4 is sigmoidal in the absence of magnesium,
but biphasic in the presence of 10 mM magnesium. In this work, evidence suggested a
change in CYP3A4 active site conformation in the presence of magnesium, resulting in
the different kinetic profile. In a similar study, Maenpaa et al. [10] observed that the
addition of 5 and 50 mM MgCl2 to microsomal incubations resulted in minimal changes
in midazolam 1’-hydroxy and 4-hydroxy metabolites, while the addition of 150 mM
MgCl2 resulted in substantial inhibition of both metabolites. Meanwhile, 1’-hydroxy and
4-hydroxy midazolam formation was completely inhibited by 30 mM CaCl2 in
microsomal incubations. In another study, acetonitrile and acetone were found to activate
the NADPH-dependent tolbutamide hydroxylation nearly 3-fold in human liver
microsomes and CYP2C9-reconstituted system when incubated at 2 to 4% final organic
solvent concentrations [48]. From these examples, it is evident that investigators must
remain cognizant of the many different conditions that may be artifactual sources of
atypical kinetics. In addition, the above list is probably not all inclusive and thus, there
may be other confounding factors involved in the observation of atypical kinetics as well.

1.10. In vivo Considerations
Although it is known that atypical kinetics exist in vitro, an important question is
whether they also occur in vivo, since they may have considerable pharmacological or
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toxicological implications. However, according to Houston and Kenworthy [41],
whether or not these types of interactions occur in vivo, and if they are clinically relevant
is not the primary issue. Even if these interactions are not observed in vivo, their
presence in vitro will affect how data is scaled from the in vitro to the in vivo situation.
Thus, it is best to fully describe the in vitro data and then abstract the useful parameter(s)
for extrapolation [41]. Nonetheless, in vivo studies designed to determine the presence of
atypical kinetics would be beneficial, but only a few have actually been performed. The
first example of activation of drug metabolism in vivo were studies by Lasker et al.
[49;50], who observed that the i.p. administration of flavone, nobiletin, tangeretin or 7,8benzoflavone concurrently with zoxazolamine immediately stimulated the total body
metabolism of zoxazolamine to its 6-hydroxy metabolite in neonatal rats in a time course
consistent with activation. This activation was found to be dose and dosing-time
dependent, as little activation of zoxazolamine metabolism was observed with a low dose
of zoxazolamine, as well as when the activator was administered 2-4 hours before
zoxazolamine [50]. It is noteworthy that Lasker and co-workers explored the possibility
that the flavone compounds could activate zoxazolamine metabolism by displacing it
from binding sites on plasma protein or from binding sites in the total body homogenates
by performing equilibrium dialysis studies. Results showed no difference in
zoxazolamine binding in the presence of flavone. Based on this observation, it was
determined that this activation in rats was likely CYP450-mediated, and thus the first
noted example of in vivo activation of drug metabolism.
More recently, it has been discovered that activation of CYP450-mediated drug
metabolism may be observed in vivo in monkeys. In previous studies, Tang et al. [51]
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observed that the formation of diclofenac metabolites via CYP3A4 increased more than
4-fold in human liver microsomes in the presence of quinidine. Since similar results
were seen in monkey liver microsomes, Tang and co-workers followed this work with an
in vivo study in monkeys and observed that in the presence of quinidine, diclofenac
clearance was enhanced in three male rhesus monkeys by 57, 56, and 56%, respectively
[51]. The plasma protein binding and blood/plasma ratio of diclofenac remained
unchanged in the presence of quinidine, and plasma samples were taken in a time frame
too short for the de novo synthesis of CYP proteins. This suggested that the interaction
was CYP450-mediated and the reduction in diclofenac levels compared to control was
not due to induction [51]. To date, no in vivo studies have been conducted to see if this
atypical kinetic phenomenon may be observed in humans.

1.11. Cytochrome P450 2C9
With the substantial increase in examples of atypical kinetics over the past few
years, much work needs to be done to better understand and predict these events and the
contributing isoforms. To date, most work has been done studying atypical kinetics in
CYP3A4. However, as mentioned in the previous sections, other CYP450 isoforms have
been shown to exhibit atypical kinetics as well, including the CYP2C9 isoform. Few
studies have been conducted on the atypical kinetics displayed by this isoform. As a
result, the work described herein will focus on the CYP2C9 isoform, and factors that
regulate its activity, including exploring potential mechanisms of atypical kinetics, and
whether they occur in vivo.
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The CYP2C enzyme subfamily found in the human liver comprises approximately
20% of total hepatic CYP enzymes [52;53], with CYP2C9 being the major isoform. The
CYP2C9 protein is composed of 490 amino acids, with a calculated molecular mass of
~55.6 KDa, and is responsible for metabolizing a vast array of xenobiotic substrates,
most of which are weak acids with pKa values ranging from 3.8-8.1 [54]. Examples
include (S)-warfarin [55], phenytoin and tolbutamide [56], and several non-steroidal antiinflammatory drugs, including diclofenac [57], ibuprofen [58], piroxicam [20], naproxen
[59;60], and flurbiprofen [61;62]. A comprehensive review of CYP2C9 substrates and
inhibitors has been presented by Miners and Birkett [54]. Interestingly, CYP2C9 is
polymorphic, with three alleles originally being identified as wild-type (CYP2C9*1), the
R144C variant (CYP2C9*2), and the I359L variant (CYP2C9*3), and allele frequencies
of 0.86, 0.08 and 0.06, respectively [63;64]. Recently, however, an I359T (CYP2C9*4)
allelic variant was identified in Japanese epileptic patients [65], while a D360E
(CYP2C9*5) variant was discovered that is apparently only expressed among African
Americans at an allele frequency of 0.03 [66]. These allelic variants of CYP2C9 have
been shown to variably affect the metabolism of a number of CYP2C9 substrates. For
example, CYP2C9*2 (R144C) allelic variant has been shown to reduce the Vmax for
tolbutamide methyl-hydroxylation by up to threefold [64;67]. In addition, Crespi and
Miller [68] observed that the R144C variant exhibited similar apparent Km values for (S)warfarin, diclofenac, and lauric acid hydroxylation compared to wild-type CYP2C9
enzyme, but had slower rates of metabolism. Meanwhile, CYP2C9*3 has a reduced
capacity to metabolize (S)-warfarin [69], while CYP2C9*2 seems to not affect the
apparent Km for (S)-warfarin 7-hydroxylation [67]. Lastly, the CYP2C9*4 variant has
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been shown to decrease the apparent intrinsic clearance of diclofenac compared to wildtype, primarily due to an effect on Vmax [70]. Although the allele frequencies for these
variants are small, the fact that these amino acid changes generally cause a decrease in
metabolic capacity has led to many questions about enzyme active site structure, and
recognition of substrates.
It has been proposed that CYP2C9, along with other CYP2 family isoforms, has
six substrate recognition sites (SRSs), which variably contribute to the recognition and
binding of certain substrates [71]. Many studies have evolved from this finding in an
attempt to better understand the substrate selectivity of CYP2C9, as well as the binding
interactions within the active site and overall three-dimensional structure of this protein.
Initially, a three-dimensional model of CYP2C9 was constructed by Korzekwa and Jones
[72], which was based on amino acid sequence alignment data and the crystal structure of
the bacterial enzyme CYP101. This homology model was considered to have low
resolution, and thus of limited utility in the prediction of substrate binding by CYP2C9.
Other molecular modeling techniques, such as pharmacophore modeling, have been
performed to probe the active site binding interactions of CYP2C9. Jones et al. [73]
rationalized the substrate specificity of nine substrates and one inhibitor of CYP2C9 in
terms of a hydrogen bond donor/acceptor model to propose an active site template model.
This model was described by A, the distance between the site of metabolism (Y) and the
hydrogen bond donor heteroatom (X), and C, the angle between this and the hydrogen
bond, with mean dimensions for the nine substrates and one inhibitor of A = 6.7 ± 1.0 Å,
C = 133 ± 21°. Mancy et al. [74] generated a pharmacophore model by analyzing the
ability of 10 derivatives of tienilic acid, a known substrate of CYP2C9, to be
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metabolized. Results showed that only derivatives containing an acidic function
underwent a 5-hydroxylation of their thiophene ring like tienilic acid. In addition, the
nonacidic derivatives were unable to competitively inhibit the hydroxylation of tienilic
acid, suggesting that they not only did not undergo hydroxylation, but also were not
recognized by the CYP2C9 enzyme. This suggested that most substrates for CYP2C9
interact through their acidic anionic site with a cationic residue of the CYP2C9 protein.
One study in particular observed that arginine 97 is important for diclofenac
hydroxylation, suggesting the presence of an important cationic binding region in the
active site, since when this amino acid was mutated to a neutral moiety, diclofenac
hydroxylation was greatly reduced [75]. Other studies confirm the importance of an
anionic binding region within the CYP2C9 active site [76;77], both of which also
mention the importance of a hydrophobic zone between the substrate hydroxylation site
and the anionic site. In addition, a molecular model of CYP2C9 was generated using the
3D-QSAR method CoMFA (comparative molecular field analysis) and 29 coumarin ringcontaining compounds to evaluate both steric and electrostatic interactions within the
active site[78]. This predictive model has since been updated with 14 new compounds
[79], due in part to the findings of Haining et al. [80] who observed the importance of a
hydrophobic residue within the CYP2C9 active site. More specifically, it was observed
that an F114L mutant decreased the Vmax for (S)-warfarin 7-hydroxylation 4-fold, and
increased the Km 13-fold, suggesting the ability of certain aromatic ligands to π-stack to
the F114 residue, with the L114 residue apparently eliminating this interaction. Another
QSAR study analyzing CY2C9 competitive inhibitors has been performed by Ekins et al.
[81]. This group generated a 3D/4D QSAR pharmacophore model of the common
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structural features of CYP2C9 inhibitors using Catalyst, a commercially available 3DQSAR technique that does not require manual alignment of molecules, unlike the
CoMFA studies of CYP2C9 [78;79]. Meanwhile, Afzelius et al. [82] generated a 3DQSAR model for 29 structurally diverse competitive inhibitors of CYP2C9, and
performed molecular modeling studies with the help of a homology model of CYP2C9,
based on the coordinates of rabbit CYP2C5, the first mammalian CYP enzyme for which
there is a crystal structure [83]. Results from this study showed the ability to predict Ki
values to within 0.5 log units of the experimental Ki values, which was more robust than
the QSAR method by Ekins et al. [81].
Cytochrome P4502C9 has usually been considered to be a well-behaved enzyme
that follows the rules of normal Michaelis-Menten type kinetics. However, it is now
becoming clear that CYP2C9 shows some atypical kinetic profiles similar to CYP3A4,
most notably activation by dapsone [3]. In this study, Korzekwa’s group suggested that
activation, as well as other atypical kinetics events, may be explained by a model that
suggests the presence of multiple binding regions within the CYP450 active site, each
having its own kinetic characteristics. However, only one group has explored this theory
in their pharmacophore models. This study explored the differences in metabolic
stability between warfarin and phenprocoumon by CYP2C9, and provided evidence to
support the multiple binding theory, as two binding sites were proposed, a π-stacking site
and an ionic binding site for organic anions [84]. This finding is similar to the other
pharmacophore studies previously mentioned, but is the first to interpret these sites as
being distinct regions in the active site. Despite these suggestions, minimal kinetic data
from CYP2C9 has been generated to provide evidence for this theory. The studies
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described herein show the ability to kinetically model activation of CYP2C9-mediated
metabolism of several compounds by dapsone with a two-binding site effector model,
along with further evidence for the presence of multiple binding regions within the
CYP2C9 active site. In addition, other factors involved in the mechanism of activation of
CYP2C9 will be explored to provide information necessary for eventually generating a
pharmacophore model of multiple binding regions within the CYP2C9 active site.

1.12. Research Study Objectives
1. Kinetically model dapsone activation of CYP2C9-mediated flurbiprofen 4’hydroxylation, naproxen O-demethylation, and piroxicam 5’-hydroxylation, as
well as explore the effect of flurbiprofen on dapsone N-hydroxylation.
2. Determine the structural requirements of dapsone activation of CYP2C9 by
screening 17 analogs of dapsone for activation of flurbiprofen, naproxen, and
piroxicam metabolism in human liver microsomes, followed by full kinetic
studies to observe the effect of different concentrations of effector on CYP2C9
activity.
3. Explore other studies for understanding the mechanism of activation of CYP2C9,
including the use of CYP2C9/19 chimeric enzymes, CYP2C19 mutant enzymes,
spectral binding studies with CYP2C9, activation of CYP2C9 allelic variants,
dapsone metabolite activation of CYP2C9, and alteration of regiospecificity of
ibuprofen metabolism.
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4. Validate a urine and plasma HPLC assay for use in analyzing samples to
determine if activation of flurbiprofen 4’-hydroxylation by dapsone also occurs
in vivo in humans.
5. Analyze urine and plasma samples and perform pharmacokinetic modeling for a
clinical study exploring the ability of dapsone to activate flurbiprofen 4’hydroxylation in 12 human subjects.
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Table 1.1. Reported Examples of Activation Kinetics
Examples of activation kinetics (heterotropic positive cooperativity) reported in the
literature in various in vitro systems.
Enzyme Source

Substrate

Pathway

RLMa
Benzo[a]pyrene
Hydroxylation
HLMb
Benzo[a]pyrene
Hydroxylation
HLM
Progesterone
6β-hydroxylation
HLM
2-hydroxylation
17β-estradiol
HepG2 expressed CYP3A4
Phenanthrene
Hydroxylation
HepG2 expressed CYP3A4
Phenanthrene
Hydroxylation
E. coli purified CYP3A4
AflatoxinB1
8,9-epoxidation
E. coli purified CYP3A4
Carbamazepine
10,11-epoxidation
HLM
Diazepam
Hydroxylation
HLM
Diazepam
N-demethylation
HLM
Phenacetin
O-deethylation
HLM
Midazolam
4-hydroxylation
HLM and B-lymphoblastoid
Midazolam
4-hydroxylation
expressed CYP3A4c
HLM and B-lymphoblastoid
Meloxicam
5’-methylhydroxylation
expressed CYP3A4c
Diclofenac
5-hydroxylation
HLM and B-lymphoblastoid
expressed CYP3A4c
Warfarin
4’-and 10-hydroxylation
HLM and B-lymphoblastoid
expressed CYP3A4c
Baculovirus purified CYP2C9
Flurbiprofen
4’-hydroxylation
a
rat liver microsomes, b human liver microsomes, c obtained from Gentest
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Effector

Reference

7,8-benzoflavone
7,8-benzoflavone
7,8-benzoflavone
7,8-benzoflavone
7,8-benzoflavone
7,8-benzoflavone
7,8-benzoflavone
7,8-benzoflavone
7,8-benzoflavone
7,8-benzoflavone
7,8-benzoflavone
Testosterone
Testosterone

[5]
[7]
[4]
Ibid.
[9]
[3]
[34]
Ibid.
[85]
Ibid.
[86]
[10]
[14]

Quinidine

[11]

Quinidine

[12]

Quinidine

[13]

Dapsone

[3]

Table 1.2. Reported Examples of Autoactivation Kinetics
Examples of autoactivation kinetics (homotropic positive cooperativity).
For a more comprehensive review, see Ekins et al., 1998a.
Enzyme Source

Substrate

Pathway

Baculovirus expressed CYP3A4
Diazepam
Baculovirus expressed CYP3A4
Diazepam
Vaccinia expressed CYP2C9
Dapsone
B-lymphoblastoid expressed
Testosterone
CYP2B6a
Estradiol
HLMb
HLM
Acetaminophen
a
obtained from Gentest, b human liver microsomes
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Reference

Hydroxylation
Demethylation
Hydroxylation
16β-hydroxylation

[43]
Ibid.
[3]
[16]

3-glucuronidation
O-glucuronidation

[17]
Ibid.

Table 1.3. Reported Examples of Substrate Inhibition Kinetics
Substrates reported to display substrate inhibition kinetics in various in vitro
systems.
Enzyme Source

Substrate

Pathway

HLMa
Tenoxicam
5’-hydroxylation
cDNA-expressed CYP2E1b
Halothane
TFA formationc
b
cDNA-expressed CYP2E1
Halothane
Bromide formation
HLM
Fluoxetine
Demethylation
HLM
Fluoxetine
Demethylation
HLM
Triazolam
1’-hydroxylation
HLM
Celecoxib
Hydroxylation
Baculovirus expressed CYP2C9
Celecoxib
Hydroxylation
Baculovirus expressed CYP1A2
Ethoxyresorufin
Resorufin formation
Baculovirus expressed CYP3A4
Benzyloxyresorufin
Resorufin formation
Baculovirus expressed CYP2D6 Dextromethorphan
O-demethylation
Baculovirus expressed CYP3A4
Progesterone
6β-hydroxylation
Baculovirus expressed CYP3A4
Testosterone
6β-hydroxylation
a
human liver microsomes, b obtained from Gentest, c trifluoroacetic acid
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Reference
[20]
[22]
Ibid.
[87]
[88]
[23]
[21]
[24]
Ibid.
Ibid.
Ibid.
Ibid.
Ibid.

Table 1.4. Reported Examples of Biphasic Kinetics
Substrates reported to display biphasic kinetics in various in vitro systems.
Enzyme Source

Substrate

Vaccinia expressed CYP2C9
Naproxen
Baculovirus expressed CYP3A4
Naphthalene
Yeast expressed CYP1A1
7-ethoxycoumarin
Yeast expressed CYP1A1
Aminopyrine
HLMa and cDNA-expressed CYP3A4 Levo-α-acetylmethadol
HLM and cDNA-expressed CYP3A4
Nor-levo-α-acetylmethadol
E. coli purified CYP1A2 b
1-methoxy-4-nitrobenzene
a
human liver microsomes, b rabbit enzyme
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Pathway
O-demethylation
Hydroxylation
O-deethylation
N-demethylation
Demethylation
Demethylation
O-demethylation

Reference
[3]
Ibid
[26]
Ibid.
[27]
Ibid.
[28]

CHAPTER II

Dapsone Activation of CYP2C9-Mediated Metabolism:
Evidence for Activation of Multiple Substrates and a Two-Site
Model

This chapter published in Drug Metabolism and Disposition [29, 1029-1034 (2001)].
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2.1. Introduction
It is becoming evident that many cytochrome P450-catalyzed reactions do not
proceed with typical Michaelis-Menten kinetics. Observations of atypical kinetic events
such as activation, autoactivation, and substrate inhibition are becoming increasingly
common, with the term “cooperativity” often being used to describe these types of
phenomena. To date, CYP3A4 has been the most studied isoform with respect to atypical
kinetics due to the large number of reactions that it catalyzes and the complexity of its active
site. However, other relevant P450s have been shown to participate in a number of these
abnormal kinetic events [1-3], making analysis of in vitro data problematic. As a result, it
has been suggested that atypical kinetics must be considered during in vitro-in vivo scaling of
kinetic data. Houston and Kenworthy [4] have demonstrated that failure to properly assess
atypical kinetics may result in under or overestimation of in vivo clearance of drugs when
based on in vitro kinetic parameter estimates. Therefore, it is imperative that the cause and
mechanism of these events be determined, as well as the isoforms affected.
Our lab has previously demonstrated that CYP2C9-mediated flurbiprofen 4’hydroxylation and naproxen demethylation are activated by dapsone in human liver
microsomes and baculovirus-expressed CYP2C9 [2]. However, kinetic effects of this
activation have yet to be fully characterized. While flurbiprofen is exclusively metabolized
by CYP2C9 [5] and shows normal Michaelis-Menten kinetics [6], naproxen is metabolized
by CYP2C9 and CYP1A2 [7;8] and has been shown to exhibit non-saturable biphasic
kinetics in microsomes [7], as well as in expressed CYP2C9 [2]. The unsaturable metabolic
profile observed in expressed CYP2C9 suggests that there may be two binding components
within the CYP2C9 active site, one with a low Km, low Vmax, the other with a high Km and
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high Vmax, similar to naphthalene metabolism by CYP3A4 [2]. Piroxicam, another NSAID
reported to be metabolized by CYP2C9 [9], has been shown to exhibit atypical kinetics as
well (substrate inhibition) in baculovirus expressed CYP2C9 (unpublished results), and has a
quite different structure than either flurbiprofen or naproxen.
Dapsone is a compound used to treat Pneumocystis carinii pneumonia in AIDS
patients, and is metabolized by CYP2C9 at therapeutic concentrations to its hydroxylamine
metabolite [10;11]. Thus, it appears that dapsone is also a substrate for the enzyme it
activates, suggesting that dapsone may cause activation by binding in the active site of
CYP2C9. This scenario is analogous to 7,8-benzoflavone, which activates CYP3A4mediated phenanthrene metabolism, in addition to being a substrate for CYP3A4 [1].
The purpose of the current study was to determine the effect of dapsone on the
kinetics of (S)-flurbiprofen, (S)-naproxen, and piroxicam, three prototypical substrates of
CYP2C9 with differing structures and kinetic profiles (Figure 2.1). It was hypothesized that
a kinetic model which suggests that both the substrate and effector may be present in the
active site simultaneously, both having access to the active oxygen was applicable [1;2;12].
Thus, kinetic data from expressed CYP2C9 were fit to the two-site model (equation 2.3) in
addition to either the Michaelis-Menten equation (equation 2.1) or a two-site biphasic model
(equation 2.2). If our hypothesized two-site model for CYP2C9 is accurate, and the activator
(dapsone) also serves as a substrate, then theoretically, near-simultaneous metabolism should
occur, and metabolites from both compounds should be measurable. Therefore, the effect of
flurbiprofen on dapsone hydroxylation kinetics was also examined by measuring dapsone
hydroxylamine formation and fitting data to the Michaelis-Menten equation.
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2.2. Methods
Chemicals and reagents. Acetonitrile and dibasic potassium phosphate were
obtained from Fisher Scientific Co. (Pittsburgh, PA). (S)-Flurbiprofen, 4’-hydroxy
flurbiprofen, and 2-fluoro-4-biphenyl acetic acid (internal standard) were gifts from
Pharmacia, Inc. (Kalamazoo, MI). (S)-naproxen and desmethylnaproxen were gifts from
Syntex Laboratories Inc. (Palo Alto, CA). Piroxicam and dapsone were obtained from
Sigma Chemical Co. (St. Louis, MO), while 5’-hydroxy piroxicam was a gift from Pfizer
Inc. (Groton, CT.). Dapsone hydroxylamine was synthesized by the method of Uetrecht et
al. [13] and was a gift from Robert Branch at the University of Pittsburgh. All other
chemicals were obtained from commercial sources and were of the highest purity available.
Incubation Conditions. Incubation mixtures in a 6X6 matrix design contained 1 pmol
purified CYP2C9 (5 pmol for piroxicam) co-expressed with reductase (Camitro Corporation,
Menlo Park, CA), with either (S)-flurbiprofen (2-300 µM), (S)-naproxen (10-1800 µM), or
piroxicam (5-900 µM) incubated with dapsone (0-100 µM) in 50 mM potassium phosphate
buffer at pH 7.4. Final incubation volume was 0.2 ml and reactions were initiated with 1 mM
NADPH and allowed to incubate at 37°C for 20 minutes (45 minutes for piroxicam).
Incubations with flurbiprofen were quenched by adding 200 µl acetonitrile containing internal
standard (180 ng/mL 2-fluoro-4-biphenylacetic acid), followed by addition of 40 µl ½-strength
H3PO4. Incubations with naproxen were quenched by adding 200 µl acetonitrile followed by
addition of 40 µl ½-strength H3PO4, while piroxicam reactions were quenched by adding 20 µl
perchloric acid, followed by directly placing incubation tubes on ice. Samples from all
incubations were then centrifuged at 10,000 rpm for 5 minutes, placed into autosampler vials,
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and 10-100 µl injected onto HPLC system. In experiments examining flurbiprofen effect on
dapsone hydroxylamine formation, flurbiprofen concentrations were 0, 2, 5, and 10 µM, with
dapsone concentrations ranging from 1-300 µM. To prevent degradation of the dapsone
hydroxylamine metabolite, 1 mM ascorbic acid was included in the 50 mM potassium phosphate
buffer in those cases where this metabolite was being measured. The reaction was stopped by
the addition of 0.1 ml of cold methanol. Samples were then spun at 20,000g for 5 minutes at 3°C
in an Eppendorf 5417R centrifuge and 15 µl injected onto an LC/MS system for immediate
dapsone hydroxylamine analysis to prevent instability issues. All other conditions were as
described above.
Analysis of 4’-hydroxy flurbiprofen. 4’-Hydroxy flurbiprofen was analyzed by HPLC
with fluorescence detection and comparison to a standard dissolved in 50:50 (v/v),
acetonitrile:50 mM potassium phosphate buffer pH 7.4. The HPLC system consisted of a
Waters 501 HPLC pump, a Waters 717 autosampler and a Waters 470 fluorescence detector
set at an excitation wavelength of 260 nm and an emission wavelength of 320 nm. The mobile
phase consisted of 45:55 (v/v), acetonitrile:20 mM K2HPO4, pH 3.0 pumped at 1 ml/min through
a Brownlee Spheri-5 C18 4.6 x 100 mm column. 4’-Hydroxy flurbiprofen and internal standard
eluted at approximately 2.2 and 4.8 minutes, respectively.
Analysis of desmethylnaproxen. Desmethylnaproxen was analyzed identically to
4’-hydroxy flurbiprofen except that the fluorescence detector was set at an excitation
wavelength of 230 nm and an emission wavelength of 340 nm, and no internal standard
was used. Desmethylnaproxen eluted at approximately 2.1 minutes.
Analysis of 5’-hydroxy piroxicam. 5’-Hydroxy piroxicam was analyzed by HPLC
with UV detection (365 nm). The HPLC system was as described above, but was fitted
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to a Waters 486 UV detector. The mobile phase consisted of 50:50 (v/v), acetonitrile:50
mM K2HPO4, pH 3.0 pumped at 1 mL/min through a Phenomenex Luna C18 5 µm, 4.6 x
150 mm column. Retention time for 5’-hydroxy piroxicam was approximately 4.3
minutes.
Analysis of dapsone hydroxylamine. HPLC/ESI-MS was performed on a Perkin Elmer
Sciex API 150ex single quadrupole mass spectrometer connected to a Perkin Elmer Series 200
LC pump and autosampler. The mass spectrometer was fitted with a turbo ion-spray source and
operated in positive-ion SIM (selective ion monitoring) electrospray mode, with an ESI spray
voltage of 5.0 kV and source temperature of 450°C. The turbo ion-spray gas flow rate was set at
7000 cc/min. Tuning of the ESI source and MS was accomplished by infusing a solution
containing 20 µg/ml dapsone hydroxylamine into the mobile phase flow path post column via a
T connector using a Harvard Apparatus (Holliston, MA) manual injector. The instrument was
controlled by a Dell Optiplex GX1 computer running Analyst version 1.1 software. Dapsone
hydroxylamine formation was confirmed by appearance of the MH+ ion at m/z of 265.1, and
chromatographic retention time corresponding to that of a synthetic standard dissolved in
DMSO. Stability of dapsone hydroxylamine metabolite was exhibited over the time required to
analyze all of the incubation samples. Analytical separation was accomplished using a Zorbax
SB-C8 2.1 x 50 mm, 5 µm microbore column with a gradient elution profile. Solvent flow
through the column was 0.7 ml/min with 30% of the flow being diverted to the mass
spectrometer. Gradient elution consisted of mobile phase A [Methanol] and mobile phase B
[100 mM Ammonium Acetate (pH 4.38)]. The gradient was initiated at a ratio of 10%A:90%B.
This ratio was altered in a linear fashion to 80%A:20%B over 1 minute, and held for 2.4 minutes
to allow elution of dapsone hydroxylamine. The system was then returned to initial conditions
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over 0.1 minutes and allowed to equilibrate for 4.4 minutes prior to the next injection. The flow
was diverted to waste for 1 minute post injection to prevent fouling of the interface from polar
compounds in the solvent front. Dapsone hydroxylamine eluted at approximately 2.9 minutes.
Data Analysis and Equations. Kinetic parameters for flurbiprofen, piroxicam, and dapsone
hydroxylation were estimated using the nonlinear regression function in Sigma Plot (Version
6.0), and the standard Michaelis-Menten velocity equation:
Vm • S
(2.1)
Km + S
Kinetic parameters for naproxen demethylation were estimated using a two-site biphasic
v=

equation:
(Vm1 • S ) + Cl int • S 2
v=
(2.2)
( Km1 + S )
where Clint is referred to as intrinsic clearance and represents the linear portion of the
biphasic kinetic curve (Vmax2/Km2).
The same data (36 points) from fits to equations 2.1 and 2.2 were also fit to a two-site model
equation [2] utilized for surface plot analysis of flurbiprofen 4’-hydroxylation, naproxen
demethylation and piroxicam 5’-hydroxylation in the presence of dapsone was as follows:
V max• [S ]
(2.3)
 [B ] 

B] 
[
1 +

1 +

K B 
αK B 


Km
+ [S ]
 β [B ]
 β [B ]
1 +

1 +

 αK B 
 αK B 
where S is the substrate, B is the effector, Vmax and Km are kinetic constants for substrate
v=

metabolism, KB is the binding constant for the effector, α is the change in Km resulting from
effector binding, and β is the change in Vmax from effector binding. For activation, α<1
and/or β>1.
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2.3. Results
Dapsone Activation of Purified CYP2C9. The kinetic parameters for flurbiprofen
and piroxicam hydroxylation were determined by fitting data to the Michaelis-Menten
equation (equation 2.1), while parameters for naproxen demethylation were estimated by
fitting data to a two-site biphasic model equation (equation 2.2). Dapsone activated
flurbiprofen 4’-hydroxylation in purified CYP2C9 (Figure 2.2), increasing Vmax from
12.6 to 20.6 pmol/min/pmol P450 while lowering the Km from 28.9 to 10.0 µM (Table
2.1). Meanwhile, the Figure 2.3 shows that the Vmax for piroxicam hydroxylation was
increased from 0.08 to 0.20 pmol/min/pmol P450, with the Km reduced from 183 to about
50 µM (Table 2.1). Likewise, naproxen demethylation was activated by the presence of
dapsone with the data fit to a biphasic equation reflecting the kinetic profile of the
reaction (Figure 2.4). The Vmax for naproxen demethylation was increased from 11.7 to
34.7 pmol/min/pmol P450, while the Km was decreased from 433 to 67.4 µM (Table 2.2),
a greater-fold change than observed with either flurbiprofen or piroxicam. While the
Clint (Vmax2/Km2) value did not change, it contributed to a lesser extent in defining the
kinetic profile of naproxen in the presence of dapsone (Table 2.2). This is observed by
the increase in Clint of the first naproxen binding site (Vmax1/Km1) from 0.027 with no
dapsone to 0.52 in the presence of 100 µM dapsone, thus displaying that the Clint of the
second site (Vmax2/Km2) contributes a smaller percentage to total naproxen demethylation
when dapsone is present. Kinetic parameters for flurbiprofen, naproxen and piroxicam
metabolism were also estimated using the two-site model equation (equation 2.3). Data
from Table 2.3. further suggests that dapsone activates the metabolism of these three
compounds, as all α values are below 1, and all β values are above 1. It is also
37

interesting to note that the binding constant for dapsone varies according to the substrate
being activated (Table 2.3). The three-dimensional activation plot for flurbiprofen can be
seen in Figure 2.5, demonstrating activation of flurbiprofen hydroxylation by dapsone.
However, flurbiprofen appeared to not substantially affect the formation of dapsone
hydroxylamine, as similar velocity curves were obtained in the presence of 0, 2, 5, and 10
µM flurbiprofen (Figure 2.6). Vmax values for dapsone hydroxylation ranged from 36-44
pmol/min/pmol P450, while Km values ranged from 81-144 µM (data not shown).
Similarly, a three-dimensional plot exhibiting activation of naproxen demethylation is
shown in Figure 2.7, while in Figure 2.8, an Eadie-Hofstee plot shows the effect of
dapsone on the kinetic profile of naproxen. In the absence of dapsone, a biphasic plot is
observed, whereas the presence of 100 µM dapsone causes the biphasic profile of
naproxen to become linear. As a result, naproxen demethylation in the presence of 100
µM dapsone was also fit to the Michaelis-Menten curve, with a Vmax of 37.0
pmol/min/pmol P450 and a Km of 80 µM (Table 2.2). Lastly, a three-dimensional plot in
Figure 2.9 shows that piroxicam, a structurally different CYP2C9 substrate, is also
activated by dapsone.
Stability of Dapsone Hydroxylamine. Dapsone hydroxylamine is known to be an
unstable compound in potassium phosphate buffer [14;15]. A standard solution was
prepared in potassium phosphate buffer containing 1 mM ascorbic acid and a 15 µl
injection was made from the same vial every 20 minutes at room temperature and
analyzed according to methods described in Materials and Methods. When subjected to
our incubation conditions over 5 hours, the peak area coefficient of variation was 2.3%
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(data not shown), demonstrating that quantitation would not be affected by metabolite
instability.

2.4. Discussion
Results from this study suggest that dapsone activates multiple substrates of
CYP2C9, being described by a model in which dapsone (effector) and substrate may fit
in the active site simultaneously. The increase in Vmax and decrease in Km for
flurbiprofen 4’-hydroxylation while dapsone hydroxylamine metabolite is also
measurable provide additional evidence for this theory. In addition, the naproxen
metabolic profile was changed from biphasic to hyperbolic in the presence of dapsone,
and piroxicam, a third CYP2C9 substrate with a distinct structure, was also metabolically
activated by dapsone.
It was once believed that most P450-mediated reactions obeyed normal
Michaelis-Menten enzyme kinetics, allowing for relatively simple prediction of kinetic
parameters. However, atypical CYP450 kinetics are now being recognized more
frequently in the area of drug metabolism, which complicates scaling kinetic data from
the in vitro to the in vivo situation. To date, CYP3A4 has been the most studied isoform
in terms of atypical kinetic behavior. For example, studies by Schwab et al. [16] and
Shou et al. [1] have shown that purified CYP3A4 enzymes are directly activated by 7,8benzoflavone. This is particularly interesting because like dapsone, 7,8-benzoflavone is a
substrate for the enzyme that it activates. More recent data suggests that P450 enzymes
other than CYP3A4 may behave in an atypical manner. Korzekwa et al. [2] suggest that
CYP1A1 mediated naphthalene metabolism shows a sigmoidal saturation curve and that
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Hep G2 expressed CYP2B6, CYP2C8, CYP2C9, and CYP3A5 may also exhibit non
Michaelis-Menten kinetics, depending on the substrate. Likewise, Ekins et al. [3] have
shown that CYP1A2 displays autoactivation kinetics for ethoxyresorufin metabolism,
although results appear to be enzyme source dependent. Despite these studies describing
activation, no clear mechanism has been determined, although many models have been
proposed. Ueng et al. [17] have described a model which suggests that an allosteric site
is involved in the cooperativity of certain CYP3A4 reactions, but the proximity of this
site is not defined. Harlow and Halpert suggest that effector binding is most likely in the
active site along with the substrate, but go on to propose that oxidation only occurs at one
binding region within the active site [18]. Another possibility that has been put forth is
the idea of kinetically distinguishable conformers of CYP3A4 [19], which was proposed
based on kinetic studies of carbon monoxide binding. However, the model we believe
that most accurately describes the activation phenomenon is that of Shou and Korzekwa
[1;2;12], which suggests that both substrate and effector are bound in the active site
simultaneously with distinctive binding regions and access to the reactive oxygen. It
should be stated that this model does not distinguish between allosteric or active site
effector binding.
From our experiments, we have observed near-simultaneous metabolism of
flurbiprofen and dapsone, although it is likely that there is only one productive
orientation at a given time. Nonetheless, this provides support to the primary hypothesis
that substrate and activator may bind in the active site simultaneously, potentially ruling
out the theory of an allosteric site causing cooperativity. The main basis for this
hypothesis is that dapsone is also a substrate for CYP2C9. Although the CYP2C9 active
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site is not as large as CYP3A4 , it still may be able to accommodate two rather small
compounds. In fact, NMR studies by Banci et al. [20] have shown that both pyridine and
imidazole can fit into the P450cam active site simultaneously. Furthermore, flurbiprofen
4’-hydroxylation, naproxen demethylation, and piroxicam 5’-hydroxylation Km values
were all decreased in the presence of dapsone (Tables 2.1 and 2.2), suggesting that
dapsone does not displace these compounds from the active site. An interesting
discovery which provides further evidence to the two-site hypothesis is the kinetic profile
of naproxen. In the absence of dapsone, naproxen exhibits a biphasic kinetic profile, as
shown by the Eadie-Hofstee plot in Figure 2.8, which suggests in itself that CYP2C9 may
have a low Km, low Vmax binding component, and a high Km, high Vmax binding
component. As a result, data were fit to a two-site biphasic equation instead of the
Michaelis-Menten equation. However, naproxen demethylation in the presence of 100
µM dapsone was best fit with the Michaelis-Menten equation (Table 2.2). The inset in
Figure 2.8 demonstrates that addition of 100 µM dapsone normalizes naproxen kinetics,
resulting in a linear Eadie-Hofstee plot and supporting a fit using the standard MichaelisMenten equation. This change in kinetic profile is most likely due to dapsone binding to
the high Km site when present in high concentrations, occupying that site such that only
one binding region of CYP2C9 is operable in naproxen metabolism. This idea is further
supported by the fact that although the Clint of the second binding site (Vmax2/Km2) did
not change, it did contribute to a lesser extent to the kinetic profile of naproxen in the
presence of dapsone (Table 2.2). Piroxicam metabolism is apparently also activated by
dapsone, which is interesting considering its structural differences and larger size as
compared to naproxen and flurbiprofen. It is worthy to note that piroxicam has been
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shown to exhibit substrate inhibition in microsomes and baculovirus-expressed CYP2C9
(unpublished data). However, this was not observed in the expression system used for
this study, confirming previous reports that many of these kinetic events are expression
system dependent [3].
Fitting of data from all three substrates to the two-site model (equation 2.3) was
done to estimate a single Km and Vmax, along with the effector binding constant (KB) and
α and β values. Results show α values (change in Km resulting from effector binding)
less than 1, and β values (change in Vmax resulting from effector binding) greater than 1
for all substrates (Table 2.3), suggesting that Km was reduced and Vmax increased in all
cases. It has been demonstrated previously that an α < 1 and/or a β > 1 is indicative of
activation [2]. It should be realized that the present two-site model equation assumes that
the kinetic profile for a substrate’s metabolism remains constant, which is not the case for
naproxen. However, a model reflecting this would be extremely complex and since no
model exists which takes this change into consideration, the results for naproxen must be
viewed in this context.
Another component that can be determined when using the two-site model is the
binding constant of dapsone. It is apparent from Table 2.3 that this constant varies
considerably depending on the substrate being activated, which argues for different
binding orientations in the active site or changes in binding efficiency. Other results
from this study show that the presence of flurbiprofen does not substantially influence the
formation of dapsone hydroxylamine, although conditions were optimized for
flurbiprofen hydroxylation, as activation conditions were desired. Close examination of
data points in Figure 2.6 indicates an inadequate estimation of Vmax, which may be the
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cause for minimal differences in Km estimates (81-144 µM). In addition, dapsone has
been shown previously to have a sigmoidal kinetic profile [2], suggesting two binding
regions for dapsone, one of which is cooperative. However, the sigmoidal portion of
dapsone’s kinetic profile was present at very low dapsone concentrations, so either not
enough low concentration data points were taken in this study to observe sigmoidal
kinetics or perhaps the presence of flurbiprofen normalized dapsone kinetics, resulting in
a hyperbolic profile. Nonetheless, Michaelis-Menten fits for dapsone hydroxylation in
the presence of flurbiprofen appear to be relatively superimposable, suggesting similar
kinetic parameters for each condition.
One factor which may affect activation is the presence of cytochrome b5 which
has been shown to affect the catalytic activity of certain P450 reactions [21]. However,
our results with baculovirus-expressed CYP2C9 show that activation of flurbiprofen 4’hydroxylation is not b5 dependent, as activation still occurs in the absence of cytochrome
b5 (data not shown). It is also possible that dapsone somehow affects the coupling of
NADPH-CYP reductase with CYP to increase catalytic activity of CYP2C9, as was
suggested by Shou et al. [1] with 7,8-benzoflavone and CYP3A4. Another potential
contributor to the activation mechanism may be the interaction with or displacement of
water molecules from the enzyme active site, thus affecting hydrogen bonding within the
active site. The exit of water molecules from the active site could possibly change the
conformation of the enzyme if the hydrogen bonds were in positions essential for
stabilizing the protein structure [3]. It is possible that one, all or even additional factors
are contributing to some degree to the activation mechanism of dapsone.
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Overall, evidence from this study suggests that dapsone activates the metabolism
of multiple substrates of CYP2C9 by binding within the active site in a region that causes
positive cooperativity. Thus, studies exploring the CYP2C9 active site will be important,
beginning with determining the effects of allelic variants and mutants of CYP2C9 on
dapsone activation, which may more conclusively prove that active site binding
interactions are of significance. With respect to CYP2C9, the *2 (R144C) and *3
(I359L) allelic variants and F114L mutant have been shown to variably affect the
metabolism of certain compounds [22;23], and thus are currently being studied to help
elucidate the mechanism of activation. Studies exploring analogs of dapsone to
determine structural requirements of activation will be reported in the next chapter.
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Figure 2.1. Structures of Three CYP2C9 Substrates
Structures of the three CYP2C9 substrates studied for activation by dapsone.
Arrows indicate site of metabolism.
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Table 2.1.5 Michaelis-Menten Parameter Estimates for Flurbiprofen and Piroxicam

4'-Hydroxyflurbiprofen (pmol/min/pmol P450)

Kinetic parameter estimates for flurbiprofen 4'-hydroxylation and piroxicam
5'-hydroxylation in the presence of dapsone. Data were fit to the Michaelis-Menten
model (equation 2.1).
(S)-Flurbiprofen
Piroxicam
Vmax (SE)
Km (SE)
Vmax (SE)
Dapsone Km (SE)
(pmol/min/pmol P450) (µM)
(pmol/min/pmol P450)
(µM)
(µM)
0
28.9 (4.2)
12.6 (0.5)
183 (56)
0.08 (0.01)
2
24.8 (4.2)
15.0 (0.7)
97.3 (14)
0.07 (0.003)
5
17.6 (2.9)
16.3 (0.8)
64.8 (10)
0.07 (0.002)
10
12.6 (1.2)
17.4 (0.4)
134 (35)
0.11 (0.01)
50
9.80 (1.1)
20.7 (0.6)
53.7 (5.6)
0.17 (0.004)
100
10.0 (1.8)
20.6 (1.0)
49.4 (2.0)
0.20 (0.002)

25
20
15
10
0 µM Dapsone
2 µM Dapsone

5

5 µM Dapsone
10 µM Dapsone
50 µM Dapsone

0

100 µM Dapsone

0

100
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300

(S)-Flurbiprofen (µM)

Figure 2.2. Michaelis-Menten Fits for Flurbiprofen 4’-Hydroxylation in Presence of
Dapsone.
Activation of Flurbiprofen 4’-Hydroxylation by Dapsone. Fits were to the MichaelisMenten Model (Equation 2.1), with parameter estimates shown in Table 2.1.
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5'-Hydroxypiroxicam (pmol/min/pmol P450)
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Figure 2.3. Michaelis-Menten Fits for Piroxicam 5’-Hydroxylation in Presence of
Dapsone.
Activation of Piroxicam 5’-Hydroxylation by Dapsone. Fits were to the MichaelisMenten Model (Equation 2.1), with parameter estimates shown in Table 2.1.
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Desmethylnaproxen (pmol/min/pmol P450)
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Figure 2.4. Biphasic Fits for Naproxen Demethylation in Presence of Dapsone.
Activation of Naproxen Demethylation by Dapsone. Fits were to a Biphasic Model
(Equation 2.2), with parameter estimates shown in Table 2.2. Notice the change in
kinetic profile from biphasic to Michaelis-Menten at 100 µM Dapsone.
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Table 2.2.6 Biphasic Kinetic Parameter Estimates for Naproxen
Kinetic parameter estimates for naproxen demethylation
in the presence of dapsone. Data were fit to a two-site biphasic
model (equation 2.2).
Vmax1 (SE)
Clint (SE)
Dapsone
Km1 (SE)
(pmol/min/pmol
(µM)
(µM)
(µl/min/pmolP450)
P450)
0
433 (252)
11.7 (4.3)
0.002 (0.002)
2
233 (73.5)
14.9 (2.4)
0.003 (0.001)
5
250 (92.4)
21.8 (4.0)
0.002 (0.002)
10
163 (30.8)
24.9 (2.0)
0.002 (0.001)
50
58.9 (18.0) 27.4 (2.7)
0.007 (0.002)
*100
67.4 (22.5) 34.7 (3.8)
0.002 (0.003)
Clint represents the linear portion of the biphasic curve (Vmax2/Km2).
*Also fit to Michaelis-Menten equation (Km=80.0 µM; Vmax=
37.0pmol/min/pmolP450)
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Table 2.3.7 Two Site Model Kinetic Parameter Estimates for Flurbiprofen,
Naproxen and Piroxicam
Kinetic parameter estimates for flurbiprofen hydroxylation, naproxen demethylation, and
piroxicam hydroxylation in the presence of dapsone. Data were fit to the two-site model
(equation 2.3).
Vmax (SE)
KB (SE)
Km (SE)
(pmol/min/pmol P450) (µM)
(µM)
α (SE)
β (SE)
(S)-Flurbiprofen 26.5 (3.4)
12.2 (0.5)
17.6 (3.6) 0.3 (0.06) 1.7 (0.1)
(S)-Naproxen
593 (128)
16.2 (1.6)
68.7 (23) 0.1 (0.04) 2.4 (0.3)
Piroxicam
110 (17.1) 0.06 (0.003)
164 (77) 0.2 (0.1) 4.0 (0.3)
Km is the Michaelis-Menten constant; Vmax is the maximal velocity; KB is the binding
constant for the effector; α is the change in Km resulting from effector binding; β is the
change in Vmax resulting from effector binding. An α or β value=1 indicates no change in
Km or Vmax, respectively.
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Figure 2.5. Dapsone Activation of Flurbiprofen 4’-Hydroxylation (3-D Plot)
Three-dimensional surface plot showing activation of flurbiprofen 4’hydroxylation by dapsone in expressed CYP2C9. The surface is the fit to equation 2.3.
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Figure 2.6. Dapsone Hydroxylation by CYP2C9
Two-dimensional plots demonstrating minimal change in dapsone hydroxylamine
formation in the presence of 2, 5 and 10 µM flurbiprofen. Kinetic parameters were
estimated using equation 2.1.
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Figure 2.7. Dapsone Activation of Naproxen Demethylation (3-D Plot)
Three-dimensional surface plot showing activation of naproxen O-demethylation by
dapsone in expressed CYP2C9. The surface is the fit to equation 2.3.
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Figure 2.9. Dapsone Activation of Piroxicam 5’-Hydroxylation (3-D Plot)
Three-dimensional surface plot showing activation of piroxicam 5’-hydroxylation by
dapsone in expressed CYP2C9. The surface is the fit to equation 2.3.
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CHAPTER III

Dapsone Activation of CYP2C9-Mediated Metabolism:
Structure Activity Relationships and Kinetics
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3.1. Introduction
Flurbiprofen is exclusively metabolized by CYP2C9 [1;2], and thus serves as a
useful probe for studying regulation of CYP2C9 activity. Dapsone has previously been
shown to activate CYP2C9-mediated flurbiprofen 4’-hydroxylation in human liver
microsomes and baculovirus-expressed CYP2C9 [3]. In addition, kinetic studies on the
activation of flurbiprofen 4’-hydroxylation, as well as naproxen demethylation and
piroxicam 5’-hydroxylation by dapsone have recently been reported [4]. Data from this
kinetic study were fit to a two-site effector model equation, showing an increase in Vmax
and decrease in Km for the metabolism of these substrates in the presence of dapsone,
suggesting the possibility of multiple binding regions within the CYP2C9 active site. In
addition, dapsone is metabolized by CYP2C9 at therapeutic concentrations to its
hydroxylamine metabolite [5;6]. Thus, dapsone is a substrate for the enzyme it activates,
further suggesting its presence in the active site during activation. This situation is
analogous to that observed with 7,8-benzoflavone, which activates CYP3A4-mediated
phenanthrene metabolism, in addition to being a substrate for CYP3A4 [7].
Many structure-activity relationship studies have been performed in describing
substrate and inhibitor interactions with CYP2C9 [8-10]. However, similar studies have
yet to be done for potential activators of CYP2C9. In a study exploring activation of
CYP3A4, a series of partial or modified structures of 7,8-benzoflavone were tested for
their ability to activate or inhibit the metabolism of phenanthrene, chrysene, and
benzo[a]pyrene in vitro [7] to determine the effector structural features necessary for the
activation of CYP3A4. We have conducted an analogous study for the activation of
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CYP2C9 by dapsone. We report data from a screen of 16 structural analogs of dapsone
incubated at a single concentration with flurbiprofen, naproxen, or piroxicam in human
liver microsomes. This was done in an attempt to determine effector structural
characteristics necessary for activation of CYP2C9. In addition, ten of these analogs
were selected, based on structure and results from the screening study, to perform kinetic
studies and determine the overall effects of varying the concentration of analog on the
metabolism of these model substrates, potentially gaining insight into the mechanism of
activation by dapsone.

3.2. Methods
Chemicals. Acetonitrile and dibasic potassium phosphate were obtained from
Fisher Scientific Co. (Pittsburgh, PA). (S)-Flurbiprofen, 4’-hydroxy flurbiprofen, and 2fluoro-4-biphenyl acetic acid (internal standard) were gifts from Pharmacia Corp.
(Kalamazoo, MI). Dapsone, sulfamethoxazole, sulfamethazine and ketoprofen were
purchased from Sigma Chemical Co. (St. Louis, MO) and all other dapsone analogs were
purchased from Aldrich Chemical Co. (Milwaukee, WI). All other chemicals were
obtained from commercial sources and were of the highest purity available.
Enzyme Preparations. Human liver tissue for preparation of microsomes was
obtained through the Liver Tissue Procurement and Distribution System. Based on chart
review, none of the patients from whom tissues were obtained was taking any
medications known to inhibit or induce the P450s. Microsomal samples were prepared
according to established methods [11]. Protein content was measured by the method of
Lowry et al. [12]and P450 content by the method of Omura and Sato [13].
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Human Liver Microsomal Incubation Conditions. Human liver microsomes (0.2
mg/ml final protein concentration, 1.0 mg/ml for piroxicam) were incubated in the
presence of 1 mM NADPH and 100 mM K2HPO4, pH 7.4, in a total volume of 200 µl to
screen for activation by dapsone analogs (Figure 3.1). These analogs were chosen based
on their structural similarity to dapsone, with modifications at various parts of the
molecule thought to potentially be important for enzyme interactions, e.g., replacement of
the amino group (dapsone) with methyl group (p-tolylsulfone). Reactions were carried
out for 20 minutes at 37°C with either 10 µM (S)-flurbiprofen, (S)-naproxen, or
piroxicam (45 minutes), and 10 µM dapsone or analog concentrations. Samples
containing flurbiprofen were quenched with 200 µl acetonitrile containing internal
standard (180 ng/ml 2-fluoro-4-biphenylacetic acid), while those containing naproxen
were quenched with 200 µl acetonitrile. Next, 40 µl ½-strength H3PO4 was added to
samples containing flurbiprofen or naproxen, followed by centrifugation at 10,000 rpm
for 5 minutes, and 10-50 µl was injected onto HPLC system. Samples containing
piroxicam were quenched by addition of 20 µl perchloric acid and immediately placed on
ice, followed by centrifugation at 10,000 rpm for 5 minutes, and 100 µl was injected onto
the HPLC system. Conditions for HPLC analysis of 4’-hydroxy flurbiprofen,
desmethylnaproxen, and 5’-hydroxy piroxicam were as described below. These reactions
were shown to be linear with respect to time and protein concentration.
Expressed CYP2C9 Incubation Conditions for Kinetic Studies. Ten dapsone
analogs were selected for full kinetic studies and included: dapsone, phenylsulfone, ptolylsulfone, 4-nitrophenylsulfonylaniline (4-NPSA), benzophenone, ketoprofen,
dicyclohexylketone, sulfadiazine, sulfamethoxazole, and sulfamethazine. Incubation
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mixtures in a 6X6 matrix design contained 1 pmol expressed CYP2C9 (5 pmol for
piroxicam) co-expressed with reductase (gift from Camitro Corporation, Menlo Park,
CA), with either (S)-flurbiprofen (2-300 µM), (S)-naproxen (10-1800 µM), or piroxicam
(5-900 µM) incubated with dapsone or dapsone analog (0-100 µM) in 50 mM potassium
phosphate buffer at pH 7.4. Dapsone and analogs were dissolved in DMSO and added to
0.2 mL incubations such that the final concentration of DMSO was less than 2.5%, and
reactions were initiated with 1 mM NADPH and allowed to incubate at 37°C for 20
minutes (45 minutes for piroxicam). Control incubations also contained 2.5% DMSO.
Samples were processed as stated above for microsomal incubation conditions.
Analysis of 4’-hydroxy flurbiprofen. 4’-Hydroxyflurbiprofen was analyzed by
HPLC with fluorescence detection. The HPLC system consisted of a Waters 501 HPLC
pump, a Waters 717 autosampler and a Waters 470 fluorescence detector set at an
excitation wavelength of 260 nm and an emission wavelength of 320 nm. The mobile
phase consisted of acetonitrile:20 mM K2HPO4, pH 3.0 (45:55, v/v) pumped at 1 ml/min
through a Brownlee Spheri-5 C18 4.6 x 100 mm column. 4’-Hydroxy flurbiprofen and
internal standard eluted at approximately 2.2 and 4.8 minutes, respectively.
Analysis of desmethylnaproxen. Desmethylnaproxen was analyzed identically to
4’-hydroxy flurbiprofen except that the fluorescence detector was set at an excitation
wavelength of 230 nm and an emission wavelength of 340 nm, and no internal standard
was used. Desmethylnaproxen eluted at approximately 2.1 minutes.
Analysis of 5’-hydroxy piroxicam. 5’-Hydroxy piroxicam was analyzed by HPLC
with UV detection (365 nm). The HPLC system was as described above, but was fitted
to a Waters 486 UV detector. The mobile phase consisted of 50:50 (v/v), acetonitrile:50
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mM K2HPO4, pH 3.0 pumped at 1 mL/min through a Phenomenex Luna C18 5 µm, 4.6 x
150 mm column. Retention time for 5’-hydroxy piroxicam was approximately 4.3
minutes.
Data Analysis and Equations. Kinetic data were fit to a two-site model [3] where
appropriate, allowing surface plot analysis and estimation of effector-related changes on
substrate Km and Vmax of flurbiprofen, naproxen, and piroxicam with the following
equation:
v=

V max• [S ]
 [B ] 

[B] 
1 +

1 +
KB 
αK B 
+ [S ] 
Km 
 β [B ]
 β [B ]
1 +

1 +

α
K
α
K


B 
B 

(3.1)

where S is substrate, B is effector, Vmax and Km are kinetic constants for substrate
metabolism, KB is the binding constant for the effector, α is the change in Km resulting
from effector binding, and β is the change in Vmax from effector binding. For activation,
α<1 and/or β>1. Percent activation/inhibition by dapsone analogs was calculated as the
mean ± S.D. from incubations run in triplicate. Flurbiprofen and piroxicam data that
exhibited little consistent change in presence of effector (resulting in negative or
unreasonable parameter estimates when fit to equation 1) were fit to the MichaelisMenten equation to estimate effector-related changes on metabolism:
v=

Vm • S
(3.2)
Km + S

Naproxen data, again exhibiting little consistent change, were fit to the following
biphasic kinetic equation to estimate effector-related changes on metabolism:
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(Vm1 • S ) + Cl int • S 2
v=
(3.3)
( Km1 + S )
where Clint is the intrinsic clearance, thought to be associated with a second binding
region within the active site, and represents the linear portion of the biphasic kinetic
curve.

3.3. Results
Dapsone Analogs. Dapsone has previously been shown to activate flurbiprofen
4’-hydroxylation in liver microsomes [3]. Thus, in the present screening study, dapsone
was included as a positive control and reference compound. Flurbiprofen 4’hydroxylation was activated in human liver microsomes ~1.6 fold by dapsone, ~1.4 fold
by phenylsulfone, and ~1.5 fold by p-tolylsulfone (Figure 3.2). All other analogs either
had no effect or were weak inhibitors. Similar results were obtained in preparations from
two other human livers (data not shown). Interestingly, only dapsone activated naproxen
demethylation (Figure 3.3), while most analogs were weak inhibitors. However,
diphenylcyclopropenone was a relatively strong inhibitor of naproxen demethylation
(~50%). In addition, the activation by dapsone was almost 3-fold, substantially more
than for flurbiprofen metabolism. For piroxicam hydroxylation, dapsone produced ~1.3fold activation, with phenylsulfone and p-tolylsulfone producing similar levels of
activation (Figure 3.4). It is interesting to note that these same analogs activated
flurbiprofen hydroxylation, albeit to differing degrees. Of the analogs screened, the
inhibitor 4-NPSA is perhaps the most interesting, considering its structural similarity to
dapsone, phenylsulfone, and p-tolylsulfone, all of which activated flurbiprofen and
piroxicam hydroxylation.
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Kinetic Studies. Analogs for full kinetic studies were selected based on their
different functional groups and spatial orientations compared to dapsone, as well as
results observed in the initial screen. Experimental data were fit to a two-site effector
model (equation 3.1) where appropriate. As has been previously shown (chapter 2), data
from dapsone activation of flurbiprofen hydroxylation fits well to this model (Figure 3.5),
with an α = 0.31, and a β = 1.73, indicating a decrease in Km and increase in Vmax,
respectively (Table 3.1). Similarly, phenylsulfone activated flurbiprofen 4’hydroxylation (Figure 3.6), with an α = 0.42, and a β = 2.80 (Table 3.1). Analogs for
which parameters were not estimated from equation 1 due to lack of consistent activation
with increasing concentration of effector, inhibition, or lack of effect on flurbiprofen 4’hydroxylation included p-tolylsulfone, benzophenone, ketoprofen, dicyclohexylketone,
sulfamethoxazole, sulfadiazine, and sulfamethazine. 4-NPSA, which contains a nitro
group in the place of an amino group, acts as a good inhibitor of flurbiprofen
hydroxylation (Table 3.2), with Dixon plot analysis suggesting a Ki of approximately 40
µM (Figure 3.7).
With regard to activation of naproxen demethylation, a good fit to the two-site
effector model (equation 3.1) in the presence of dapsone was observed (Figure 3.8), with
an α = 0.09 and β = 2.40 (Table 3.1), indicating a substantially greater decrease in Km
and increase in Vmax (activation) compared to flurbiprofen. Similar to analog screening
data, no other analog produced activation comparable to dapsone, although both ptolylsulfone and sulfamethazine activated at high concentrations (Figures 3.9 and 3.10),
with an increase in Vmax noted in the presence of effector (Table 3.3). Interestingly, both
phenylsulfone and 4-NPSA inhibited naproxen demethylation (Figures 3.11 and 3.12),
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with kinetic parameters shown in Tables 3.4 and 3.5, respectively. Inhibition by 4-NPSA
was pronounced only at high concentrations. Analogs for which parameters were not
estimated included benzophenone, ketoprofen, dicyclohexylketone, sulfadiazine, and
sulfamethoxazole, as no measurable effect was observed at any concentration. Table 3.1
also shows the kinetic parameters for activation of the metabolism of piroxicam, a
structurally distinct CYP2C9 substrate. Similar to flurbiprofen, piroxicam 5’hydroxylation in the presence of dapsone (Figure 3.13) and phenylsulfone (Figure 3.14)
gave α and β parameter estimates indicative of activation (Table 3.1), while
benzophenone activated at high concentrations (Figure 3.15), with an increase in both
Vmax and Km (Table 3.6). Interestingly, 4-NPSA completely inhibited formation of 5’hydroxy piroxicam. All other analogs had minimal effects on piroxicam 5’hydroxylation.

3.4. Discussion
It has previously been observed that CYP2C9 displays atypical kinetics, as
evidenced by dapsone activation of CYP2C9-mediated flurbiprofen 4’-hydroxylation [3].
In addition, the kinetic effects of this activation on the metabolism of three prototypical
CYP2C9 substrates (flurbiprofen, naproxen, and piroxicam) have been reported [4]. To
gain insight into activation by dapsone, sixteen analogs of dapsone were studied with
these same three substrates to determine structural requirements for activation of
CYP2C9-mediated metabolism. Additionally, ten of these analogs were selected for
kinetic studies to determine the effect of varying the concentrations of effector on
CYP2C9 activity. Screening results suggest that the level of activation is substrate
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dependent, and that a sulfone moiety between two benzene rings is necessary for
activation of CYP2C9. Activation of naproxen demethylation appears to be the most
restrictive, as only dapsone was able to consistently activate this metabolic event.
Kinetic studies produced similar results, although certain analogs exhibited effects at high
concentrations.
In terms of atypical kinetic behavior, CYP3A4 has been the most studied isoform.
Several studies have shown that purified CYP3A4 enzymes are directly activated by 7,8benzoflavone [7;14]. This is particularly interesting since 7,8-benzoflavone is a substrate
for the enzyme that it activates, analogous to dapsone and CYP2C9 [3;4], suggesting
similar activation characteristics between these isoforms. In addition, Shou et al. have
explored the structural requirements for activation of CYP3A4 by studying the effects of
structural analogs of 7,8-benzoflavone on CYP3A4 activity [7]. To this end, similar
studies have been performed for CYP2C9. Experimental data from dapsone analogs
suggest that some very strict structural constraints are necessary for activation of
CYP2C9, as dapsone, phenylsulfone, and p-tolylsulfone activated flurbiprofen and
piroxicam metabolism (Figures 3.2 and 3.4, respectively), while only dapsone activated
naproxen demethylation (Figure 3.3). The common functional group within these
activators is a sulfone group directly between two benzene rings. Replacement of this
sulfone with a carbonyl (benzophenone), sulfide (diphenylsulfide), sulfoxide
(diphenylsulfoxide), or sulfilimine (diphenylsulfilimine) functional group resulted in
elimination of activation properties, suggesting that the sulfone group directly between
two benzene rings is vital for binding to an effector site region that results in positive
cooperativity (activation) of CYP2C9. In fact, some analogs were inhibitors of CYP2C9-
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mediated metabolism. Interestingly, if one of the terminal amino groups on dapsone is
replaced by a nitro (4-NPSA), then the analog becomes an inhibitor, whereas replacement
of both terminal amino groups by two methyl groups (p-tolylsulfone) or left vacant
(phenylsulfone) had little effect on the ability to activate flurbiprofen and piroxicam.
With respect to naproxen, only dapsone activated its demethylation, with a substantially
higher degree of activation than either flurbiprofen or piroxicam hydroxylation. This
suggests even greater effector structural requirements for activation of naproxen
metabolism. It is hypothesized that naproxen may have a different binding orientation
than either flurbiprofen or piroxicam, resulting in slightly different requirements for
activation of its metabolism. In addition, other analogs with two benzene rings, two
cyclohexyl groups or the sulfone moiety in a different spatial arrangement (sulfonamide
analogs) generally resulted in inhibition, further arguing for the direct association of a
sulfone group with two benzene rings for activation.
Analogs for kinetic studies were selected based on results from screening data, in
addition to selection based on variety of functional group composition. Kinetic data
generally agreed with the analog screening data, with activation by dapsone noted for all
three reporter substrates. In addition, data for phenylsulfone activation of flurbiprofen
and piroxicam metabolism fit well to the two-site effector model, while no other analog
substantially activated naproxen demethylation. However, for some analogs, activation
was observed at higher effector concentrations (Figures 3.9, 3.10, and 3.15), signifying a
lower affinity of the “effector site” for some analogs. Of these, benzophenone activation
of piroxicam 5’-hydroxylation at high concentrations (Figure 3.15) was the most
intriguing, considering it was the only analog without a sulfone group that caused any
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type of activation. The absence of the sulfone group may have been responsible for the
lowered affinity for benzophenone, resulting in no effect at low concentrations. In
addition, there were examples in which increasing concentrations of effector had variable
effects on the substrate’s metabolism (i.e. initial increase then a decrease in metabolism,
or vice versa). This concentration dependent observation, which resulted in an inability
to fit data to the two-site effector model (equation 3.1), has been noted by other groups,
as well. Wang et al. observed that low concentrations of midazolam slightly activated
terfenadine metabolism in human liver microsomes, but inhibited this pathway at higher
concentrations [15]. The possibility should also be mentioned that some of the analogs
may elicit their effects by other means than binding to the effector site, contributing to
this variability. An example in which the screening and kinetic data did not coincide
included the effect of p-tolylsulfone on flurbiprofen 4’-hydroxylation, as well as on
naproxen demethylation. Screening data at a single concentration suggested that this
analog activated flurbiprofen 4’-hydroxylation (Figure 3.2), and had no effect on
naproxen demethylation (Figure 3.3). Meanwhile, kinetic data obtained using multiple
substrate and effector concentrations suggested minimal changes in flurbiprofen 4’hydroxylation (data not shown), while naproxen demethylation was activated at high
concentrations of p-tolylsulfone (Figure3.9). It is possible that some of this incongruency
may be due to the different source of enzyme used for the two studies (human liver
microsomes vs. expressed CYP2C9 microsomes). In addition, kinetic studies suggest
that phenylsulfone acts as an inhibitor of naproxen demethylation, eventually changing
the kinetic profile from biphasic to hyperbolic at 100 µM (Figure 3.11), while it clearly
activates both flurbiprofen and piroxicam hydroxylation (Figures 3.6 and 3.14). The

67

observed change in naproxen kinetic profile from biphasic to hyperbolic in the presence
of phenylsulfone is similar to that observed for dapsone (chapter 2), only inhibition is the
end result instead of activation. A clear explanation for this is not altogether apparent at
this time. It is possible that naproxen binds in a different orientation than either
flurbiprofen or piroxicam, resulting in the difference in observed effects. In fact,
naproxen has been shown to display biphasic kinetics [3;4;16], suggesting multiple
binding orientations for itself, which may contribute to this difference.
One of the most intriguing analogs is 4-NPSA, which inhibited both flurbiprofen
(Ki ~ 40 µM) and naproxen (Ki not estimated due to biphasic nature) metabolism, while
completely eliminating piroxicam hydroxylase activity. The similarities in structure of 4NPSA to dapsone, and yet the substantial differences in effect on CYP2C9-mediated
metabolism are striking. Possible explanations for these observations include steric and
electronic effects of the nitro group compared to the amino group. Many studies have
suggested that the active site of CYP2C9 has positive residues which interact with
negatively charged groups on substrates [17-20]. Perhaps some type of electrostatic
interaction between the nitro group of 4-NPSA and one of these active site residues may
orient it in such a way as to cause inhibition rather than activation. Dixon plot analysis
for flurbiprofen hydroxylation suggests that 4-NPSA is acting in a noncompetitive
manner, for which binding of substrate and inhibitor is not mutually exclusive. Another
interesting observation is that of the effect of p-tolylsulfone and sulfamethazine at high
concentrations on naproxen demethylation, showing a minimal effect on Km but a rather
substantial effect on Vmax (Table 3.3). A similar effect on piroxicam 5’-hydroxylation
was observed at high concentrations of benzophenone (Table 3.6). Reasons for the direct
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effect on Vmax, with minimal effect on Km could be numerous. One possibility may be
alteration of uncoupling mechanisms by the effector, most notably a decrease in
hydrogen peroxide release due to exclusion of water molecules from the active site by the
effector, resulting in enhanced catalytic activity [21]. Another possibility may be that the
effector enhances the interaction of CYP450 with cytochrome b5, which has been shown
to decrease uncoupling to hydrogen peroxide formation, thereby increasing the
concentration of active oxygen species for catalysis [22].
Overall, analog results for activation of CY2C9 suggest that specific activatorprotein interactions may be involved in the recognition and binding of effector, as even
small deviations from the core structure of dapsone resulted in variable effects or
inhibition. Results from this study do not conclusively establish whether the effector site
lies within or separate from the active site. Although the location of the effector site has
not been conclusively proven, many models have been proposed. Ueng et al. [23] have
described a model suggesting that an allosteric site is involved in the cooperativity of
certain CYP3A4 reactions, but the proximity of this site is not defined. Harlow and
Halpert suggest that effector binding is most likely in the active site along with the
substrate, as they were able to create an active site double mutant of CYP3A4 that
reduced positive cooperativity in the presence of 7,8-benzoflavone[24]. Another model
proposed by Shou and Korzekwa suggests that both substrate and effector are bound in
the active site simultaneously, each having a distinctive binding region and access to the
reactive oxygen [3;7]. Recently, it was reported that this two-site binding model applies
to CYP2C9 [4]. However, the most appropriate model may be dependent on the substrate
and effector in question. In addition, there is the possibility of conformational changes
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due to binding of effector, for which these models can not predict. Therefore, one of the
most reasonable explanations for the cause of atypical kinetics is one in which the
multiple binding-site model and a conformationally based model are combined, as
suggested by Atkins et al. [25]. Regardless of the most appropriate model, kinetic data
from previous studies suggest that the effector site for CYP2C9 is within the active site
[4]. Therefore, it is important to more fully characterize critical active site binding
regions and residues that may be involved in binding of dapsone and/or some of its
analogs. He et al. have suggested that the CYP2C9 active site has two regions that bind
electronegative groups, one of which may be the sulfone group of dapsone [19]. In
addition, the positive arginine residues at positions 97 and 105 have been shown to be
important in the catalytic function of CYP2C9 [20]. It would be interesting to mutate
these to neutral residues and observe if there is any effect on activation by dapsone. In
similar studies, Domanski et al. selected certain residues to mutate based on sequence
alignments of CYP3A4 with bacterial enzymes, and have been able to demonstrate which
residues are most likely involved in 7,8-benzoflavone activation of steroid hydroxylation
[26;27]. This group concluded that progesterone and 7,8-benzoflavone bind at separate
locations within the CYP3A4 active site, even though they both appear to have equal
access to the reactive oxygen. A reasonable starting point for CYP2C9 would be to
determine the effects of allelic variants and mutants of CYP2C9 on activation, which may
more conclusively prove that active site binding interactions are of substantial
importance. The *2 and *3 allelic variants and F114L mutant have been shown to
variably affect the metabolism of certain compounds [28;29], suggesting similar
characteristics as those observed with mutants of CYP3A4. More specifically, the *2
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allele change shows evidence of affecting the interaction of the P450 with oxidoreductase
[30], which would affect electron flow and perhaps the activation process. Studies
exploring the critical residues of CYP2C9 involved in binding of various substrates and
activation by dapsone have been performed and will be reported in the next chapter.
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metabolism.
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Figure 3.2.11 Screen of Dapsone Analog Effect on Flurbiprofen 4’-Hydroxylation
Activation/inhibition of flurbiprofen 4’-hydroxylation by dapsone and analogs.
Incubations were performed in triplicate with 10 µM flurbiprofen and 10 µM effector
(dapsone or analog).
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Figure 3.3.12 Screen of Dapsone Analog Effect on Naproxen Demethylation
Activation/inhibition of naproxen demethylation by dapsone and analogs. Incubations
were performed in triplicate with 10 µM flurbiprofen and 10 µM effector (dapsone or
analog).
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Figure 3.4.13 Screen of Dapsone Analog Effect on Piroxicam 5’-Hydroxylation
Activation/inhibition of piroxicam 5’-hydroxylation by dapsone and analogs. Incubations
were performed in triplicate with 10 µM flurbiprofen and 10 µM effector (dapsone or
analog).
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Table 3.1.8 Two-Site Kinetic Parameter Estimates for Dapsone and Analogs
Kinetic parameters (SE) derived from two-site effector model (equation 3.1) for
activation of CYP2C9-mediated metabolism.
Flurbiprofen 4’-hydroxylation
Analog
Vmax
O
S

H2N

O

Km

KB

α

β

R2

12.2
(0.6)

26.5
(3.4)

17.6
(3.6)

0.31
(0.06)

1.73
(0.09)

0.99

6.5
(0.6)

26.0
(6.1)

113.3
(98.7)

0.42
(0.28)

2.80
(0.44)

0.95

NH2

Dapsone
O
S
O

Phenylsulfone

Naproxen Demethylation

16.2
(1.6)

O
S

H2N

O

593.4
(128.2)

68.7
(22.7)

0.09
(0.03)

2.40
(0.26)

0.99

NH2

Dapsone

Piroxicam 5’-hydroxylation
O
S

H2N

O

Dapsone

O
S
O

0.07
(0.01)

22.6
(10.5)

76.5
(73.4)

0.45
(0.45)

5.92
(0.94)

0.94

0.08
(0.005)

31.3
(6.1)

299.2
(298.9)

0.18
(0.17)

4.41
(0.38)

0.98

NH2

Phenylsulfone

Vmax is in pmol/min/pmol P450; Km and KB are in µM
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Figure 3.5.14 Dapsone Activation of Flurbiprofen 4’-hydroxylation (3-D Plot)
Three-dimensional surface plot showing activation of flurbiprofen 4’-hydroxylation by
dapsone. The surface is the fit to equation 3.1, and is the same as seen in chapter 2.
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Figure 3.6.15 Phenylsulfone Activation of Flurbiprofen 4’-Hydroxylation (3-D Plot)
Three-dimensional surface plot showing activation of flurbiprofen 4’-hydroxylation by
phenylsulfone. The surface is the fit to equation 3.1.
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Figure 3.7.16 4-NPSA Inhibition of Flurbiprofen 4’ Hydroxylation (Dixon Plot)
Dixon plot suggestive of noncompetitive inhibition of flurbiprofen 4’-hydroxylation by 4NPSA, with a Ki ~ 40 µM.

Table 3.2.9 4-NPSA Inhibition of Flurbiprofen 4’ Hydroxylation
Kinetic parameters (SE) for flurbiprofen 4’-hydroxylation estimated from MichaelisMenten equation (equation 3.2) in presence of 4-NPSA.
O

0µM

2µM

5µM

10µM

50µM

100µM

Vmax

9.0 (0.7)

8.3 (0.4)

7.6 (0.3)

7.4 (0.6)

5.3 (0.3)

3.0 (0.3)

Km

31.0 (8.0) 23.0 (4.0) 19.8 (2.6) 39.0 (10.6)

27.8 (5.4)

28.8 (8.7)

O2N

S
O

4-NPSA
NH2

Vmax=pmol/min/pmol P450; Km=µM
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Figure 3.8.17 Dapsone Activation of Naproxen Demethylation (3-D Plot)
Three-dimensional surface plot showing activation of naproxen demethylation by
dapsone. The surface is the fit to equation 3.1, and is the same as seen in chapter 2.
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Figure 3.9.18 Activation of Naproxen Demethylation by p-Tolylsulfone
Activation of naproxen demethylation at high concentrations of p-tolylsulfone. Fits were
to a biphasic kinetic equation (equation 3.3). Notice the change toward a more
hyperbolic function in the presence of 100 µM p-tolylsulfone.
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Figure 3.10.19 Activation of Naproxen Demethlyation by Sulfamethazine
Activation of naproxen demethylation at high concentrations of
sulfamethazine. Fits were to a biphasic kinetic equation (equation 3.3).
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Table 3.3.10 Activation of Naproxen Demethylation by p-Tolysulfone and
Sulfamethazine
Kinetic parameters (SE) for naproxen demethylation
estimated from biphasic kinetic equation (equation 3.3) showing
activation by p-tolylsulfone and sulfamethazine at 50 and 100µM.
O
S

H3C

0µM

50µM

100µM

2.8 (0.6)
45.7 (26.5)
0.01 (.0003)

19.2 (4.1)
130.5 (70.8)
0.003 (.002)

21.8 (4.4)
67.0 (54.0)
0.003 (.003)

0µM

50µM

100µM

7.9 (0.4)
208.6 (22.9)
0.003 (.0002)

8.1 (0.4)
155.7 (15.5)
0.004 (.0002)

11.1 (0.9)
233.8 (44.1)
0.002 (.0004)

O

p-Tolylsulfone
CH3

Vmax 1
Km1
Clint
CH3
N
H3C

N

O
N
H

S
O

Sulfamethazine

Vmax 1
Km1
Clint

NH2

Vmax1=pmol/min/pmol P450; Km1=µM; Clint=Vmax2/Km2
(µl/min/pmol P450)
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Figure 3.11.20 Inhibition of Naproxen Demethylation by Phenylsulfone
Biphasic kinetic plots showing inhibition of naproxen demethylation
by phenylsulfone. Fits were to a biphasic kinetic equation (equation 3.3). Note the
change in profile to hyperbolic function in presence of 100 µM phenylsulfone.

Table 3.4.11 Inhibition of Naproxen Demethylation by Phenylsulfone
Kinetic parameters (SE) for naproxen demethylation estimated from biphasic kinetic
equation (equation 3.3) showing inhibition by phenylsulfone.
O
S

0µM

2µM

5µM

10µM

50µM

100µM

4.9 (1.7)

3.8 (0.1)

2.8 (0.6)

3.2 (1.4)

1.9 (0.1)

2.2 (0.3)

140.5 (93.4)

52.4 (5.3)

34.2 (25.3)

53.7 (70.1)

3.7 (1.6)

2.3 (3.1)

O

Phenylsulfone

Vmax 1
Km1
Clint

0.008
0.005
0.004
0.003
0.002
0.001
(.0006)
(.0001)
(.0004)
(.001)
(.0001)
(.0003)
Vmax1=pmol/min/pmol P450; Km1=µM; Clint=Vmax2/Km2 (µl/min/pmol P450)
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Figure 3.12.21 Inhibition of Naproxen Demethylation by 4-NPSA
Biphasic kinetic plots showing inhibition of naproxen demethylation
by 4-NPSA, particularly at 100 µM. Fits were to a biphasic kinetic equation
(equation 3.3).

Table 3.5.12 Inhibition of Naproxen Demethlyation by 4-NPSA
Kinetic parameters (SE) for naproxen demethylation
estimated from biphasic kinetic equation (equation 3.3) showing
inhibition by 4-NPSA, most notably at 100µM.
O

0µM

S

O2N

10µM

100µM

O

4-NPSA
NH2

Vmax 1
Km1
Clint

15.9 (7.1)
11.2 (4.4)
695 (427.6) 586 (320.6)
0.002 (.002) 0.003 (.001)

1.4 (0.2)
124.3 (40.2)
0.001 (.0001)

Vmax1=pmol/min/pmol P450; Km1=µM; Clint=Vmax2/Km2
(µl/min/pmol P450)
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Figure 3.13.22 Dapsone Activation of Piroxicam 5’-Hydroxylation (3-D Plot)
Three-dimensional surface plot showing activation of piroxicam
5’-hydroxylation by dapsone. The surface is the fit to equation 3.1 and is the same as
seen in chapter 2.
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Figure 3.14.23 Phenylsulfone Activation of Piroxicam 5’-Hydroxylation (3-D Plot)
Three-dimensional surface plot showing activation of piroxicam 5’-hydroxylation by
phenylsulfone. The surface is the fit to equation 3.1.
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Figure 3.15.24 Activation of Piroxicam 5’-Hydroxylation by Benzophenone
Michaelis-Menten plots showing activation of piroxicam 5’-hydroxylation
by benzophenone at 50 and 100 µM. Fits were to the Michaelis-Menten equation
(equation 3.2).
Table 3.6.13 Activation of Piroxicam 5’-Hydroxylation by Benzophenone
Kinetic parameters for piroxicam 5’-hydroxylation
estimated by Michaelis-Menten equation (equation 3.2) showing
activation by benzophenone at 50 and 100 µM.
O

0µM

50µM

100µM

0.1 (.005)
74.8 (13.8)

0.17 (.005)
85.5 (9.3)

0.21 (.01)
121.5 (19.1)

Benzophenone

Vmax
Km

Vmax=pmol/min/pmol P450; Km=µM
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CHAPTER IV

Dapsone Activation of CYP2C9 Allelic Variants
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4.1. Introduction
Many studies have suggested that certain CYP450 enzymes may behave in a non
Michaelis-Menten or atypical fashion [1-3]. Our lab has demonstrated previously that
dapsone activates CYP2C9-mediated flurbiprofen 4’-hydroxylation in microsomes and
purified enzyme [2]. More recently, we have described the kinetic effects of dapsone
activation of flurbiprofen metabolism, as well as effector structural requirements for this
activation. In these studies, data supported a two-site model, which suggested that
dapsone and flurbiprofen bind to distinctive regions within the active site simultaneously,
each having access to the active oxygen, and thus being metabolized. Therefore, it is
hypothesized that binding interactions within the active site are of prime importance to
the CYP2C9 activation mechanism, which has yet to be fully characterized.
Allelic variants of CYP2C9 (*2 (R144C) and *3 (I359L)) along with the F114L
mutant have been shown to variably affect the metabolism of certain compounds [4-8].
These differences in metabolism likely result from these residues being in a position
important for either substrate binding, protein conformation, or perhaps electron flow to
the P450, and thus may be an important factor in the activation mechanism. The purpose
of the current study was to determine the effects of dapsone on the metabolism of the
CYP2C9 substrates (S)-flurbiprofen [9;10], (S)-naproxen [11;12], and piroxicam [13]
when incubated with wild-type CYP2C9, allelic variants of CYP2C9, or the F114L
mutant. Wang et al. [14] suggested that in vitro drug-drug interaction patterns with
CYP3A4 are substrate dependent, giving credence to analogous studies with CYP2C9.
These three substrates potentially have different binding orientations in the CYP2C9
active site, perhaps resulting in differences in the ability to be metabolically activated. In
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addition, effects of dapsone on flurbiprofen kinetics in allelic variants and the F114L
mutant were measured to better understand the CYP2C9 enzyme structural requirements
necessary for activation.
By observing the effects of these variants and mutant on dapsone activation of
various CYP2C9 substrates, insight may be gained into the active site interactions
necessary for activation with respect to each substrate, providing us with mechanistic
details for dapsone activation of CYP2C9.

4.2. Methods
Chemicals. Acetonitrile and dibasic potassium phosphate were obtained from
Fisher Scientific Co. (Pittsburgh, PA). (S)-flurbiprofen, 4’-hydroxyflurbiprofen, and 2fluoro-4-biphenylacetic acid (internal standard) were gifts from Pharmacia Corp.
(Kalamazoo, MI). (S)-naproxen and desmethylnaproxen were gifts from Syntex
Laboratories Inc. (Palo Alto, CA). Piroxicam and dapsone were purchased from Sigma
Chemical Co. (St. Louis, MO), and 5’-hydroxy piroxicam was a gift from Pfizer Inc.
(Groton, CT.). CYP2C9 allelic variant and F114L mutant enzymes were provided by Dr.
Allan Rettie of University of Washington. All other chemicals were obtained from
commercial sources and were of the highest purity available.
Enzyme Preparation. Baculovirus-mediated CYP2C9 expression and purification
from insect cells were carried out by growth and passage of Trichopulsia ni (Gibco BRL)
cells using the HyQCCM-3 medium (HyClone Laboratories). Cotransfection of T. ni
cells with Bsu361-digested BacPAK6 viral DNA and the appropriate CYP2C9 mutant
transfer vector was carried out with the reagents and procedures provided by Clontech
Laboratories, Inc. for construction and amplification of recombinant viral stocks. Cells
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were pelleted 2-3 days postinfection, resuspended, washed once in glycerol-containing
buffer (100 mM potassium-phosphate, 20% glycerol, 0.33 mM DTT, and 1 mM EDTA
(pH 7.4)), repelleted, and stored at -80°C until further use. Cultures exhibiting
expression levels of 75 nmol/L were used for enzyme purification. Purification of
enzyme was achieved from detergent-solubilized T. ni cell pellets using sequential
chromotography on Octyl-Sepharose, DEAE-Sepharose, and ceramic hydroxyapatite to
specific contents in excess of 10 nmol of holoenzyme/mg of protein for each enzyme.
Purified CYP2C9 Enzyme Incubation Conditions. All purified P450 enzymes
were reconstituted with P450 reductase (PanVera, Madison, WI) and cytochrome b5
(PanVera, Madison, WI) in a 1:2:1 ratio with dilauroylphosphatidylcholine vesicles (10
µg) extruded through a 200 nm pore-sized membrane. The reconstituted enzymes were
incubated in the presence of either 10 µM (S)-flurbiprofen, (S)-naproxen, or piroxicam
with 10 µM dapsone in 50 mM potassium phosphate buffer, pH 7.4 in a final volume of
200 µL. Reactions were initiated by the addition of 1 mM NADPH and carried out for 20
minutes (piroxicam for 45 minutes) at 37°C. Kinetic studies involving (S)-flurbiprofen
and dapsone were performed as described above with (S)-flurbiprofen concentrations
ranging from 2-150 µM. Dapsone concentrations were 0, 2, and 5 µM. All reactions
were shown to be linear with respect to time and protein concentration.
Analysis of 4’-hydroxy flurbiprofen. 4’-Hydroxy flurbiprofen was analyzed by
HPLC with fluorescence detection. Samples were quenched with 200 µL of acetonitrile
containing 180 ng/mL of 2-fluoro-4-biphenylacetic acid (internal standard) and acidified
with 40 µL ½-strength phosphoric acid. Samples were then centrifuged at 10,000 rpm for
5 minutes and 10-50 µL injected onto the HPLC system. The HPLC system consisted of
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a Waters 501 HPLC pump, a Waters 717 autosampler and a Waters 470 fluorescence
detector set at an excitation wavelength of 260 nm and an emission wavelength of 320
nm. The mobile phase consisted of acetonitrile:20 mM K2HPO4, pH 3.0 (40:60) pumped
at 1 mL/min through a PE-Brownlee Spheri-5 C18 4.6 x 100 mm column. 4’-hydroxy
flurbiprofen and internal standard eluted at approximately 3.5 and 9.0 minutes,
respectively.
Analysis of desmethylnaproxen. Desmethylnaproxen was analyzed identically to
4’-hydroxy flurbiprofen except that the fluorescence detector was set at an excitation
wavelength of 230 nm and an emission wavelength of 340 nm, and no internal standard
was used. Desmethylnaproxen eluted at approximately 2.1 minutes.
Analysis of 5’-hydroxy piroxicam. 5’-Hydroxy piroxicam was analyzed by HPLC
with UV detection (365 nm). Samples were quenched with 20 µL of perchloric acid,
vortexed and placed on ice. Samples were then centrifuged at 10,000 rpm for 5 minutes
and 100 µL injected onto HPLC system. The HPLC system was as described above, but
was fitted to a Waters 486 UV detector. The mobile phase consisted of acetonitrile:50
mM K2HPO4, pH 3.0 (50:50) pumped at 1 mL/min through a Phenomenex Luna C18 5
µm, 4.6 x 150 mm column. Retention time for 5’-hydroxy piroxicam was approximately
4.3 minutes.
Data Analysis. Velocities were calculated as the mean of incubations done in
triplicate. Kinetic parameters were estimated following nonlinear regression using Sigma
Plot (Version 6.0).
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4.3. Results
Dapsone activation of flurbiprofen, naproxen, and piroxicam in CYP2C9
variants. Activation of flurbiprofen, naproxen, and piroxicam (Figure 4.1) metabolism
by dapsone was determined in purified CYP2C9*1 (wild-type), *2 (R144C) and *3
(I359L) variants, and F114L mutant by incubating each particular substrate at 10 µM
with 10 µM dapsone in triplicate. Flurbiprofen hydroxylation was activated about 2-fold
in the presence of dapsone for CYP2C9 wild-type, as well as *2 and *3 variants (Figure
4.2, A). However, in the F114L mutant, flurbiprofen was activated almost 5-fold (Figure
4.2, A). Naproxen demethylation (Figure 4.2, B), was activated by dapsone almost 6-fold
in the wild-type enzyme, substantially higher than observed for flurbiprofen. The *2
variant and F114L mutant displayed about the same level of activation as observed with
wild-type enzyme, while only 1.5-fold activation was observed in the *3 variant. Results
of piroxicam hydroxylation (Figure 4.2, C) demonstrate an approximately 2-fold
activation in the wild-type enzyme, with slightly higher activation in the *2 variant.
Activation in the *3 variant could not be determined due to low initial activity in the
absence of dapsone, although detectable activity was subsequently observed when
dapsone was added. Interestingly, no activation of piroxicam hydroxylation by dapsone
was noted in the F114L mutant even though the turnover of piroxicam by this mutant was
2-fold higher than observed with wild-type enzyme.
Flurbiprofen kinetic studies. To more completely assess this activation
phenomenon, kinetic studies were carried out to determine the effect of dapsone on
flurbiprofen 4’-hydroxylation in wild-type CYP2C9, its variants and the F114L mutant.
Kinetic parameter estimate results (Table 4.1) indicate that dapsone activates flurbiprofen
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4’-hydroxylation in all enzymes tested, increasing Vmax, while lowering Km. Twodimensional plots exhibiting this activation are presented in Figures 4.3-4.6, with inset
Lineweaver-Burke plots indicative of ternary complex formation, as oppose to the pingpong model. Only the Lineweaver-Burke plot for the *3 variant did not show ternary
complex formation. For wild-type CYP2C9, *2 variant, and F114L mutant, Vmax was
increased only slightly. However, Km values were substantially reduced with increasing
dapsone concentration. Conversely, the Vmax for flurbiprofen 4’-hydroxylation in the *3
variant almost doubled in the presence of 5 µM dapsone, although initial activity was
considerably lower. The most substantial effect on Km was observed with the F114L
mutant, where Km was reduced from 246 µM to 44 µM by dapsone co-incubation.

4.4. Discussion
The activation of CYP enzymes in vitro has been observed for virtually every
isoform involved in human drug metabolism. However, little is known about the effect
of this activation on substrate binding and in particular, the importance of various critical
amino acid residues. To this end, studies were undertaken to identify substrate
differences with regard to CYP2C9 activation as well as differences among the common
allelic variants of CYP2C9 and a mutant with a substitution made in a critical pi-stacking
binding region. In the current study, 10 µM dapsone activated flurbiprofen 4’hydroxylation about 1.5-fold in wild-type CYP2C9, with similar results observed in the
*2 and *3 variants, while almost 5-fold activation was observed in the F114L mutant.
Meanwhile, dapsone activation of naproxen demethylation in wild-type CYP2C9 was
almost 6-fold, substantially higher than observed for flurbiprofen, while the *2 variant
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and F114L mutant exhibited an approximately 5-fold activation. Interestingly, piroxicam
5’-hydroxylation activity in the F114L mutant was almost 2-fold higher than wild-type
CYP2C9 in the absence of dapsone. However, no activation was observed in the F114L
mutant despite this higher turnover rate, whereas the wild-type *2 and *3 variants all
exhibited 2-3-fold activation. Kinetic studies with dapsone and flurbiprofen
demonstrated that Km values for flurbiprofen were decreased in all recombinant CYP2C9
enzymes in the presence of dapsone, with the greatest effect observed for the F114L
mutant, while Vmax estimates generally increased. These results suggest that dapsone
binding results in positive cooperativity regarding binding interactions within the active
site.
Observations of non Michaelis-Menten or atypical CYP450 kinetics have
increased in the area of drug metabolism, with the CYP3A4 isoform being the most
studied [1;2;15;16]. Atypical kinetic events such as activation, autoactivation, and
substrate inhibition are now being observed in other relevant CYP450 isoforms,
suggesting that these observations may be common to all CYP450 isoforms to some
extent [2;3]. This in vitro phenomenon is particularly relevant because it makes
predicting in vivo pharmacokinetic behavior very complex [17]. Our lab has
demonstrated that CYP2C9-mediated flurbiprofen 4’-hydroxylation is activated by
dapsone in human liver microsomes, as well as purified CYP2C9 [2]. We have since
demonstrated the full kinetic effects of dapsone on flurbiprofen metabolism [18].
However, the exact mechanism for this activation remains to be defined, although it is
believed that dapsone and flurbiprofen are bound in the active site simultaneously, being
described by a two-site model describing activation [1;2]. Therefore, active site
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properties and binding interactions may be of substantial importance in the mechanism of
dapsone activation.
CYP2C9 is polymorphically expressed in humans, with the three major alleles
being referred to as CYP2C9*1 (wild-type), *2 (R144C), and *3 (I359L). These allelic
variants, along with an F114L mutant affecting the “pi-stacking” region of CYP2C9,
have been shown to variably affect the metabolism of certain substrates [4-8]. Studies
utilizing these variant enzymes have been instrumental in determining structure-function
relationships. Because of these allelic functional differences, it was hypothesized that
study of the variants and F114L mutant with various substrates and dapsone would
provide insight into binding characteristics and the activation phenomenon.
Within the CYP2C9 active site, it has been suggested that there are six substrate
recognition sites (SRS), which variably contribute to the recognition and binding of
substrates [19]. While it has been shown that position 144 is not in any known substrate
recognition sequence [19], Crespi and Miller [6] suggest that this residue plays an
important role in the interaction between CYP2C9 and oxidoreductase. However,
position 359 falls within SRS 5, and thus would be expected to affect binding of certain
substrates. The F114L mutant is also important in substrate recognition, as it lies within
SRS1, and is believed to play a critical role in pi-pi stacking interactions between certain
aromatic substrates and the active site of CYP2C9 [8]. Therefore, it is likely that these
variants and F114L mutant will have an affect on dapsone activation of CYP2C9.
Similar studies by Domanski et al. [20;21] have demonstrated the importance of specific
active site residues in the cooperativity of CYP3A4 by α-naphthoflavone. Additional
evidence through the use of a L211F/D214E double mutant in the analysis of CYP3A4
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cooperativity suggests that the effector site is part of the active site [22]. Thus, it is
possible that the CYP2C9 effector site is also present in the active site.
While we have shown that dapsone activates flurbiprofen metabolism in vitro, it
is important to determine how dapsone affects other CYP2C9 substrates. It has been
demonstrated with CYP3A4 that in vitro drug-drug interactions are substrate dependent
[14], and thus, similar observations may be noted with CYP2C9. Naproxen and
piroxicam have been shown to be O-demethylated and hydroxylated, respectively, by
CYP2C9 [11-13]. As a result, these compounds were chosen as prototypical substrates of
CYP2C9 in addition to flurbiprofen. Thus, by determining the effects of dapsone on
various substrates of CYP2C9 in allelic variant and mutant enzymes, the role of various
active site residues important to the mechanism of activation by dapsone was more fully
elucidated.
Experimental results indicate that position 114 in SRS1 is an important
determinant of CYP2C9 activation of flurbiprofen and piroxicam. Firstly, flurbiprofen
hydroxylation was activated almost 5-fold in the F114L mutant, compared to 1.5-fold
activation in wild-type. This suggests that without the phenylalanine residue and the
resulting lack of pi-stacking interaction in the active site, flurbiprofen can bind in a more
productive orientation (less restricted), resulting in enhanced flurbiprofen hydroxylase
activity. Alternatively, piroxicam metabolism was not activated in the F114L mutant. In
fact, activity was higher in the F114L mutant than wild-type CYP2C9 in the absence of
dapsone, suggesting that a pi-stacking interaction with the phenylalanine residue perhaps
limits maximal piroxicam metabolism. The results from naproxen are interesting in that
its metabolism was activated substantially more than either flurbiprofen or piroxicam,
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suggesting that naproxen may have a different binding orientation than the other CYP2C9
substrates. This is not completely unexpected since naproxen demethylation exhibits a
biphasic kinetic profile suggestive of homotropic cooperativity in and of itself [12]. In
addition, there was no substantial difference in the level of activation for the *2 variant
and F114L mutant when compared to wild-type, indicating that these residues are not
important determinants in the activation of naproxen. Conversely, the *2 variant did
seem to have a minor positive effect on the activation of piroxicam (3-fold activation),
compared to wild-type CYP2C9 (2-fold activation). However, the effect was opposite of
what would be expected if the theory of Crespi et al. [6] is followed, which argues that
the arginine at position 144 provides an important charge pair for the
P450/oxidoreductase interaction. Thus, a decrease in the degree of activation in this
variant with piroxicam would have been expected, due to reduced electron flow. This
argues that the R144C variant more likely alters piroxicam activation by having the less
bulky cysteine residue present in the active site, resulting in enhanced productive binding
by piroxicam.
Kinetic studies with dapsone and flurbiprofen support the theory that dapsone and
flurbiprofen have their own distinctive binding regions within the active site, as dapsone
lowered flurbiprofen Km in all enzymes (Table 4.1), thus increasing the affinity and not
displacing flurbiprofen from the active site. The greatest affect was observed by the
F114L mutant, where the Km for flurbiprofen hydroxylation decreased from 246 to 44
µM, additional evidence suggesting the importance of the pi-stacking region to the
activation of flurbiprofen. In a previous manuscript, we have measured both flurbiprofen
and dapsone metabolite in a single incubation [18], further supporting the presence of
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dapsone in the active site, and thus the two-site binding model. In addition, LineweaverBurke plots shown in figure 4.3-4.6 were indicative of ternary complex formation, except
for the *3 variant (Figure 4.5). Reasons for this may be the almost linear MichaelisMenten fits due to substantially lower activity. The ternary complex model is in
opposition to the ping pong model, which describes the release of one product at a time.
It appears likely then that dapsone binding within the CYP2C9 active site causes a
change in the active site conformation, resulting in a heterotropic positive cooperativity
that differentially affects CYP2C9 substrates, depending upon binding location in the
active site.
Overall, results suggest that the interactions important for activation most likely
take place in the active site, as the F114L mutant displayed enhanced activation for
flurbiprofen, while diminishing activation for piroxicam, and not affecting naproxen
activation. This, coupled with naproxen being activated substantially more than
flurbiprofen or piroxicam support the notion that the level of CYP2C9 activation by
dapsone is substrate dependent. These results provide additional evidence that dapsone
activation (positive cooperativity) occurs as a result of binding interactions within the
CYP2C9 active site, and not at an external allosteric site. Studies utilizing chimeric
2C9/19 and CYP2C19 mutant enzymes to more specifically determine important
regions/residues for binding of the prototypical CYP2C9 substrates, as well as spectral
binding studies for flurbiprofen in the absence/presence of dapsone are ongoing and will
be reported in the next chapter.
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Table 4.1.14 Activation of CYP2C9 Allelic Variant Enzymes by Dapsone
Kinetic parameters for formation of 4'-hydroxy flurbiprofen in absence and presence of
dapsone (Standard Error)
Vmax expressed as pmol/min/pmol P450, Km as µM
Treatment
2C9 WT
2C9*2
2C9*3
2C9
(R144C)
(I359L)
(F114L)
Vmax

0 Dapsone
2µM Dapsone
5µM Dapsone

13.2 (0.3)
14.5 (0.9)
13.0 (0.4)

3.3 (0.2)
3.7 (0.2)
3.5 (0.1)

0.46 (0.1)
0.59 (0.1)
0.78 (0.05)

5.8 (0.3)
5.1 (0.2)
5.9 (0.1)

Km

0 Dapsone
2µM Dapsone
5µM Dapsone

30.6 (1.8)
26.0 (4.6)
16.0 (1.5)

28.1 (4.8)
17.2 (2.9)
10.8 (1.1)

81.3 (19.9)
73.8 (22.7)
64.5 (8.1)

246 (21.1)
64.4 (4.7)
44.1 (1.5)
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Figure 4.1.25 Structures of Three CYP2C9 Substrates
Structures of the three CYP2C9 substrates studied for activation by dapsone. Arrows
indicate site of metabolism.
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Figure 4.2.26 Screen of Dapsone Activation of CYP2C9 Allelic Variants and F114L
Mutant
Activation of flurbiprofen 4’-hydroxylation (Panel A), naproxen demethylation (Panel
B), and piroxicam 5’-hydroxylation (Panel C) by 10 µM dapsone in CYP2C9 WT, *2
(R144C) and *3 (I359L) allelic variants, and F114L mutant. Flurbiprofen, naproxen and
piroxicam concentrations were also at 10 µM. Numbers in parentheses above shaded
bars indicate (-fold) activation by dapsone.
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Figure 4.3.27 Dapsone Activation of Flurbiprofen 4’-Hydroxylation in CYP2C9
Wild Type
Kinetic effects of 2 and 5 µM dapsone on flurbiprofen 4’-hydroxylation in purified
CYP2C9 wild-type enzyme. Inset shows Lineweaver-Burke plot displaying formation of
a ternary complex.
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Figure 4.4.28 Dapsone Activation of Flurbiprofen 4’-Hydroxylation in CYP2C9 *2
Kinetic effects of 2 and 5 µM dapsone on flurbiprofen 4’-hydroxylation in purified
CYP2C9*2 (R144C) variant. Inset shows Lineweaver-Burke plot displaying formation of
a ternary complex.
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Figure 4.5.29 Dapsone Activation of Flurbiprofen 4’-Hydroxylation in CYP2C9 *3
Kinetic effects of 2 and 5 µM dapsone on flurbiprofen 4’-hydroxylation in purified
CYP2C9*3 (I359L) variant. Inset shows Lineweaver-Burke plot displaying lack of
formation of a ternary complex.
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Figure 4.6.30 Dapsone Activation of Flurbiprofen 4’-Hydroxylation in F114L
Mutant
Kinetic effects of 2 and 5 µM dapsone on flurbiprofen 4’-hydroxylation in purified
CYP2C9 F114L mutant. Inset shows Lineweaver-Burke plot displaying formation of a
ternary complex.
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CHAPTER V

Additional Studies into the Mechanism of CYP2C9 Activation

107

5.1. Introduction
The cytochrome P450 superfamily of enzymes are the most important enzymes
responsible for metabolism of exogenous xenobiotic substrates. It has been found that
many of these substrates, particularly those metabolized by CYP3A4, display kinetic
profiles that are not consistent with the Michaelis-Menten model. In fact, it was initially
thought that CYP3A4 was the only major CYP isoform contributing to atypical kinetic
profiles. Other groups have since shown that other CYP isoforms can display atypical
kinetics as well [1-3]. Recently, our group has shown that dapsone, a compound used to
treat Pneumocystis carinii infections in AIDS patients, can activate the metabolism of a
number of CYP2C9 substrates, including flurbiprofen, naproxen, and piroxicam [4].
Kinetic evidence from this study supports our main hypothesis, which is that both
effector (dapsone) and the substrate may be present in the active site simultaneously, both
having access to the reactive oxygen. Studies have been conducted to determine the
structural requirements for this activation (chapter 3), as well as the effects of amino acid
mutations on the ability of dapsone to activate CYP2C9-mediated metabolism (chapter
4). However, evidence is still lacking for what regions or residues within the active site
are important in the catalysis of certain CYP2C9 substrates relative to one another within
the active site, and just how dapsone affects this binding and/or orientation of substrates.
It has been proposed that the CYP2C enzymes possess six substrate recognition
sites (SRSs) or regions that variably recognize and bind substrates [5]. One approach to
determining the important regions and residues within a given CYP for catalytic activity
is the use of chimeric and mutant enzymes. Human P450s CYP2C9 and CYP2C19 both
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metabolize a number of clinically relevant drugs. However, these isoforms have very
different substrate specificities despite differing in only 43 of 490 amino acids. For
example, CYP2C9 metabolizes many NSAIDs such as flurbiprofen [6;7], naproxen [8;9],
and ibuprofen [10], whereas CYP2C19 lacks substantial activity towards these substrates.
As a result, amino acid regions may be interchanged between these enzymes through
cloning techniques to determine which ones are vital to binding certain substrates or
inhibitors. For example, it has been shown that by replacing amino acids 227-338 (SRS 3
and 4) in CYP2C19 with the corresponding region of CYP2C9, a high-affinity enzyme
for binding of the CYP2C9 inhibitor sulfaphenazole was created [11]. In addition, it was
found that two amino acid substitutions in CYP2C19 (N286S, I289N), which are present
in SRS 4, also result in high-affinity sulfaphenazole binding [11]. This same technique
was utilized to determine binding regions important for catalytic activity towards
flurbiprofen, naproxen, and piroxicam, as well as activation of these chimeric and mutant
enzymes by dapsone.
Despite kinetic evidence suggesting the presence of dapsone in the active site
during activation of CYP2C9 [4], and literature suggesting that dapsone is also a
substrate for CYP2C9 [12], conclusive evidence for the mechanism of how dapsone
causes activation is still lacking. Examples of possible mechanisms are that dapsone
simply causes flurbiprofen to bind with higher affinity, or in a more productive
orientation due to steric or electronic constraints imposed upon the active site. A
technique often used to measure affinity for binding to CYP isoforms is difference visible
spectroscopy, or spectral binding studies. To date, spectral binding studies involving
CYP2C9 are few in number. However, spectral binding studies have been performed to
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determine structural requirements for sulfaphenazole inhibition of CYP2C9 [13;14], for
which it is a known potent, selective inhibitor [15] [16]. We have performed similar
studies with the goal of determining if the presence of dapsone directly affects the affinity
of CYP2C9 for binding of flurbiprofen, as kinetic evidence suggests [4].
In addition to dapsone affecting the binding affinity of substrates, it may also
affect the binding orientation of substrate within the active site. Ibuprofen is a chiral
substrate for CYP2C9, with both the (S)- and (R)-enantiomers being 2- and 3hydroxylated [10]. Having two major products from both enantiomers has allowed study
of the regiospecificity and enantioselectivity for activation of CYP2C9-mediated
ibuprofen metabolism. Similar studies have been performed with CYP3A4 by studying
the ratio of 1’- and 4-hydroxy triazolam formed from triazolam under different incubation
conditions [17]. Thus by observing a difference in the ratio of 2- and 3-hydroxy
ibuprofen formation, the effects of dapsone on the relative orientation of ibuprofen within
the active site will be studied in hopes of discovering additional evidence for the presence
of multiple binding regions within the CYP2C9 active site.
In addition to dapsone analog studies for activation of CYP2C9-mediated
flurbiprofen 4’-hydroxylation (chapter 3), it has been theorized that perhaps the major
metabolite of dapsone, hydroxy dapsone, could also be an activator of CYP2C9. To our
knowledge, this would represent the first example of a non-parent compound (metabolite)
activating CYP-mediated metabolism. Consequently, studies were performed to screen
the ability of hydroxy-dapsone to activate flurbiprofen, naproxen, and piroxicam
metabolism. Overall, this group of studies has been performed to gain an increased
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understanding of the binding characteristics and activation of CYP2C9-mediated
metabolism.

5.2. Methods
Chemicals. Acetonitrile and dibasic potassium phosphate were obtained from
Fisher Scientific Co. (Pittsburgh, PA). (S)-Flurbiprofen, 4’-hydroxy flurbiprofen, and 2fluoro-4-biphenyl acetic acid (internal standard) were gifts from Pharmacia Corp.
(Kalamazoo, MI). Dapsone was purchased from Sigma Chemical Co. (St. Louis, MO)
and hydroxy-dapsone was a gift from Reggie Frye at Pittsburgh University. All other
chemicals were obtained from commercial sources and were of the highest purity
available. CYP2C9/19 chimeric enzymes were constructed by Dr. Robert L. Haining and
provided to us by Dr. Allan E. Rettie at the University of Washington as described below.
CYP2C19 mutant enzymes were also provided by Dr. Allan E. Rettie at the University of
Washington and constructed as described below. CYP2C9 expressed microsomes were a
gift from Camitro Corp. (Menlo Park, CA).
Chimera construction. The plasmids pFB2C9 and pFB2C19 were used for all
DNA manipulations, taking advantage of the common, unique, and naturally occurring
restriction-endonuclease sites SmaI (at the codon specifying amino acid 228), PstI (291292), and SphI (340) within each cDNA. Standard techniques were used for the
digestion, analysis, isolation, and subsequent re-ligation of subcloned DNA fragments.
Insertions were confirmed by restriction mapping and the complete re-sequencing of each
newly created cDNA. Reconstructed plasmids (pFB2C9/19 [340-490], pFB2C19/9 [340490], pFB2C19/9 [228-292], pFB2C9/19 [228-292], pFB2C9/19 [228-340]) were used
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directly in the creation of recombinant baculovirus DNA by the Bac-to-BacTM method
(Life Technologies). Recombinant ‘bacmid’ DNA was then used to transfect T.ni cells,
resulting in a long-term viral stock for subsequent amplification and infection of T.ni
expression cultures. All five purified chimeric proteins provided typical P450 spectra
with little or no evidence of P420 formation upon treatment with carbon monoxide and
sodium dithionite.
Chimera incubation conditions. Chimeric P450 enzymes were reconstituted with
P450 reductase and cytochrome b5 in a 1:2:1 ratio (5 pmol P450: 10 pmol reductase: 5
pmol b5 per incubation) with dilauroylphosphatidylcholine vesicles (10 µg) extruded
through a 200 nm filter. The reconstituted enzymes were incubated in the presence of
300 µM (S)-flurbiprofen, (S)-naproxen, or piroxicam and 50 mM potassium phosphate
buffer, pH 7.4 in a total volume of 200 µL (in triplicate). Reactions were initiated by the
addition of 1mM NADPH and carried out for 20 minutes (45 minutes for piroxicam) at
37°C. Incubations with flurbiprofen were quenched by adding 200 µl acetonitrile
containing internal standard (180 ng/mL 2-fluoro-4-biphenylacetic acid), followed by
addition of 40 µl ½-strength H3PO4. Incubations with naproxen were quenched by
adding 200 µl acetonitrile followed by addition of 40 µl ½-strength H3PO4, while
piroxicam reactions were quenched by adding 20 µl perchloric acid, followed by directly
placing incubation tubes on ice. Samples from all incubations were then centrifuged at
10,000 rpm for 5 minutes, placed into autosampler vials, and 10-100 µl injected onto
HPLC system. Incubations examining dapsone (20 µM) activation of chimeras
exhibiting flurbiprofen hydroxylase activity were carried out as described above with 300
µM (S)-flurbiprofen.
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CYP2C19 mutant enzymes. CYP2C19 mutant enzymes are labeled as 2C19 KS,
KSN, KSEN, KN, and SN(2). Amino acid mutations were made at positions 241 (Glu
(E) to Lys (K)), 286 (Asn (N) to Ser (S)), 288 (Val (V) to Glu (E)), and 289 (Ile (I) to
Asn (N)) in various combinations, and were constructed according to methods previously
reported [11]. Incubation conditions of CYP2C19 mutants with (S)-flurbiprofen were
same as described above for 2C9/19 chimeric enzymes with regards to activity screening
and dapsone activation.
Analysis of 4’-hydroxy flurbiprofen. 4’-Hydroxy flurbiprofen was analyzed by
HPLC with fluorescence detection and comparison to a standard dissolved in 50:50 (v/v),
acetonitrile:50 mM potassium phosphate buffer pH 7.4. The HPLC system consisted of a
Waters 501 HPLC pump, a Waters 717 autosampler and a Waters 470 fluorescence
detector set at an excitation wavelength of 260 nm and an emission wavelength of 320
nm. The mobile phase consisted of 45:55 (v/v), acetonitrile:20 mM K2HPO4, pH 3.0
pumped at 1 ml/min through a Brownlee Spheri-5 C18 4.6 x 100 mm column. 4’Hydroxy flurbiprofen and internal standard eluted at approximately 2.2 and 4.8 minutes,
respectively.
Analysis of desmethylnaproxen. Desmethylnaproxen was analyzed identically to
4’-hydroxy flurbiprofen except that the fluorescence detector was set at an excitation
wavelength of 230 nm and an emission wavelength of 340 nm, and no internal standard
was used. Desmethylnaproxen eluted at approximately 2.1 minutes.
Analysis of 5’-hydroxy piroxicam. 5’-Hydroxy piroxicam was analyzed by HPLC
with UV detection (365 nm). The HPLC system was as described above, but was fitted
to a Waters 486 UV detector. The mobile phase consisted of 50:50 (v/v), acetonitrile:50

113

mM K2HPO4, pH 3.0 pumped at 1 mL/min through a Phenomenex Luna C18 5 µm, 4.6 x
150 mm column. Retention time for 5’-hydroxy piroxicam was approximately 4.3
minutes.
Data Presentation. All bar graph data of CYP2C9/19 chimeric and 2C19 mutant
enzymes are presented as mean of three determinations with error bar signifying standard
deviation.
Hydroxy-dapsone activation of flurbiprofen. Hydroxy dapsone was incubated
with (S)-flurbiprofen (2-300µM) in a 6x6 matrix design experiment containing 1 pmol
expressed CYP2C9 microsomes co-expressed with reductase (Camitro Corporation,
Menlo Park, CA). Hydroxy dapsone was dissolved in methanol and added to incubations
such that incubations did not exceed 2.5% organic concentration, with appropriate
controls used. Final incubation volume was 0.2 ml and reactions were initiated with 1
mM NADPH and allowed to incubate at 37°C for 20 minutes. Incubations were
quenched by adding 200 µl acetonitrile containing internal standard (180 ng/mL 2-fluoro4-biphenylacetic acid), followed by addition of 40 µl ½-strength H3PO4. Samples were
then centrifuged at 10,000 rpm for 5 minutes, placed into autosampler vials, and 30-50 µl
injected onto the HPLC system. 4’-Hydroxy flurbiprofen was analyzed as described
above, and data were fit in Sigma Plot (Version 6.0) to the two-site model equation [1]:
v=
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where S is the substrate, B is the effector, Vmax and Km are kinetic constants for substrate
metabolism, KB is the binding constant for the effector, α is the change in Km resulting
from effector binding, and β is the change in Vmax from effector binding. For activation,
α<1 and/or β>1.
Spectral Binding Studies. Expressed CYP2C9 microsomes (gift from Camitro
Corp.) were diluted from 0.7 to 0.2µM in 50mM potassium phosphate buffer with 1mM
EDTA and 1mM N-acetyl cysteine (an antioxidant to prevent breakdown of hydroxydapsone), at pH 7.4, and equally divided between sample and reference blocked cuvettes
(900µL). The instrument used was a DW-2000 UV-Vis Spectrophotometer (SLM
Instruments, Inc.), specifically designed to analyze turbid samples. In the study with
flurbiprofen alone, 5µL of a methanolic solution (6% DMSO) was added to both cuvettes
as a background control, since both dapsone and hydroxy-dapsone were dissolved in this
vehicle. After a baseline was recorded, 5µL aliquots of racemic-flurbiprofen was added
to the sample cuvette, with the same volume of 100mM potassium phosphate pH 7.4
being added to the reference cuvette. After 3 minutes, the difference spectra were
recorded between 350 and 500nm at room temperature. Concentrations of flurbiprofen
ranged to 155µM with successive aliquot additions. The binding experiments of
flurbiprofen in the presence of dapsone and hydroxy dapsone (20µM added at the
beginning) were carried out exactly the same as flurbiprofen alone. The slit width was
set to 6.0nm and a scan rate of 1.0nm/sec was used. The difference in absorbance
between the peak (~390nm) and trough (~420nm) of a type I spectra was then plotted vs.
flurbiprofen concentration and analyzed by nonlinear regression (Sigma Plot, Version
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6.0) to estimate the Ks (spectral binding constant) from the titration binding curve using
the following equation:
∆A = BmaxS/Ks + S (5.2)

Ibuprofen-Dapsone Incubation Conditions. Human liver tissue for preparation of
microsomes was obtained through the Liver Tissue Procurement and Distribution
System. Based on chart review, none of the patients from whom tissues were obtained
was taking any medications known to inhibit or induce the P450s. Microsomal samples
were prepared according to established methods [18]. Protein content was measured by
the method of Lowry et al. [19] and P450 content by the method of Omura and Sato [20].
The final microsomal protein concentration was 200 µg/mL and the total incubation
volume was 500 µL in 100 mM potassium phosphate, pH 7.4. Either (R)- or (S)ibuprofen (5-200 µM) was added to each tube in the absence or presence of 5 or 10 µM
dapsone, and reactions were initiated with 1 mM NADPH and allowed to run for 20
minutes at 37°C. Reactions were quenched by addition of 500 µL of ethyl acetate:
hexane (80:20 v/v), and 200 ng ketoprofen was added as internal standard, followed by
addition of 50 µL 40% phosphoric acid. Next, 3 mL ethyl acetate:hexane (80:20 v/v) was
added and samples were vortexed for 20 seconds, then centrifuged at 2000 g for 10
minutes. The organic layer was then pipetted off and transferred to a 13x100 tube and
evaporated to dryness. These tubes were then sent to Mitch Hamman at Indiana
University Division of Clinical Pharmacology for analysis. Data were analyzed and fit
the Michaelis-Menten equation to generate Km and Vmax estimates for ibuprofen 2- and 3hydroxylation.
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v=

Vm • S
(5.3)
Km + S

5.3. Results
CYP2C9/19 Chimeric Enzyme Studies. CYP2C9/19 chimeric enzymes (Figure
5.1) were constructed in order to determine which amino acid regions were important for
catalysis of flurbiprofen, naproxen, and piroxicam. This provided insight into the active
site binding characteristics of these compounds. Results from incubations with
CYP2C9/19 chimeric enzymes and flurbiprofen show that chimeras 2C9/19 (340-490)
and 2C19/9 (228-292) had flurbiprofen hydroxylase activity, with mean velocities of 7.38
and 6.92 pmol/min/pmol P450, respectively (Figure 5.2). All other chimeras exhibited
minimal activity towards flurbiprofen. These same chimeras catalyzed naproxen
demethylation, although less than CYP2C9 wild-type (Figure 5.3), while only the 2C19/9
(228-292) chimera exhibited substantial piroxicam hydroxylase activity (Figure 5.4). In
fact, this chimera showed higher piroxicam hydroxylase activity than wild-type CYP2C9
(Figure 5.4). For activation studies with dapsone involving the chimeras with
flurbiprofen hydroxylase activity, the 2C9/19 (340-490) chimera was activated in the
presence of 20 µM dapsone 1.2-fold, while the 2C19/9 (228-292) chimera showed no
activation (Figure 5.5).
CYP2C19 Mutant Enzyme Studies. CYP2C19 mutant enzymes were constructed
to determine which residues could confer flurbiprofen hydroxylase activity to CYP2C19,
which has minimal activity towards this substrate. As can be seen in Figure 5.6, the
2C19 KSN and KSEN mutants had the greatest activity towards flurbiprofen, with the
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KSN mutant exhibiting higher activity than wild-type CYP2C9. Activation studies with
these enzymes showed that dapsone did not activate flurbiprofen hydroxylase activity in
either of these CYP2C19 mutants (Figure 5.5).
Hydroxy-Dapsone Activation of Flurbiprofen 4’-Hydroxylation. Hydroxydapsone (HDA), the major phase I metabolite of dapsone, was found to activate
flurbiprofen 4’-hydroxylation. Data were fit to the two-site effector model equation
(equation 5.1) to generate a surface plot (Figure 5.7), yielding an α value of 0.98 and a β
of 1.5 (Table 5.1), indicating no effect on Km, but a increase in Vmax. This is different
from dapsone, which affected both the Km and Vmax of flurbiprofen 4’-hydroxylation
(Figure 5.8) with an α of 0.23 and a β of 1.9 (Table 5.1). Eadie Hofstee plots were
prepared to confirm effects on Km and Vmax of flurbiprofen 4’-hydroxylation by hydroxydapsone (Figure 5.9) and dapsone (Figure 5.10). Interestingly, activation by hydroxydapsone became saturated around 50 µM, while activation by dapsone saturated around
100 µM (Figures 5.7 and 5.8).
Spectral Binding Studies. To determine whether dapsone and hydroxy-dapsone
affect binding of flurbiprofen directly, spectral binding titration studies were performed.
Plotting the difference in absorbance between the peak at ~390 nm and trough at ~420
nm vs. flurbiprofen concentration yields a hyperbolic curve that can be fit by nonlinear
regression to equation 5.2 to estimate the spectral binding constant (Ks). In the absence
of effector, flurbiprofen gave a type I spectra (Figure 5.11, A) with a Ks of 14.1 µM
(Figure 5.11, B), while in the presence of 20 µM dapsone, flurbiprofen also gave a type I
spectra (Figure 5.12, A), but with a lower Ks of 2.1 µM (Figure 5.12, B), indicating that
the presence of dapsone increases the affinity of CYP2C9 for flurbiprofen. On the other
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hand, in the presence of hydroxy-dapsone, flurbiprofen gave a type I spectra (Figure 5.13,
A), with a Ks of 14.0 µM (Figure 5.13, B), similar to flurbiprofen alone, suggesting that
hydroxy-dapsone does not affect binding of flurbiprofen directly, agreeing with kinetic
data showing no effect of hydroxy-dapsone on the Km of flurbiprofen.
Ibuprofen-Dapsone Interaction. In the absence of dapsone, ibuprofen is
regioselectively metabolized, with 3-hydroxylation being greater than 2-hydroxylation
(Figure 5.14). In the presence of dapsone, however, 3-hydroxylation of (S)-ibuprofen
was substantially activated (Figure 5.15A), with the Vmax increasing from 1435 to 3026
pmol/min/mg protein and Km decreasing from 14.2 to 9.2 µM (Table 5.2). Meanwhile,
dapsone minimally affected 2-hydroxylation of (S)-ibuprofen (Figure 5.15B). In
contrast, dapsone inhibited both the 3- and 2-hydroxylation of (R)-ibuprofen (Figures
5.16A and B), as Vmax values decreased from 408 to 281 pmol/min/mg protein and 765 to
569 pmol/min/mg protein, respectively (Table 5.2).

5.4. Discussion
In this study, CYP2C9 substrate metabolism was monitored by using CYP2C9/19
chimeric and CYP2C19 mutant enzymes to better understand important binding
regions/residues within the active site, and perhaps shed some light on atypical kinetics
(i.e. activation) observed by this isoform. In addition, the direct effect of dapsone, as
well as hydroxy-dapsone, on binding of flurbiprofen was studied to provide mechanistic
information of why dapsone activates flurbiprofen 4’-hydroxylation, and to confirm
observed kinetic effects of dapsone on CYP2C9. Lastly, the effect of dapsone on the
regioselectivity of ibuprofen metabolism was studied to show how the presence of
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effector can potentially alter the binding orientation of substrate within the active site of
CYP2C9. Briefly, the CYP2C19/9 (228-292) and 2C9/19 (340-490) chimeras displayed
good activity towards flurbiprofen, naproxen, and piroxicam, while the CYP2C19 KSN
mutant showed the greatest activity towards flurbiprofen, suggesting the importance of
residues 241, 286, and 289 in catalysis of this substrate. Dapsone was only able to
activate flurbiprofen 4’-hydroxylation in the 2C9/19 (340-490) chimera. It was also
discovered that hydroxy-dapsone can activate flurbiprofen 4’-hydroxylation similar to
dapsone, although primarily through a Vmax effect, which spectral binding studies
confirmed. Lastly, ibuprofen metabolism was regioselectively and stereoselectively
altered by dapsone, suggesting a change in ibuprofen binding orientation in the presence
of dapsone.
Despite the numerous studies describing atypical kinetics such as positive
cooperativity, progress has been limited in clearly defining the underlying causes of this
phenomenon. Cytochrome P450 3A4 is particularly interesting, considering it is the most
abundant CYP enzyme and metabolizes numerous compounds [21;22]. It has been
observed that many substrates of CYP3A4 show atypical kinetic profiles [1;23-26], and
thus, with respect to atypical kinetics, CYP3A4 has been by far the most studied isoform.
The preponderance of evidence suggests that there are at least two distinct binding
regions within the CYP3A4 active site. One model in particular suggests that both
substrate and effector may be present in the active site simultaneously, each having
access to the reactive oxygen [1;24]. Our lab has shown evidence that this two-site
model applies to CYP2C9, an isoform for which dapsone has been shown to cause
heterotropic positive cooperativity (activation) [4]. However, this study only provides
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kinetic evidence to support the simultaneous presence of multiple compounds within the
active site. Studies exploring binding within the active site would be more helpful in
understanding the interactions necessary for positive cooperativity to occur.
Studies with CYP2C9/19 chimeric enzymes suggest that amino acid region 228292 is necessary for catalysis of flurbiprofen, naproxen, and piroxicam, as substantial
activity towards these substrates was conferred when this amino acid region from
CYP2C9 was placed into CYP2C19. According to Gotoh, this region lies in SRS 3 and
part of SRS 4, two of the six proposed substrate recognition sites of CYP2C enzymes [5].
Interestingly, the CYP2C19 mutants KSN and KSEN, which have single mutations
within SRS 3 also had good activity towards flurbiprofen 4’-hydroxylation. The
mutation at residue 241 (Glutamate to Lysine) is proposed to be within helix G, while
those at 286 (Asparagine to Serine), 288 (Valine to Glutamate), and 289 (Isoleucine to
Asparagine) are proposed to be within helix I, which is associated with the substrate
binding pocket and is one of the most structurally conserved regions of CYP450s [27;28].
Similar studies have been performed to determine important binding regions for other
compounds with CYP2C9. Jung et al. reported that replacement of amino acids 227-338
in 2C19 with the corresponding region of 2C9 lead to an enzyme with a high affinity for
sulfaphenazole [11]. In addition, two amino acid substitutions in 2C19 (N286S and
I289N) conferred high-affinity sulfaphenazole binding [11]. Likewise, Klose et al. found
that residues 286 and 289 were important in conferring diclofenac and ibuprofen
hydroxylase activity to CYP2C19 [29]. However, it must be understood that this does
not necessarily suggest that residues 286 and 289 directly contact the substrate. In fact,
based on a homology model generated by Jung et al. [11], these residues are too far away
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from the heme to directly contact the substrate. In addition, it was deduced from this
homology model that the I289N difference lies at the interface of helix I with helix G,
which has a considerable range of motion according to molecular dynamics studies. This
mutation could thus serve to alter the motion of these helices, which in turn could affect
access of substrate to the heme oxygen or overall protein conformation [11]. However,
other factors are likely contributing. Overall, the regions/residues important for catalysis
of flurbiprofen, naproxen, and piroxicam appear to coincide with a number of other
studies.
The effect of dapsone on chimeric and mutant enzyme activity was also
examined. It was found that only the CYP2C9/19 (340-490) chimera could be activated
by dapsone, albeit only 1.2-fold. We suspect that this may result from this chimeric
enzyme being primarily CYP2C9 (only residues 340-490 are from CYP2C19), thus still
possessing the region allowing dapsone to bind and cause positive cooperativity. In
addition, the 2C19/9 (228-292) chimera also has residues 340-490 from 2C19, in addition
to residues corresponding to SRS 1 and 2, and was unable to be activated by dapsone.
On the other hand, SRS 1 and 2 in the 2C9/19 (340-490) chimera (activated) were from
CYP2C9, suggesting that these regions may be important for binding dapsone. This is
assuming that the catalytic site and effector site for dapsone are one in the same.
Interestingly, He et al. [30] suggest that perhaps dapsone may interact electrostatically in
the active site through its sulfone group. In addition, Ridderstrom et al. have noted that
Arginines 97 and 108 are important in the catalytic activity of CYP2C9 [31], which are
present in SRS 1 according to Gotoh [5], implicating this as a possible binding
determinant for dapsone. Unfortunately, no chimeric or mutant enzyme has been
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constructed to explore this potential binding region and its effects on activation. Until
more mammalian P450s are crystallized for modeling these interactions, predictions of
binding sites will be difficult and remain theoretical.
In addition to dapsone activating CYP2C9-mediated metabolism, it has also been
shown to be a substrate for this isoform [12;32], with N-hydroxy dapsone being the major
metabolite. In previous studies, we have explored effector structural requirements for
activation of CYP2C9. One compound that we did not initially screen for activation was
the hydroxy metabolite of dapsone. Our studies show that hydroxy-dapsone does activate
flurbiprofen 4’-hydroxylation, but not naproxen or piroxicam metabolism. To our
knowledge, this is the first example of a metabolite that activates CYP-mediated
metabolism. Compared to dapsone, however, hydroxy-dapsone causes an increase in
Vmax without much effect on the Km for flurbiprofen 4’-hydroxylation, whereas dapsone
increases Vmax and decreases Km, as can be seen by α and β values in table 5.1. EadieHofstee plots confirm these effects on Km and Vmax estimates by hydroxydapsone and
dapsone (Figures 5.9 an 5.10). In particular, it can be seen that the slope of the EadieHofstee plots in the presence of increasing concentrations of hydroxy-dapsone are
relatively parallel, suggesting minimal changes on Km, whereas slopes in the presence of
dapsone are not parallel, indicating a Km effect. Based on this kinetic evidence, dapsone
increases the affinity (decreases Km) of CYP2C9 for flurbiprofen, whereas hydroxydapsone does not. With regard to the Vmax effects of hydroxy-dapsone on CYP2C9,
similar results have been observed for CYP3A4, as Shou et al. [24] observed that 7,8benzoflavone increased the Vmax for phenanthrene metabolism with minimal changes to
the Km.
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To confirm the effects of dapsone and hydroxy-dapsone on binding affinity of
flurbiprofen, spectral titration binding studies were performed. Results confirm that the
presence of dapsone does cause flurbiprofen to bind CYP2C9 more efficiently, as
spectral binding constant (Ks) estimates for flurbiprofen were decreased from 14.1 to 2.1
µM. This increased binding efficiency likely contributes to an increase in catalytic
efficiency for CYP2C9-mediated flurbiprofen 4’-hydroxylation. It is conceivable to
suggest that the presence of dapsone effectively reduces the size of the active site, thus
forcing flurbiprofen to bind more tightly, explaining the Km and Ks effects observed. On
the other hand, the presence of hydroxy-dapsone had no direct effect on binding of
flurbiprofen, with Ks values remaining unchanged. Nonetheless, hydroxy-dapsone is still
able to activate flurbiprofen 4’-hydroxylation. Reasons for this difference are likely
numerous and complicated. One possibility is that hydroxy-dapsone may in some way
provide an environment which leads to more efficient electron flow, and hence, reactive
oxygen. It has also been suggested that hydrogen bonding and disordering the orientation
of water molecules within the active site may affect catalytic activity of the enzyme. For
example, through site-directed mutagenesis studies, Atkins and Sligar have found an
important role for hydrogen bonding within the active site of cytochrome P450cam [33].
They determined that a hydrogen bond between Tyr96 and the ketone group of camphor
placed camphor in such a position as to promote efficient catalysis. By mutating this
residue to a phenylalanine (resulting in no H-bond), it was found that the free energy
(∆G) for binding was unaffected, while the ∆G for spin state conversion was much higher
compared to wild-type enzyme, with only 59% conversion from low to high spin, versus
95% for wild-type enzyme [33]. This was rationalized by suggesting that the hydrogen

124

bond placed camphor in such a way as to protect the heme from solvent interaction, thus
promoting efficient electron flow to the heme, and hence higher spin state conversion
[33]. Other groups have proposed that Vmax effects may stem from expulsion of water
molecules from the active site, which may help prevent uncoupling of the P450 cycle,
leading to production of hydrogen peroxide or excess water formation [34-36]. It is
reasonable to suggest that hydroxy-dapsone, although it has a very similar structure,
interacts within the active site differently than does dapsone, perhaps disrupting the water
orientation and driving the enzyme towards a higher percentage of high-spin state without
affecting binding of the activated substrate.
Similar to the NSAIDs flurbiprofen and naproxen, ibuprofen is a substrate whose
metabolism is activated by dapsone. Ibuprofen is a chiral substrate for CYP2C9 that
undergoes both 2- and 3-hydroxylation for both enantiomers. We have observed that 3hydroxylation of these enantiomers is greater than 2-hydroxylation, which agrees with a
previous study [10]. Interestingly, in the presence of dapsone, the 3-hydroxylation of (S)ibuprofen is activated (Figure 5.15), while 2-hydroxylation is minimally affected.
Meanwhile, dapsone appears to weakly inhibit the 2- and 3-hydroxylation of (R)ibuprofen. Thus, there appears to be a regioselective, as well as an enantioselective effect
of dapsone on ibuprofen metabolism. Results from (S)-ibuprofen suggest that dapsone
not only alters the regioselectivity towards 3-hydroxylation, but activates the enzyme
overall, as the sum of the velocities for 2- and 3-hydroxylation are substantially
increased. This information suggests that dapsone does alter the shape of the active site,
such that the binding orientation of ibuprofen is altered, as opposed to just increasing the
catalytic activity of the CYP2C9 enzyme through some other mechanism. This is not to
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say that alteration of active site shape is the only factor involved, but it likely contributes
to activation. Similar studies have been conducted with CYP3A4 and triazolam
metabolism. Schrag and Wienkers [17] studied the 1’- and 4-hydroxylation of triazolam
by CYP3A4 and observed altered ratios of the 4-hydroxy to 1’-hydroxy metabolite under
different incubation conditions. They rationalized their findings by suggesting that data
was consistent with a two-site model for binding. Whether the change in active site
topology induced by dapsone is a result of dapsone being in the active site, or due to a
change in protein conformation still remains unclear. However, kinetic evidence from
one of our previous studies suggests the presence of dapsone in the active site
simultaneously with substrate [4]. Results for (R)-ibuprofen are different in that dapsone
appears to inhibit 2- and 3-hydroxylation of this enantiomer, although rather weakly. It is
likely that the (R)-enantiomer itself has a slightly different binding orientation than the
(S)-enantiomer, resulting in the observed differences and suggesting multiple binding
domains or sites.
Overall, results from these studies provide additional information about binding
of substrates to CYP2C9 active site, as well as possible mechanisms of activation, one of
which is alteration of binding orientation by dapsone. Perhaps the most interesting result
from these studies is the discovery that the major metabolite of dapsone (hydroxydapsone) can also serve to activate flurbiprofen 4’-hydroxylation, although apparently
through a slightly different mechanism. Future studies will include measuring oxygen
consumption and hydrogen peroxide formation by CYP2C9 in the presence of dapsone
and hydroxy-dapsone to characterize potential effects on uncoupling mechanisms.
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Figure 5.1.31 Constructed CYP2C9/19 Chimeric Enzymes
CYP2C9/19 chimeric enzymes constructed for binding region studies.
SRS refers to substrate recognition sequences and restriction enzymes are shown at
splice sites. All chimeras were composed of 490 residues.
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Figure 5.2.32 Flurbiprofen 4’-Hydroxylation by CYP2C9/19 Chimeric Enzymes
Flurbiprofen 4’-hydroxylation in CYP2C9/19 chimeric enzymes. Activity for CYP2C9
and 2C19 wild-type are included for comparison.
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Figure 5.3.33 Naproxen Demethylation by CYP2C9/19 Chimeric Enzymes
Naproxen demethylation in CYP2C9/19 chimeric enzymes. Activity for CYP2C9 and
2C19 wild-type are included for comparison.
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Figure 5.4.34 Piroxicam 5’-Hydroxylation by CYP2C9/19 Chimeric Enzymes

Flurbiprofen 4'-Hydroxylation (pmol/min/pm ol P450)

Piroxicam 5’-hydroxylation in CYP2C9/19 chimeric enzymes. Activity for CYP2C9 and
2C19 wild-type are included for comparison.
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Figure 5.5.35 Dapsone Activation in CYP2C9/19 Chimeric and 2C19 Mutant
Enzymes
Screen for activation of flurbiprofen 4’-hydroxylation in active 2C9/19 chimeras and
2C19 mutants.
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Figure 5.6.36 Flurbiprofen 4’-Hydroxylation in CYP2C19 Mutant Enzymes
Flurbiprofen 4’-hydroxylation in E.coli purified CYP2C19 mutant enzymes. Mutated
residues are explained in the Methods section.
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Figure 5.7.37 Hydroxy-Dapsone Activation of Flurbiprofen 4’-Hydroxylation (3-D
Plot)
Three-dimensional surface plot showing activation of flurbiprofen 4’-hydroxylation by
hydroxy-dapsone. The surface is the fit to equation 5.1.
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Figure 5.8.38 Dapsone Activation of Flurbiprofen 4’-Hydroxylation (3-D Plot)
Three-dimensional surface plot showing activation of flurbiprofen 4’-hydroxylation by
dapsone. The surface is the fit to equation 5.1.
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Table 5.1.15 Activation of Flurbiprofen 4’-Hydroxylation by Hydroxy-Dapsone and
Dapsone
Kinetic parameters for activation of flurbiprofen 4’-hydroxylation by dapsone and
hydroxy-dapsone (HDA). Parameters were estimated by fitting data to equation 5.1.
Vmax (SE)
KB (SE)
(pmol/min/pmol
(µM)
α (SE)
β (SE)
P450)
Dapsone
6.6 (0.5)
6.8 (0.2)
35.7 (5.7) 0.2 (0.03) 1.9 (0.06)
HDA
9.5 (1.2)
7.3 (0.3)
2.6 (0.8) 0.98 (0.2) 1.5 (0.1)
Km is the Michaelis-Menten constant; Vmax is the maximal velocity; KB is the binding
constant for the effector; α is the change in Km resulting from effector binding; β is the
change in Vmax resulting from effector binding. An α or β value=1 indicates no change in
Km or Vmax, respectively.
Effector

Km (SE)
(µM)
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Figure 5.9.39 Eadie-Hofstee Plot for Hydroxy-Dapsone Effect on Flurbiprofen 4’Hydroxylation
Eadie-Hofstee plots showing the effect of hydroxy-dapsone on flurbiprofen 4’hydroxylation. Relatively parallel lines indicates minimal effect on Km, while different
y-axis intercepts indicate increase in Vmax.
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Figure 5.10.40 Eadie-Hofstee Plot for Dapsone Effect on Flurbiprofen 4’Hydroxylation
Eadie-Hofstee plots showing the effect of dapsone on flurbiprofen 4’-hydroxylation.
Different slopes indicate effect on Km while different y-axis intercepts indicate increase
in Vmax.
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Figure 5.11.41 Flurbiprofen Type I Difference Spectra
Titration of CYP2C9 with flurbiprofen alone. (A) Observed type I difference spectra. (B)
Plot of ∆A 390-420 (from A) vs flurbiprofen concentration fit to equation 5.2 with a Ks =
14.1.
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Figure 5.12.42 Flurbiprofen Type I Difference Spectra in Presence of Dapsone
Titration of CYP2C9 with flurbiprofen in presence of 20 µM dapsone. (A) Observed type
I difference spectra. (B) Plot of ∆A 390-420 (from A) vs flurbiprofen concentration fit to
equation 5.2 with a Ks = 2.1.
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Figure 5.13.43 Flurbiprofen Type I Difference Spectra in Presence of HydroxyDapsone
Titration of CYP2C9 with flurbiprofen in the presence of 20 µM hydroxy-dapsone. (A)
Observed type I difference spectra. (B) Plot of ∆A 390-420 (from A) vs flurbiprofen
concentration fit to equation 5.2 with a Ks = 14.0.
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Figure 5.14.44 Ibuprofen Metabolism
Metabolic pathways for both (S)- and (R)-ibuprofen.
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Figure 5.15.45 (S)-Ibuprofen 2- and 3-Hydroxylation
(S)-ibuprofen 3-hydroxylation (A) and 2-hydroxylation (B) in absence and presence of 5
and 10 µM dapsone. Fits were to equation 5.3.

141

(R)-Ibu 3-Hydroxylation (pmol/min/mg protein)

A
1000
800
600
400
0 Dapsone fit
0 Dapsone
Dapsone 5 µM fit
Dapsone 5 µM
Dapsone 10 µM fit
Dapsone 10 µM

200
0

0

50

100

150

200

250

(R)-Ibuprofen (µM)

(R)-Ibu 2-Hydroxylation (pmol/min/mg protein)

B
500
400
300
200
0 Dapsone fit
0 Dapsone
Dapsone 5µM fit
Dapsone 5 µM
Dapsone 10 µM fit
Dapsone 10 µM

100
0

0

50

100

150

200

250

(R)-Ibuprofen (µM)

Figure 5.16.46 (R)-Ibuprofen 2- and 3- Hydroxylation
(R)-ibuprofen 3-hydroxylation (A) and 2-hydroxylation (B) in the absence and presence
of 5 and 10 µM dapsone. Fits were to equation 5.3.
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Table 5.2.16 Effect of Dapsone on (S)- and (R)-Ibuprofen Metabolism
Kinetic parameters for (S)- and (R)-ibuprofen metabolism in the absence and presence of
dapsone. Data were fit to Michaelis-Menten equation (equation 5.3).

Dapsone
µM
0
5
10

(S)-Ibuprofen 3-hydroxylation
Vmax (SE)
Km (SE)
pmol/min/mg protein
µM
1435.1 (89.7)
14.2 (4.0)
1949.5 (139.2)
12.4 (4.2)
3025.2 (117.2)
9.2 (1.9)

(S)-Ibuprofen 2-hydroxylation
Vmax (SE)
Km (SE)
pmol/min/mg protein
µM
615.4 (40.3)
18.5 (5.1)
472.1 (64.6)
66.2 (23.7)
700.8 (43.5)
26.9 (6.1)

Dapsone
µM
0
5
10

(R)-Ibuprofen 3-hydroxylation
Vmax (SE)
Km (SE)
pmol/min/mg protein
µM
764.3 (65.2)
23.7 (7.7)
749.1 (81.8)
13.1 (6.6)
569.4 (65.6)
16.6 (8.3)

(R)-Ibuprofen 2-hydroxylation
Vmax (SE)
Km (SE)
pmol/min/mg protein
µM
407.8 (41.3)
19.6 (8.1)
313.8 (17.4)
11.4 (3.1)
281.0 (30.3)
14.4 (7.0)
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CHAPTER VI

Sensitive and Specific High-Performance Liquid
Chromatographic Assay for 4'-Hydroxyflurbiprofen and
Flurbiprofen in Human Urine and Plasma

This chapter published in Journal of Chromatography B [749, 119-125 (2000)].
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6.1. Introduction
Flurbiprofen is an arylpropionic non-steroidal anti-inflammatory drug used in the
treatment of pain and inflammation. In humans, flurbiprofen is eliminated primarily by
oxidation to form 4'-hydroxyflurbiprofen (Fig. 6.1), which accounts for about 86% of the
oxidative metabolites [1]. The oxidative metabolites and parent compound are also
subject to glucuronidation or sulfation [2;3]. It has been shown that the formation of 4'hydroxyflurbiprofen is mediated almost exclusively by cytochrome P450 2C9 in a nonstereoselective manner [4;5]. As a result, flurbiprofen may be used as an in vitro probe
for CYP2C9 activity, without the need for measuring the enantiomers. More recently, it
has been shown that flurbiprofen may be used as an in vivo probe to estimate the activity
of CYP2C9 in human subjects [6].
Other HPLC methods have been described for the detection of racemic
flurbiprofen and its metabolites in urine and plasma [3;7-9], in which the analytes must
be extracted from their respective biological matrices. This paper describes a sensitive
and specific procedure for the detection of flurbiprofen and its 4’-hydroxy metabolite in
which no extraction step is utilized, thus reducing the amount of time and error involved
in quantitation. The method involves a reverse-phase liquid chromatography column and
fluorescence detection, and is sufficiently sensitive to quantitate flurbiprofen and 4'hydroxyflurbiprofen in amounts as low as 0.25 µg/ml and 0.05 µg/ml, respectively. This
assay was used to quantitate concentrations of flurbiprofen and 4'-hydroxyflurbiprofen in
urine and plasma from human subjects to evaluate the use of flurbiprofen as an in vivo
probe for cytochrome P450 2C9 activity.
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6.2. Methods
Reagents and chemicals. Acetonitrile, dibasic potassium phosphate buffer,
hydrochloric acid and phosphoric acid were obtained from Fisher Scientific Co.
(Pittsburgh, PA, USA). rac-Flurbiprofen was purchased from Sigma Chemical (St.
Louis, MO, USA). 4’- Hydroxyflurbiprofen and 2-fluoro-4-biphenylacetic acid (internal
standard (IS)) were gifts from Pharmacia (Kalamazoo, MI, USA). All other chemicals
were obtained from commercial sources and were of the highest purity available. Drugfree human plasma was obtained from the blood bank and drug-free human urine was
obtained from laboratory personnel.
Instrumentation. The HPLC system consisted of a Waters 501 HPLC pump, a
Waters 717  autosampler and a Waters 470  scanning fluorescence detector set at an
excitation wavelength of 260 nm and an emission wavelength of 320 nm (Waters Assoc.,
Milford, MA, USA). The mobile phase for both urine and plasma consisted of
acetonitrile—20 mM K2HPO4, pH 3.0 (40:60, v/v) pumped at 1 ml/min through a
Brownlee Spheri-5  C18 4.6 x 100 mm reversed phase column, with a typical pressure of
67 bar.
Preparation of stock solutions. Flurbiprofen and 4'-hydroxyflurbiprofen stock
solutions were prepared by dissolving each in 50:50 acetonitrile:H20 to make a 1 mg/ml
solution. From this stock solution, dilutions were made to prepare 50, 10, 5, and 0.5
µg/ml solutions for preparation of the standards. 2-fluoro-4-biphenylacetic acid (IS) was
dissolved in acetonitrile to prepare a 1 mg/ml stock solution. From this stock solution a
1000 ng/ml solution was prepared by adding 0.5 ml of the 1 mg/ml stock to 500 ml
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acetonitrile. A 500 ng/ml internal standard solution was prepared by adding 0.25 ml of
the 1 mg/ml stock to 500 ml acetonitrile. All stock solutions were stored at 4°C.
Flurbiprofen and 4'-hydroxyflurbiprofen in urine. Urine samples (50 µl) were
prepared by adding 400 µl of purified water and 100 µl 6 M HCl, followed by vortexing
and incubation at 90°C for 30 minutes to facilitate glucuronide cleavage via acidhydrolysis. Following incubation, 500 µl acetonitrile containing IS (1000 ng/ml of 2fluoro-4-biphenylacetic acid) was added and the samples vortexed. The samples were
then centrifuged at 14,000g for 5 minutes, and 150 µl of sample transferred to
autosampler vials and 3-12 µl injected onto the HPLC system for analysis. Standard
amounts for flurbiprofen and 4'-hydroxyflurbiprofen ranged from 0.5 to 40 µg/ml (0, 0.5,
1.0, 2.0, 5, 10, 20, and 40 µg/ml). Appropriate amounts of 4’-hydroxyflurbiprofen and
flurbiprofen were added to 50 µl blank urine to prepare standards and then brought to
final volume of 450 µl by addition of purified water and treated as subject samples.
Flurbiprofen and 4'-hydroxyflurbiprofen in plasma. Plasma samples (100 µl)
were prepared by adding 100 µl acetonitrile, 200 µl IS (500 ng/ml of 2-fluoro-4biphenylacetic acid in acetonitrile), and 40 µl of ½-strength H3PO4 (50:50 H3PO4 : H20),
followed by vortexing. The samples were then centrifuged at 14,000g for 10 minutes,
and 150 µl placed into autosampler vials and 20-75 µl injected onto the HPLC. The
standards were prepared to contain concentrations of 0, 0.05, 0.1, 0.25, 0.5, 1.0, 2.0, and
3.0 µg/ml for 4'-hydroxyflurbiprofen and 0, 0.25, 0.5, 1.0, 2.5, 5.0, 10, and 15 µg/ml for
flurbiprofen. Appropriate amounts of 4’-hydroxyflurbiprofen and flurbiprofen were
added to 100 µl blank plasma and acetonitrile was then added to bring the final volume to
200 µl, followed by treatment as with the subject samples.
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Assay validation procedure. Urine assay validation consisted of replicates of a
low concentration (1 µg/ml), a middle concentration (12 µg/ml), and a high concentration
(30 µg/ml) quality control (QC) sample for flurbiprofen and 4’-hydroxyflurbiprofen.
Plasma assay validation QC concentrations were 1 µg/ml, 12 µg/ml, and 30 µg/ml for
flurbiprofen, and 0.1 µg/ml, 0.5 µg/ml, and 1.5 µg/ml for 4’-hydroxyflurbiprofen. Intraday variability was tested with 12 replicates of each quality control concentration. Interday variability was conducted over three days with 6 replicates of each QC concentration.
Furthermore, low and high QC concentrations (in triplicate) were subjected to three
freeze-thaw cycles and analyzed. Finally, processed stability after pretreatment was
tested by injecting low and high QC samples every 2 hours for 24 hours. Means,
standard deviations and coefficients of variation were calculated by standard methods.

6.3. Results
Representative HPLC chromatograms illustrating the analysis of 4'hydroxyflurbiprofen and flurbiprofen in urine and plasma, as well as a blank for each, are
shown in Figures 6.2-6.5. 4'-Hydroxyflurbiprofen, IS, and flurbiprofen were separated
within 16 minutes, with retention times of approximately 3.6, 9.0, and 14.0 minutes,
respectively. The standard curves for 4'-hydroxyflurbiprofen and flurbiprofen in urine
were linear through 40 µg/ml, while the curves for 4'-hydroxyflurbiprofen and
flurbiprofen in plasma were linear through 3 µg/ml and 15 µg/ml, respectively. Limits of
quantitation for 4'-hydroxyflurbiprofen and flurbiprofen in urine and plasma were 0.5
µg/ml in urine and 0.05 µg/ml and 0.25 µg/ml, respectively, in plasma. A representative
subject log plasma concentration versus time curve in Figure 6.6 shows the ability of this

148

assay to sensitively detect flurbiprofen and low 4'-hydroxyflurbiprofen concentrations in
plasma. In addition, in 12 subjects receiving flurbiprofen orally, the average urinary
recovery of total drug after acid cleavage of glucuronide metabolite was 21 mg out of a
50 mg dose, or about 42% (data not shown).
Calibration and linearity. Calibration curves were constructed using seven
standard concentrations in urine or plasma. Curves were obtained daily for four days by
plotting the peak-area ratios of flurbiprofen and 4’-hydroxyflurbiprofen to the IS against
the corresponding nominal concentration. Linear calibration curves were generated by
weighted (1/y) linear regression analysis. The mean ± s.d. coefficients of determination
and slopes for 4’-hydroxyflurbiprofen and flurbiprofen in urine (n=4) were 0.996 ± 0.005
(slope = 6.84 x 10-4 ± 3.99 x 10-5) and 0.994 ± 0.003 (slope = 1.92 x 10-3 ± 1.40 x 10-4),
respectively, while in plasma (n=4) they were 0.995 ± 0.004 (slope = 4.49 x 10-3 ± 1.78 x
10-4) and 0.996 ± 0.001 (slope = 1.42 x 10-2 ± 2.45 x 10-4), respectively. The lower limit
of quantitation (LOQ) for flurbiprofen and 4’-hydroxyflurbiprofen in each matrix was
selected as the lowest concentration of the standard curve
Precision and accuracy. The precision and accuracy of the urine and plasma
assays were determined by three days of quality control analysis. Intra-day (n=12) and
inter-day (n=3 days; n=24 samples) variability is shown in Tables 6.1 and Table 6.2,
respectively. Analyte stability was demonstrated in both urine and plasma by subjecting
the samples to three freeze-thaw cycles, and injecting the processed quality control
samples every two hours over a 24 hour period. Three freeze-thaw cycles had no effect
on the stability of the analytes in both urine and plasma, as the accuracy of all low and
high QC concentrations (n=3) for flurbiprofen and 4’-hydroxyflurbiprofen was within
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15% of expected values (Tables 6.1 and 6.2). In addition, the coefficients of variation
were below 11% for all LC and HC amounts (data not shown). Likewise, processed
stability after processing was not a factor, as the accuracy of all low and high QC
concentrations (n=12) was within 10% of expected values, and all coefficients of
variations were within 8.5% (Tables 6.1 and 6.2).

6.4. Discussion
This study describes a rapid and sensitive HPLC method for the detection and
quantitation of flurbiprofen and 4'-hydroxyflurbiprofen in urine and plasma. The method
uses simple protein precipitation with acetonitrile followed by direct sample injection
resulting in short sample preparation times. Quality control analysis indicates that the
assay is precise (C.V.<14%) and accurate (within 15%). The urinary recovery data and
the representative plasma concentration-time curve suggest that this method is sufficient
for attaining accurate clinical pharmacokinetic data following single dose administration
of flurbiprofen. This assay has been used to validate use of the flurbiprofen eight hour
urinary recovery ratio ( FLRR =

4' OHF
) as an in vivo probe of cytochrome P450
4' OHF + F

2C9 activity in human subjects ({Frye, Tracy, et al. 2000 2493 /id}, manuscript in
preparation). Applications of this methodology will allow determination of relative
CYP2C9 metabolizing capacity in individuals, phenotypic identification of individuals
possessing mutant CYP2C9 alleles (e.g., *2 and *3 [10;11]) which result in altered
metabolizing capacity and determination of the effects of disease states on CYP2C9
activity.
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Table 6.1.17 Detection of Flurbiprofen and 4’-Hydroxflurbiprofen in Urine
Intra- and Inter-day precision and accuracy for flurbiprofen and 4'-hydroxyflurbiprofen
in urine
Compound

Intra-assay reproducibilitya
Flurbiprofen

4'-hydroxyflurbiprofen

Inter-assay reproducibilityb
Flurbiprofen

4'-hydroxyflurbiprofen

Freeze-thaw stabilityc
Flurbiprofen
4’-hydroxyflurbiprofen

Processing stabilityd
Flurbiprofen
4’-hydroxyflurbiprofen

Concentration
Added
(µg/ml)

Found

C.V. (%)

% Deviation

1.0
12.0
30
1.0
12.0
30

Mean+/- S.D.
0.90+/-0.09
10.29+/-0.40
28.23+/-2.58
1.12+/-0.06
11.46+/-0.47
29.96+/-2.77

9.5
3.9
9.1
5.8
4.1
9.3

-10.0
-14.2
-6.0
10.0
-4.2
-0.3

1.0
12.0
30
1.0
12.0
30

Mean +/- S.E.
0.88+/-0.02
10.39+/-0.34
29.34+/-1.10
1.09+/-0.03
11.30+/-0.39
30.54+/-1.00

2.7
3.6
3.8
3.0
3.5
3.4

-10.0
-13.3
-2.3
10.0
-5.8
1.7

1.0
30
1.0
30

Mean +/- S.D.
0.85+/-0.07
29.64+/-1.56
1.01+/-0.04
30.65+/-1.39

8.2
5.3
4.0
4.5

-14.5
-1.2
1.0
2.2

1.0
30
1.0
30

Mean +/- S.D.
0.92+/-0.03
31.14+/-0.76
1.01+/-0.02
31.99+/-0.63

3.3
2.4
2.0
2.0

-7.7
3.8
0.8
6.6

a,d

Twelve samples per concentration
Six samples per day per concentration for three days
c
Three samples per concentration
b
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Table 6.2.18 Detection of Flurbiprofen and 4’-Hydroxyflurbiprofen in Plasma
Intra- and Inter-day precision and accuracy for flurbiprofen and 4'-hydroxyflurbiprofen in plasma
Compound

Concentration
Added

Found

C.V. (%)

%Deviation

(µg/ml)
Intra-assay reproducibility
Flurbiprofen

a

4'-hydroxyflurbiprofen

Inter-assay reproducibilityb
Flurbiprofen

4'-hydroxyflurbiprofen

Freeze-thaw stabilityc
Flurbiprofen
4’-hydroxyflurbiprofen

Processing stabilityd
Flurbiprofen
4’-hydroxyflurbiprofen

0.5
6.0
15
0.1
0.5
1.5

Mean+/- S.D.
0.48+/-0.03
5.49+/-0.23
13.93+/-0.69
0.12+/-0.02
0.46+/-0.03
1.39+/-0.07

6.3
4.2
4.9
13.7
6.9
4.9

-4.0
-8.3
-7.3
16.7
-8.0
-6.7

0.5
6.0
15
0.1
0.5
1.5

Mean +/- S.E.
0.46+/-0.02
5.41+/-0.18
13.97+/-0.04
0.10+/-0.02
0.45+/-0.01
1.41+/-0.02

4.4
3.3
0.3
14.3
2.7
1.2

-8.0
-10.0
-6.7
1.0
-10.0
-6.7

0.5
15
0.1
1.5

Mean +/- S.D.
0.49+/-0.01
14.51+/-1.41
0.09+/-0.01
1.45+/-0.16

2.0
9.7
11.1
11.0

-2.9
-3.2
-6.9
-3.3

0.5
15
0.1
1.5

Mean +/- S.D.
0.52+/-0.02
14.11+/-0.55
0.09+/-0.01
1.45+/-0.04

3.8
3.9
11.1
2.8

4.2
-5.9
-8.6
-3.1

a,d

Twelve samples per concentration
Six samples per day per concentration for three days
c
Three samples per concentration
b
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Figure 6.1.47 Flurbiprofen Metabolism
Structures for flurbiprofen and its primary metabolite, 4'-hydroxyflurbiprofen.
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Figure 6.2.48 HPLC Chromatogram of Flurbiprofen and 4’-Hydroxyflurbiprofen in
Urine
Representative HPLC chromatogram illustrating the detection of 4’-hydroxy flurbiprofen (5
µg/mL), internal standard, and flurbiprofen (5 µg/mL) in urine.
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Figure 6.3.49 HPLC Chromatogram from Blank Urine Sample
Representative HPLC chromatogram from a blank urine sample.
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Figure 6.4.50 HPLC Chromatogram of Flurbiprofen and 4’-Hydroxyflurbiprofen in
Plasma
Representative HPLC chromatogram illustrating the detection of 4’-hydroxy flurbiprofen (0.05
µg/mL), internal standard, and flurbiprofen (0.25 µg/mL) in plasma.
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Figure 6.5.51 HPLC Chromatogram from Blank Plasma Sample
Representative HPLC chromatogram from a blank plasma sample.

157

Concentration (µg/mL)

10.0

1.0

0.1

Flurbiprofen
4'-hydroxy flurbiprofen
0.0
0

5

10

15

20

25

Time (hr)

Figure 6.6.52 Flurbiprofen Log Plasma Concentration Time Profile
Representative log plasma concentration-time profile for flurbiprofen and 4'hydroxyflurbiprofen from a healthy subject who received a 50 mg dose of racemic
flurbiprofen.
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CHAPTER VII

Minimal In vivo Activation of CYP2C9-Mediated Flurbiprofen
Metabolism by Dapsone

This chapter published in European Journal of Pharmaceutical Sciences [14 , 47-52
(2001)].
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7.1. Introduction
The CYP450 enzymes are one of the most important groups of enzymes involved
in the biotransformation of hydrophobic compounds such as drugs, carcinogens, and
other xenobiotics. The majority of CYP450 reactions are oxidations (e.g., hydroxylation)
that exhibit Michaelis-Menten kinetics and competitive inhibition between substrates. As
a result, most pharmacokinetic properties can be predicted with standard kinetic analyses,
which may be helpful in the prediction of drug interactions. However, it has been shown
that some CYP450 reactions show unusual enzyme kinetics such as activation,
autoactivation, and substrate inhibition [1;2]. Though reactions involving atypical
kinetics are most commonly associated with CYP3A4, they have also been noted with
CYP2C9 [2]. CYP2C9 is responsible for metabolizing several clinically relevant drugs
such as S-warfarin, phenytoin, and many of the NSAIDs [3]. One NSAID in particular,
flurbiprofen, is metabolized exclusively by CYP2C9 [4;5], and thus serves as a selective
in vitro probe for CYP2C9 activity. Furthermore, this CYP2C9 mediated metabolism of
flurbiprofen is non-stereoselective [4;5], implying that administration of commercially
available racemic-flurbiprofen would be feasible for in vivo studies of CYP2C9
metabolism. To this end, we have recently shown that flurbiprofen may also be useful as
an in vivo probe for CYP2C9 activity [6]
Dapsone is a sulfone drug that has been used in the treatment of leprosy, and more
recently for the treatment of Kaposi’s sarcoma and pneumocystis carinii in patients with
AIDS [7]. Dapsone itself is metabolized by CYP2C9 [CYP3A4 and CYP2E1 may also
provide a contribution] [8-11], and has been shown to participate in a complex in vitro
interaction with flurbiprofen, whereby it can activate CYP2C9-mediated flurbiprofen
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metabolism [2]. The addition of dapsone in vitro can increase CYP2C9 mediated
flurbiprofen metabolism by 50-100% in human liver microsomes and purified CYP2C9
enzyme, respectively [2]. This observation of CYP2C9 activation in vitro at
concentrations of both dapsone and flurbiprofen observed in vivo, suggests that CYP2C9
might display cooperativity in vivo and thus leads to the hypothesis that dapsone may
activate flurbiprofen metabolism (via CYP2C9) in vivo. In this study, flurbiprofen was
administered in the presence and absence of low and high concentrations of dapsone, to
evaluate whether the metabolism of flurbiprofen could be activated in vivo by dapsone.

7.2. Methods
Chemicals and reagents. S-Flurbiprofen, 4’-hydroxyflurbiprofen, and 2-fluoro-4biphenyl acetic acid (internal standard) were gifts from the Pharmacia, Inc. (Kalamazoo,
MI, USA). Dapsone was obtained from Sigma Chemical Co. (St Louis, MO, USA) and
monoacetyl-dapsone was synthesized by the method of Uetrecht et al. [12]. All other
chemicals and solvents were obtained from commercial sources and were of the highest
purity available.
Inclusion/exclusion criteria. Twelve healthy subjects between 18 and 45 years of
age participated in the study. The study protocol was approved by the Institutional
Review Boards of both the University of Pittsburgh and West Virginia University and all
subjects gave written, informed consent. The subjects consisted of non-smoking men and
women who underwent screening tests based on history, physical examination and
routine biochemical and urinalysis tests. Women must not have been pregnant at the time
of the study, and all subjects must have abstained from alcohol (of any form) for 8 days
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and any caffeine containing products for 48 hours before and during the period of study.
Subjects were specifically questioned about the last time they consumed alcohol or any
caffeine containing products.
Flurbiprofen-dapsone pharmacokinetic study. The pharmacokinetics of
flurbiprofen were evaluated before (visit A) and after the first and seventh dose(s) of
dapsone 100mg (visits B and C, respectively). Visits A and B (before and after dapsone)
were separated by at least 2 weeks. Racemic-Flurbiprofen (Ansaid®) 50mg was
administered orally after an overnight fast on each occasion and given 2 hours after the
single or seventh dose of dapsone (Avlosulfon®). Prior to drug administration, 40 ml of
blood was obtained. Following drug administration, blood samples (20 ml with sodium
EDTA) were obtained at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours. Total voided
urine was collected before and at the following time intervals after flurbiprofen
administration: 0-2 hr, 2-4 hr, 4-6 hr, 6-8 hr, 8-10 hr, 10-12 hr, and 12-24 hr. Subjects
were kept at the Clinical Research Unit for 12 hours during each study and returned the
next morning for the 24 hr blood sample draw and to provide the overnight (12-24 hr)
urine collection. Plasma was obtained from the blood samples by centrifugation and
together with aliquots of the urine samples, stored frozen at -20°C until analysis.
Urine 4’-hydroxyflurbiprofen and flurbiprofen concentration analysis. Plasma
and urinary concentrations of 4’-hydroxyflurbiprofen and flurbiprofen were measured
using the method of Hutzler et al., [13]. Samples were prepared using 50µl of urine,
followed by addition of 400 µl of purified water and 100 µl 6M HCl. The samples were
then incubated at 90°C for 30 minutes to facilitate deconjugation of the glucuronides of
flurbiprofen and its 4’-hydroxy metabolite. Once cooled, 500µl of acetonitrile containing
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internal standard (500ng of 2-fluoro-4-biphenyl acetic acid) was added. Samples were
then vortexed and centrifuged at 10,000 rpm for 5 minutes. Next, 150 µl of the
supernatant was transferred to autosampler vials and injected onto the HPLC. The HPLC
system consisted of a Waters 501 HPLC pump, a Waters 717 autosampler and a
Waters 470 fluorescence detector set at an excitation wavelength of 260nm and an
emission wavelength of 320nm. The mobile phase consisted of acetonitrile:20mM
K2HPO4, pH 3.0 (40:60) pumped at 1mL/min through a Brownlee Spheri-5 C18 4.6 x
100mm column. The inter-day coefficients of variation for 4’-hydroxyflurbiprofen and
flurbiprofen in urine were less than 5%.
Plasma 4’-hydroxyflurbiprofen and flurbiprofen concentration analysis. Plasma
samples were prepared by adding 200 µl internal standard solution (180 ng/ml 2-fluoro4-biphenylacetic acid in acetonitrile) to 100 µl plasma, followed by brief vortexing.
After 200 µl acetonitrile was added, samples were vortexed and centrifuged for 10
minutes. Next, 100µl of sample was transferred to HPLC autosampler vials, and 50µl
was injected. The mobile phase was pumped in a gradient fashion through a Thomson
20-20 column C18 4.6 x 200mm 5µm column. Mobile phase A consisted of acetonitrile,
containing 0.1% acetic acid, and mobile phase B consisted of 0.1% acetic acid. Using a
Hewlett Packard 1050 HPLC system pumping at 1mL/min, the gradient was initiated at a
ratio of 30%A:70%B and altered in a linear fashion to 100% A over 20 minutes. The
system was returned to initial conditions over 6 minutes and then allowed to equilibrate
for 5 minutes, for a total run time of 31 minutes. Samples were quantitated with
fluorescence detection using an excitation wavelength of 260nm and an emission
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wavelength of 320nm. The inter-day coefficients of variation for 4’-hydroxyflurbiprofen
and flurbiprofen in plasma were 14.3% or less.
Plasma dapsone and N-acetyldapsone concentration analysis. The
concentrations of dapsone and N-acetyl dapsone were determined by HPLC as described
previously {May, Arns, et al. 1992 1140 /id}. The inter-day coefficients of variation for
dapsone and N-acetyldapsone in plasma were 13% or less.
Data analysis. Plasma concentration-time data were analyzed by noncompartmental methods. Pharmacokinetic parameters including half-life, clearance, area
under the concentration-time curve (AUC) and metabolite formation clearance were
estimated using WinNonlin (Pharsight, Palo Alto, CA). The AUC for flurbiprofen and
4'-hydroxyflurbiprofen were determined using the trapezoidal rule with extrapolation to
infinity. Flurbiprofen apparent oral clearance was calculated as Cl/F = Dose/AUC. 4’hydroxyflurbiprofen formation clearance (4’-OHF FCL) was calculated as:
OH
CL4FM
= Urinary excretion of 4’-OHF (24hours)
AUC Flurbiprofen (0-∞)

The AUC (0-12 hours) for dapsone and N-acetyl dapsone was also determined using the
trapezoidal rule. Mean concentrations were calculated by dividing the AUC of these
compounds by the time interval (12 hours).
Statistical analysis. Data are presented as mean ± s.d. Data were analyzed by
repeated measures analysis of variance followed by Tukey’s multiple comparison test.
Clearance values were log transformed prior to analysis. Differences were regarded as
statistically significant when P values were ≤ 0.05. All analyses were performed using
SAS software (v. 6.12).
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7.3. Results
The apparent oral clearances of flurbiprofen during each of the treatment periods
are presented in Figure 7.1. The apparent oral clearance of flurbiprofen was unchanged
when given concomitantly with a single dose of dapsone but increased slightly (~11%)
(P<0.02) after seven days of dapsone dosing (Table 7.1). It is of note that though there
were substantial differences in baseline flurbiprofen apparent oral clearance values
among the patients, the reproducibility of changes within subjects were similar in extent
(Figure 7.1). Thus, averaging of the data somewhat obscures the changes noted within an
individual patient. The remaining pharmacokinetic parameter estimates for all three
visits are listed in Table 7.1.
To assess whether dapsone affected the glucuronidation of flurbiprofen and its 4’hydroxyflurbiprofen metabolite, urine samples from Visits A and C (without and with
dapsone) from three patients were analyzed with and without acid hydrolysis of the
glucuronides (data not shown). The ratio of 4’-hydroxyflurbiprofen recovered to total
parent and metabolite recovered from Visit A (no dapsone) did not differ regardless of
whether unconjugated flurbiprofen and metabolite or total flurbiprofen and metabolite
after hydrolysis were measured. Furthermore, the same equality was found in the
hydrolyzed and un-hydrolyzed urine samples from patients taking dapsone concurrently.
Likewise, measuring unconjugated drug did not alter the calculations of percent
activation as compared to measuring total drug excreted. These findings suggest that
dapsone had no effect on excretion of the flurbiprofen and metabolite glucuronides.
The AUC (0-12h) of dapsone and N-acetyldapsone estimated by the trapezoidal
rule is shown in Table 7.2. Average plasma dapsone levels after single and multiple
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doses were 5 ± 2µM and 11 ± 4µM, respectively (Table 7.2). Likewise, mean Nacetyldapsone levels in plasma were 2 ± 1µM after a single dose and 4 ± 2µM after seven
daily doses (Table 7.2). These average concentrations of dapsone (5 µM and 11 µM)
were well within the range of dapsone concentrations shown to produce activation of
CYP2C9 mediated flurbiprofen metabolism in vitro [2]. Furthermore, there was no
correlation between N-acetylator status (slow or rapid acetylators) and degree of
activation as measured by the flurbiprofen recovery ratio (data not shown).

7.4. Discussion
The present study evaluated the ability of dapsone to activate (interact
cooperatively with) flurbiprofen metabolism to 4-hydroxyflurbiprofen in vivo.
Flurbiprofen is an NSAID that is exclusively metabolized by CYP2C9 via 4’hydroxylation [4;5]. As a result, it may be used as a selective probe to monitor the
activity of CYP2C9 under various in vitro conditions. More recently, it has been
determined that flurbiprofen may also be used as a phenotypic measure of CYP2C9
activity in vivo [6]. Results of the present study demonstrate minimal activation of
flurbiprofen metabolism in vivo by dapsone, as reflected by an increase in flurbiprofen
apparent oral clearance.
In vitro experiments utilizing microsomes and purified CYP2C9 enzyme have
shown that dapsone activates 2C9-mediated flurbiprofen 4’-hydroxylation [2]. This
activation phenomenon was first discovered in microsomes, where a 50% activation was
observed, with maximum activation occurring at approximately 10µM dapsone
concentrations [2]. Studies using a purified CYP2C9 reconstituted enzyme system were
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also conducted, with flurbiprofen metabolism being doubled in the presence of low
concentrations of dapsone, and the maximum effect again at 10µM dapsone [2]. Our
laboratory has determined that this activation is not an isolated case, as observations that
dapsone can activate CYP2C9 mediated metabolism of the NSAID naproxen in vitro
have also been made [2].
Activation of CYP-mediated metabolism has primarily been associated with
CYP3A4. Studies by Schwab et al. [14] and Shou et al. [1] have shown that purified
CYP3A enzymes are activated by 7,8-benzoflavone. Likewise, purified CYP3A4mediated meloxicam metabolism was activated by quinidine in a dose-dependent manner,
160% at 10µM and 510% at 100µM compared to control experiments [15]. Most
recently, Tang et al. demonstrated in rhesus monkeys substantial (2-fold) in vivo
activation of CYP3A4 metabolism of diclofenac by quinidine [16]. More recent evidence
from Korzekwa et al., [2] and Ekins et al. [17] suggest activation is not unique to
CYP3A4 and that other isoforms may undergo activation as well.
Based on in vitro data showing activation of CYP2C9, we hypothesized that
similar findings might be observed in vivo using the CYP2C9 probe flurbiprofen.
Though the direction of the observed change in flurbiprofen apparent oral clearance is
consistent with this hypothesis, the in vivo interaction is of much lesser magnitude than
observed in vitro. At this time it is unclear why the degree of activation observed in vitro
is of a greater magnitude than observed in vivo. One factor that may contribute to the
decreased activation in vivo is protein binding. Recent work by McLure et al. [18]has
demonstrated that the binding of naproxen (an NSAID structurally related to
flurbiprofen) exhibits very little non-specific binding to microsomal (enzyme) protein in
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vitro. The in vitro binding of dapsone in microsomal preparations is unknown.
However, both flurbiprofen (99.95%) [19;20], and dapsone (~70-90%) [21] are
substantially bound to serum albumin in vivo. If a drug is highly protein bound, then the
amount of free drug available for metabolism and/or activation may be small. Since total
levels of dapsone were measured, and dapsone is 70-90% protein bound, then we may
assume that only about 20% of the dapsone was available to act on CYP2C9 in vivo,
potentially resulting in less activation compared to in vitro. As previously mentioned, the
average concentrations of dapsone in the subjects after one and seven doses were 5 ± 2
µM and 11 ± 4 µM, respectively, which corresponds to free dapsone concentrations of ~
1 µM and 2 µM, respectively, assuming 80% protein binding. By taking the average
AUC0-∞ of flurbiprofen from visit A, the average flurbiprofen concentration can be
calculated as being approximately 7 µM, resulting in an unbound concentration of 0.0035
µM. These estimated unbound concentrations result in an average in vivo unbound
dapsone/flurbiprofen molar ratio of ~600 after seven days of dapsone therapy. Even
without knowing the in vitro non-specific binding of dapsone, it is obvious that the
unbound dapsone/flurbiprofen ratio in vitro is less than 600 suggesting that though
protein binding may play some role in the lack of in vitro-in vivo correlation, it is
probably not the entire explanation.
Dapsone and flurbiprofen both have several routes of metabolism, which may also
have affected our in vivo observations. Dapsone is metabolized via both oxidative and
conjugative pathways, forming the hydroxylamine of dapsone and the N-acetylated
metabolites monoacetyldapsone and hydroxymonoacetyldapsone [22;23]. In vivo,
dapsone is concurrently undergoing both oxidative and conjugative metabolism, resulting
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in less dapsone available to act upon the CYP2C9 isoform and potentially reducing
activation, as compared to our in vitro experiments [2] in which only phase I pathways
were operational. Besides dapsone metabolism, another potential confounder in these in
vitro-in vivo correlations is that flurbiprofen also undergoes glucuronidation [24;25],
which may serve as a competitive reaction, lowering the effective flurbiprofen
concentration available for oxidation, even though dapsone does not appear to affect
flurbiprofen glucuronidation. Thus, protein binding and additional metabolism pathways
likely play a role in the disparity between in vitro and in vivo degrees of flurbiprofen
activation by dapsone. However, it is possible that other unidentified factors may also
participate in the modulation of activation in vivo.
In conclusion, the activation of flurbiprofen metabolism by dapsone observed in
vitro has been observed in man. However, the activation does not appear to occur at the
same magnitude. Thus, it can be expected that co-administration of dapsone with other
CYP2C9 substrates would not result in clinically significant interactions. It remains
possible that in vivo study of compounds exhibiting greater in vitro activation than
flurbiprofen or involving other CYP isoforms (e.g., CYP3A4 with its broad substrate
specificity) may result in a greater change in clearance. An improved understanding of
this activation phenomenon should permit a better assessment of its potential clinical
significance.
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Table 7.1.19 Flurbiprofen Pharmacokinetic Parameter Estimates
Mean flurbiprofen kinetic parameter estimates.
Variable

Units

Visit A

Visit B

Visit C

AUC 0-∞

µg/L*hr

43.8±13.8

39.3±9.4

38.3±8.5

L/hr

1.23±0.32

1.33±0.29

1.37±0.30*

Cmax

µg/ml

10.5±2.9

9.9±4.2

10.0±3.4

T1/2

hours

3.7±1.0

3.6±1.3

3.3±0.6

Tmax

hours

1.5±0.9

1.8±1.0

1.4±0.8

Vd/F

L

6.2±1.2

6.9±3.2

6.5±2.2

L/hr

0.38±0.14

0.39±0.13

0.40±0.16

Cl/F

4’-OH FCl

Data are mean values ±SD
Visit A = Flurbiprofen 50mg alone.
Visit B = Flurbiprofen 50mg + Dapsone 100mg.
Visit C = Flurbiprofen 50mg after 7 days of Dapsone 100mg daily.
AUC 0-∞ ,area under the plasma concentration-time curve extrapolated to infinity; Cl/F, clearance; T1/2,
half-life; 4’-OH FCl, 4’-hydroxy flurbiprofen formation clearance.
*P<0.02

Table 7.2.20 Plasma Levels of Dapsone and N-acetyl Dapsone
Mean plasma levels for dapsone and N-acetyl dapsone.
Dapsone
Visit

N-acetyl dapsone

B

C

B

C

59.5±18.8

130.5±45.9

24.0±15.0

47.8±24.5

Cmax (µM)

7.5±2.2

14.5±4.9

3.3±2.3

5.9±3.4

Caverage (µM)

5.0±1.6

10.9±3.8

2.0±1.2

4.0±2.0

AUC (0-12h)µM*hr

Dapsone dose =100mg
B=single dose
C=7th dose
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Clearance (L/hour)

0.85

0.75

0.65

0.55

Visit A

Visit B

Visit C

Figure 7.1.53 Flurbiprofen Oral Clearance in 12 Healthy Subjects
Comparison of flurbiprofen oral clearance in the 12 subjects when receiving either
flurbiprofen alone (Visit A), flurbiprofen and single dose dapsone (Visit B) or seven days
of dapsone therapy and then flurbiprofen (Visit C).
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Summary and Conclusions
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Over the past several years, it has come to our attention that CYP450 enzymes do
not always behave as would be expected. Many display kinetics that are not consistent
with the Michaelis-Menten model, resulting in data that is often hard to interpret and
correlate to the in vivo situation. As a result, it is important that we understand, as best
we can, the underlying causes of atypical kinetics. This understanding will help to better
predict when atypical kinetics are likely to occur. Historically, CYP3A4 has been the
focus of study because it has presented the most examples of atypical kinetics. However,
it is now being discovered that other isoforms often show atypical kinetic profiles as well.
Our lab has discovered that dapsone can activate CYP2C9-mediated metabolism of
several compounds. This was first discovered in human liver microsomes, but little was
known about the underlying causes. The work done since that initial discovery, and
reported here, has shed some light on this subject and provided valuable information
regarding the mechanism of activation of CYP2C9.
It was first discovered that dapsone activated flurbiprofen 4’-hydroxylation, but
we know now that naproxen demethylation and piroxicam 5’-hydroxylation are also
activated by dapsone, indicating that multiple CYP2C9 substrates can be activated by
dapsone. Kinetic studies exploring the activation of these substrates indicates that
activation of CYP2C9 may be explained by a two-site binding model, which suggests that
both dapsone and substrate may fit in the active site simultaneously, both having access
to the active oxygen. In addition, we have the capability of fitting activation kinetic data
to a two-site effector model equation, which gives α and β values indicative of activation.
Next we have shown that the effector structural requirements are rather strict,
which is consistent with other specific protein-substrate interactions. It is evident from
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these dapsone analog studies that the best activators possess a sulfone moiety, preferably
directly between two benzene rings. Para positions on these benzene rings also are
important, as replacement of an amino group (dapsone) with a nitro group (4-NPSA)
results in inhibition of CYP2C9. This small structural change in 4-NPSA, linked to the
substantial change in enzyme activity in its presence, suggests that the effector site that
causes activation is very specific, and may be in the active site. To study the effects of
active site changes on activation of dapsone, we have studied the *2 and *3 allelic
variants and F114L mutant of CYP2C9. Results suggested that the F114 residue may
play a role in activation, as 5-fold activation of flurbiprofen 4’-hydroxylation was
observed in this mutant, compared to 1.5-fold in wild-type CYP2C9. In addition,
piroxicam 5’-hydroxylase activity was higher in the F114L mutant than wild-type
CYP2C9 in the absence of dapsone, indicating that active site conformation alone
contributes to enzyme activity.
In addition, it has been found that CYP2C9 may be activated by more than one
mechanism. Hydroxy-dapsone has been found to activate flurbiprofen 4’-hydroxylation,
although differently from dapsone. Hydroxy-dapsone activates CYP2C9 solely through a
Vmax effect, with no effect on Km, whereas dapsone affects both Vmax and Km. These
effects were confirmed by spectral binding studies which showed the direct effect of
dapsone on the binding affinity for flurbiprofen, while hydroxy-dapsone had no effect on
affinity for flurbiprofen. This Vmax effect by hydroxy-dapsone may be the result of
disrupting ordered water molecules within the active site, resulting in decreased
uncoupling of the P450 cycle and enhanced product formation. This suggests that
multiple factors are likely involved in activation of CYP2C9 activity. We have also
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found from CYP2C9/19 chimeric and CYP2C19 mutant enzymes the important
regions/residues for catalytic activity towards flurbiprofen, naproxen, and piroxicam.
Additionally, only the CYP2C9/19 (340-490) chimera was able to be activated to any
extent by dapsone. Results from the same study suggest that dapsone may bind in SRS 1
of CYP2C9, but this has yet to be confirmed. Lastly, the orientation of ibuprofen is
apparently changed in the presence of dapsone, as a different ratio of 3-hydroxy to 2hydroxy ibuprofen is produced in the presence of dapsone, indicating the active site
conformation effects of dapsone on CYP2C9.
One of the ongoing arguments regarding effector binding and atypical kinetics is
exactly where the effector site is. Most data presented in the literature suggests that the
effector site is in the active site, while others still believe in the presence of an allosteric
site, which upon binding by effector causes a conformational change in the protein. None
of our studies have conclusively shown the presence of the effector site in the active site.
However, we have shown some pretty compelling kinetic and structural evidence to
support this theory, including the ability to measure dapsone metabolite formation in the
presence of flubiprofen, indicating dapsone’s presence in the active site (chapter 2).
Despite the information collected thus far to help in the understanding of activation of
CYP2C9, there is still much to be studied before we can truly state that we fully
understand atypcal kinetic profiles. It is also possible that overall protein conformational
changes are contributing to the observed activation of CYP2C9, which is an area of focus
for the future. The information reported here, while important, is just the beginning.
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